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For the patients, activists and personnel of the DREAM Program in Africa 
 
 
 
You are not useless if you are HIV-positive. Being HIV-positive can also be the opportunity to begin a new 
life, to approach life with greater responsibility, working towards a future world that is free of HIV. I am HIV 
positive, but I am sure that with my work, I am making a contribution to the development of the country. In 
my heart I have the lively sensation that I am fulfilling the noble mission of helping the others to live with 
this disease. 
 
Olivia Albino Mavie, activist of the DREAM Program in Mozambique 
Summit of the Southern African Development Community (SADC), Maputo, 17.08.2012 
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Abstract 
Objective of the study was to evaluate the prevalence and risk factors of ART-associated hepatotoxicity and 
anemia under d4T- and AZT-based regimens. The study was a multicenter retrospective observational study 
using pooled data from four AIDS-treatment sites in Mozambique and three in Malawi from 01.01.2006 to 
31.08.2012. 
 
Computerized records of 10,567 HIV-infected, ART-naïve, non-pregnant adults, who started ART and had at 
least 12 months of follow-up after initiation of ART, were reviewed. Initial first-line ART regimens consisted 
of d4T- and AZT-based combinations; 95% of the patients received NVP as NNRTI. CD4 cell count, plasma 
HIV RNA (viral load, VL), body mass index (BMI), GOT and hemoglobin (HB) were measured before starting 
ART. GOT as indicator for hepatotoxicity and HB as indicator for anemia was measured after month 1, 2, 3, 
6, 9 and 12. Prevalence of hepatotoxicity grade 1+2 and 3+4 and anemia grade 1+2 and 3+4 in d4T-based 
and AZT-based regimens during the 12-months follow-up were analyzed. The possible risk factors for 
prevalence increase “type of ART combination”, “CD4 count before ART”, “VL before ART”, “nutritional 
status before ART (BMI)”, sex and “malaria events after the start of ART” were identified by univariate 
and/or multivariate analysis. 
 
Results 
The cohort of 10,567 patients was dichotomized in a “d4T-based arm”(n= 8231, 77.9%) and an “AZT-based 
arm” (n= 2306, 21.8%).  
Cumulative prevalence of hepatotoxicity 1+2 and 3+4 before starting ART was 18.1% and 0.5% respectively. 
Prevalence of ART-associated hepatotoxicity 1+2 declined until month 3, and of hepatotoxicity 3+4 until 
month 6 of follow-up. In the “d4T-based arm”, prevalence of ART-associated hepatotoxicity 1+2 was during 
the follow-up higher than in the “AZT-based arm”. 
Cumulative prevalence of anemia 1+2 and 3+4 before starting ART was 28.5% and 6.7% respectively. The 
prevalence of ART-associated anemia declined constantly during follow-up. The prevalence of ART-
associated anemia 1+2 and 3+4 was during the complete follow-up (anemia 3+4 not in month 1) higher in 
the “AZT-based” than in the “d4T-based arm”. 
 
Risk factors for increased hepatotoxicity prevalence under d4T- and AZT-based regimens 
In the univariate analysis, a d4T-based combination was during the complete follow-up a statistically 
significant risk factor for higher prevalence of hepatotoxicity grade 1+2 compared to AZT-based 
combinations, and never for higher prevalence of hepatotoxicity grade 3+4. 
In the multivariate analysis, a d4T-based combination was statistically significant associated at month 1, 2, 
3, 6 and 9, and female sex at month 1, 2, 3, 6 and 12 with increased hepatotoxicity 1+2 prevalence. 
A pre-ART BMI>18.5 was a statistically significant protection factor against increased hepatotoxicity 1+2 
prevalence in the first three months of ART. Pre-ART CD4 count and pre-ART VL were never statistically 
significant associated with increased hepatotoxicity prevalence. 
 
Risk factors for increased anemia prevalence under d4T- and AZT-based regimens 
In the univariate analysis an AZT-based combination was a statistically significant risk factor for higher 
prevalence of anemia grade 1+2 during the complete follow-up, and for higher prevalence of anemia grade 
3+4 at month 2, 3 and 6, compared to d4T-based combinations. 
In the multivariate analysis cumulative malaria was a statistically significant risk factor for an increased 
prevalence of anemia 1+2 in all months of the follow-up, and of anemia 3+4 in month 2 and 6. 
AZT-based combination was statistically significant associated with increased anemia 1+2 prevalence only 
in month 1, and with increased anemia 3+4 prevalence in month 2, 3 and 6. 
A pre-ART BMI>18.5 was a statistically significant protection factor against anemia 1+2 in month 1 and 2, 
and against anemia 3+4 in month 2. Pre-ART CD4 count was never and pre-ART VL only in month 1 
statistically significant associated with increased anemia 1+2. 
 
The identification of risk factors, using univariate analysis, for increase of prevalence of overall, not only 
ART-associated hepatotoxicity and anemia prevalence separately in the d4T- and AZT- based arm identified 
as most frequent statistically significant factors pre-ART VL>100,000 c/ml (risk factor) and pre-ART 
BMI>18.5 (protection factor). Pre-ART anemia was never and a high pre-ART CD4 count only once 
statistically significant associated with an increased hepatotoxicity and anemia prevalence. 
19 of 22 statistically significant factors were identified in the first 3 months of ART. 17 of 22 statistically 
significant factors were identified in the “d4T-based arm”. In the “AZT-based arm” all 5 identified 
statistically significant factors were associated with anemia prevalence in the first 3 months of ART. 
 
Conclusion 
Hepatotoxicity prevalence under d4T- and AZT-based regimens 
In sub-Saharan settings, a d4T-based combination and female sex are the most frequent statistically 
significant and independent risk factors for increased prevalence of ART-associated hepatotoxicity 1+2. A 
good nutritional status (pre-ART BMI>18.5) protects statistically significant against an increase of 
hepatotoxicity 1+2. In a comparison of overall hepatotoxicity prevalence a pre-ART VL>100,000 c/ml was a 
statistically significant risk factor for hepatotoxicity 1+2 in the first 3 months of d4T-based ART (univariate 
analysis). 
 
Anemia prevalence under d4T- and AZT-based regimens 
In sub-Saharan settings, cumulative malaria increased significantly and independently the risk for anemia 
1+2 during 12 months after the start of ART, and for anemia 3+4 at months 2 and 6. An AZT-based 
combination is only at month 1 a significant, independent risk factor for anemia 1+2, but until month 6 for 
anemia 3+4. A pre-ART BMI>18.5 was a significant and independent protective factor against anemia in the 
first two months of ART. In the comparison of overall anemia prevalence a pre-ART VL>100,000 c/ml was a 
frequent statistically significant risk factor for anemia 1+2 and 3+4, mainly in the “d4T-based arm“ 
(univariate analysis). 
 
The influence of pre-ART VL, sex and the “African factors” pre-ART BMI and “Malaria events during ART” on 
ART-associated hepatotoxicity and anemia must be considered when the composition of the initial first-line 
combination is decided. Transaminases and HB must be monitored closely during the first 12 months or 
ART, especially under d4T- and AZT-based regimens, in order to prevent clinical relevant hepatotoxicity and 
anemia. Nevertheless less toxic first-line drugs than d4T, AZT and NVP must be introduced in sub-Sahara 
Africa. 
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1. Introduction 
1.1 The antiretroviral therapy (ART) 
Antiretroviral treatment (ART, also Highly active antiretroviral treatment – HAART) is one of the fastest 
developing areas in modern medicine. The understanding of the dynamics of HIV infection, social and 
epidemiological aspects, of prevention methods and antiretroviral treatment has grown in an impressive 
way. The actually available antiretroviral treatment options are indeed not able to eradicate HIV from a 
HIV-infected person and to lead to complete healing, which is the most desirable aim. But the prognosis of 
HIV infected patients has improved a lot since antiretroviral therapy (ART) was introduced in 1996. Patients 
in ART must take ART lifelong, i.e. for some decades. ART has been available for only 16 years, but a more 
or less normal life expectancy of people in ART is anticipated (Hill 2010). 
ART is the most important instrument to prolong the survival of HIV-infected persons (Egger 1997, Mocroft 
1998, Palella 1998, Hogg 1999). ART reduces the risk of AIDS to progress, the AIDS related (Porter2003, 
Kousignian 2005, Sterne 2005) and the not-AIDS-related mortality due to hepatic, cardiac and cancer 
diseases (Weber 2005). Several seroconverter cohorts showed that the mortality rate of HIV-patients in the 
first 5 years after the infection did not increase compared to the seronegative population, except for 
patients who had been infected as injection drug users (IDUs) (Porter 2008). The decrease of mortality was 
confirmed also in some prospective randomized controlled trial with clinical endpoints (Hammer 1997, 
Cameron 1998, Stellbrink 2000). 
ART effects the incidence of AIDS defining diseases (e.g. Cryptosporidiosis, progressive multifocal 
leukoencephalopathy-PML, Kaposi sarcoma) to different degrees. The decline of viral opportunistic 
infections (OIs) is the most obvious, but also fungal opportunistic infections lessened, even if less 
pronounced than viral OIs (d'Arminio Monforte 2005). The positive effect on their clinical course is 
confirmed. 
 
Virologic success of ART is defined as a HIV-RNA viral load below the limit of detection of 50 copies/ml. The 
faster and lower viral load is reduced, the longer the treatment will be effective (Kempf 1998, Powderly 
1999). An undetectable viral load (<50c/ml) should be reached after three to four months. A viral load 
above >50 c/ml after 6 months of ART is considered as virologic failure, as well as a confirmed increase of 
viral load under antiretroviral treatment. 
 
1.2 The HIV-epidemic in sub-Saharan Africa 
According to the latest UNAIDS Report “Together we will end AIDS” sub-Saharan Africa continues to be the 
hardest hit continent by the HIV-pandemic (UNAIDS Report 2012): At the end of 2011, out of 34.2 million 
(range 31.8-35.9 million) HIV-infected people worldwide 23.5 million (22.2-24.7 million) lived in sub-
Saharan Africa. In 2011 in sub-Saharan Africa, 1.7 million adults and children got newly infected (worldwide 
2-5 million [2.2-2.8 million]), and 1-2 million (1.1-1.3 million) adults and children died because of HIV/AIDS 
(worldwide 1.7 million [1.6-1.9 million]). 
UNAIDS states that “East and Southern Africa remain the areas most heavily affected by the HIV epidemic. 
Out of the total number of people living with HIV worldwide in 2009, 34% resided in 10 countries of 
Southern Africa.” (www.unaids.org/en/regionscountries/regions/easternandsouthernafrica/, accessed 12 
September 2012). “The HIV prevalence in West and Central Africa remains comparatively low, with the 
adult HIV prevalence estimated at 2% or under in 12 countries in 2009…. The prevalence of HIV is highest in 
Cameroon at 5.3%, Central African Republic 4.7%, Côte d’Ivoire 3.4%, Gabon 5.2%, and Nigeria 3.6%” 
(www.unaids.org/en/regionscountries/regions/westandcentralafrica/ , accessed 12 September 2012). 
 
The access to antiretroviral treatment improved a lot in the last years. But even if the “treatment 
coverages” improved, the quality of many services often remains worryingly low. The UNAIDS Report 2012 
states that “more people than ever are receiving antiretroviral therapy, as treatment coverage continues to 
expand. Just over 8 million people in low- and middle-income countries were receiving treatment in 2011, 
 2 
with coverage reaching 54% [range 50–60%]. This is 1.4 million more people than in 2010 and significantly 
higher than the 400 000 people receiving treatment in 2003. ….The most dramatic progress has been in 
sub-Saharan Africa, where treatment coverage increased by 19% between 2010 and 2011. … In sub- 
Saharan Africa, more than half (56% [53–60%]) the people needing treatment were getting it. … In sub-
Saharan Africa, increased access to HIV treatment has reduced the number of people dying from AIDS-
related causes from an annual peak of 1.8 million [1.6 million–1.9 million] in 2005 to 1.2 million [1.1 
million–1.3 million] in 2011. Almost half these deaths occurred in southern Africa.” 
 
The experience of the recent years shows that it is feasible, effective and cost-effective to administer ART 
in sub-Saharan Africa (Laurent 2002, Weidle 2002, Marazzi 2005, Goldie 2006). Barth RE et al. showed in a 
systematic review that 78% of sub-Saharan patients had a virological suppression after 6 months of ART 
(76% after 12 months, 67% after 24 months). “First-line antiretroviral therapy regimens used in sub-
Saharan Africa are effective” (Barth 2010). 
In contrast to the resistance, which still occurred a few years ago, it is now accepted that ART in resource-
limited settings is feasible, cost-effective and efficient. But future activities must go in two directions: 
 The access to medical services, to HCT (HIV Counselling and Testing) and to ART must continue to 
improve, still much more people must get access to treatment, and 
 in many cases the quality of the medical services must improve (medical, pharmaceutical, 
laboratory, social services et cetera). 
 
Differences between HIV/AIDS in developed and sub-Saharan countries 
An important background presupposition of this thesis is that there are major differences between both 
the HIV-epidemic and HIV-patients in developed and underdeveloped countries. Data from studies carried 
out in industrialized countries may not be automatically implemented for HIV-patients in developing 
countries. Findings from trials performed in developed countries should be confirmed in resource limited 
settings. 
This is true also for adverse effects (AEs) of ART. Most information about adverse effects is from 
publications based on data from industrialized countries. The data about adverse effects of ART in “African 
patients under African conditions” are not sufficient (1.4.2 Review of the literature). 
 
Differences between the HIV-epidemic and the HIV-patient are: 
 
A, HIV-1 Group M(ain) is responsible for the global HIV-1 pandemic. While the epidemic in western 
countries is driven by HIV-1 subtype-B; HIV-1 subtype C represents around 56% of all circulating group M 
strains in India, China, south Asia, East Africa and the southern Africa (Esparza 2000, Thomson 2002). In 
Mozambique and Malawi the predominant strain is HIV-1 subtype C, too. 
Drugs, laboratory methods and standards are developed in western countries with high prevalence of 
subtype B, and it cannot automatically be taken for granted that non-subtypes B are responding like 
subtype B. 
 
B, The prevalence and the populations affected by HIV/AIDS are different in sub-Saharan Africa and in 
western countries. According to the UNAIDS Report 2012 the average prevalence of HIV in Sub-Saharan 
Africa is 4.8% (4.6-5.1%); so in absolute numbers around 23.5 million (22.2 million – 24.7 million) people in 
Sub-Saharan Africa are HIV-infected. In Western and Central Europe the prevalence is 0.2% respectively 
860.000 (780.000–960.000) HIV-positive persons. Also in Africa the prevalence is not homogeneously 
distributed, with the highest prevalence in southern African countries (UNAIDS Report 2012): 
 
 Swaziland 25.9% 
 Botswana 24.8% 
 Lesotho 23.6% 
 South Africa 17.8% 
 Zimbabwe 14.3% 
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 Zambia 13.5% 
 Namibia 13.1% 
 Mozambique 11.5% 
 Malawi 11.0% 
 
C, Genetic differences between Africans and Caucasians may cause different adverse effects against 
antiretroviral drugs: 
 Neutropenia has been described as being more frequent in African American patients receiving 
HAART (Reisler 2003), whereas the frequency of AZT anemia has not been found to be statistically 
different between Caucasian and African American patients (Jacobson 1996). “Ethnic neutropenia” 
describes the hypothesis, that persons with African ancestry have a lower neutrophil count, as the 
consequence of a reduced number of bone marrow progenitor cells in comparison with the 
numbers present in Caucasians (Shaper 1971, Rezvani 2001). It is hypothesized that cotrimoxazole-
associated neutropenia is more frequent in sub-Saharan Africans or American African adults than in 
Caucasian adults (Huët 2000). 
 Some authors recommend for African Americans to take a lower limit of normal of hemoglobin (HB) 
concentrations than for the white population. Possible reason for the difference is that the gene 
frequency for α-thalassemia is extraordinarily high in the black population, and that other yet 
unidentified genes could be involved. Using the same ranges to diagnose anemia in white and black 
populations could lead to an overestimation of anemia rates in black or an underestimation in 
white patients (Beutler 2005, Beutler 2006). 
 White race may be an independent risk factor for the d4T-associated lipodystrophy (Mallal 2000, 
Lichtenstein 2003). 
 Black African patients seem to have a genetic predisposition for efavirenz (EFV)-associated adverse 
effects of the central nervous system (CNS) in comparison to Caucasians, due to a variant of hepatic 
enzyme CYP2B6 they may cause slower clearance of EFV from plasma and increased neurotoxicity 
(Haas 2004, Wyen 2008). 
 
D, The transmission ways of HIV are the same in resource limited settings and industrialized countries: 
 Sexual intercourse with an infected partner 
 Mother to child transmission of HIV (MTCT) or vertical transmission 
 Sharing and reusing of syringes in people who inject drugs (injection drug users, IDUs) 
 Unsafe medical injections, contaminated blood transfusions or use of contaminated blood products 
 
However, the portion of the possible transmission ways differs a lot: 
In Sub-Saharan Africa the key modes of HIV transmission are heterosexual unprotected intercourse and 
transmission during pregnancy, delivery and breastfeeding (mother to child transmission - MTCT). UNAIDS 
reports that about one-fifth of new infections occur among people with multiple sexual partners and 
another one-third occurs in stable couples who do not currently report outside partners. Having 
unprotected sex with multiple partners remains the greatest risk factor for HIV in the region. About 10% of 
new HIV-infections are the result of sex work. Parenteral transmission is insignificant (UNAIDS 2010. New 
HIV Infections by mode of transmission in West Africa) 
In Germany more than 60% of the people living with HIV/AIDS are men who are having sex with men 
(MSM), followed by people who got HIV through heterosexual sex with a much lower percentage of approx. 
14%. The next groups are immigrants from high-prevalence-countries (approx. 12%) and injection drug 
users (approx. 9%) (Robert Koch-Institut 2011). 
 
E, African patients are often confronted with comorbidities that do not exist - or not to that extent- in the 
developed world. The elevated presence of infections (e.g. malaria, tuberculosis, parasitosis) or 
pathological status such as malnutrition or anemia are additional burdens that aggravate the AIDS disease. 
Mortality rates among patients treated in developing countries are significantly higher than those observed 
in patients living in western countries, particularly within the first 3 months of therapy (Braitstein 2006). 
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There is evidence that malnutrition with a BMI<18 and a low HB (<8g/100cm3) in Mozambican and 
Malawian patients are factors independently associated with increased mortality, regardless of CD4 cell 
count values. Malaria, anemia and tuberculosis are main causes of mortality in the first months after 
initiation of HAART (Marazzi 2008). 
 
In summary, African patients are taking ART under different health and living conditions influencing the 
kind and impact of adverse effects. The background morbidity common in African countries must be taken 
into account. A consequence that could be drawn from possible genetic differences between Africans and 
Caucasians (as described in C) and the higher disease burden in sub-Sahara Africans (see point E) is to 
consider differences of reference values for clinical chemistry and hemogram between African and 
European patients and to revise them (Bunders 2006, Wells 2006). 
 
1.3 Excursion: Short history of the AIDS-epidemic and the fight against HIV/AIDS in sub- 
       Saharan Africa 
       (Avert 2012, Kaiser Family Foundation 2012, Vella 2012) 
 
HIV originated in sub-Saharan Africa. It probably emerged in the 1920s or ‘30s when the Simian 
Immunodeficiency Virus (SIV), a viral ancestor of HIV, jumped host from chimpanzees to humans in south-
east Cameroon, Western Africa (Korber 2000, Keele 2006, Worobey 2008). The oldest HIV-positive human 
blood sample was found in Kinshasa (Zaire, now the Democratic Republic of Congo) and dates back to 1959. 
In the 1940 occurred the transfer of HIV-2 from monkeys to humans, probably in Guinea Bissau (Lemey 
2003). The first serological evidence for HIV infection was found in human sera from Zaire (Zaire, now the 
Democratic Republic of Congo) dating to 1959, Uganda dating back to1972 and Malawi to 1974 – evidence 
that HIV was circulating in Africa at those times. Afterwards in the early 1980s HIV spread quickly in Eastern 
Africa, especially in areas bordering Lake Victoria. At the same time HIV-1 and HIV-2 spread in Western 
Africa, but never reached the prevalence observed in countries of eastern and southern Africa. In the 
second half of the 1980s the epidemic continued to move from Eastern Africa to southern African countries 
which in the end surpassed the HIV prevalence of East Africa. 
 
 
Figure 1. Increase of number of people with HIV and prevalence since 1985 (Source: Avert 2012) 
 
In the western world, the year 1981 is generally referred to as the beginning of the HIV/AIDS epidemic: In 
January 1981, the young assistant professor Michael S. Gottlieb at the University of California at Los 
Angeles School of Medicine identified a first patient with low CD4 cell count and a Pneumocystis carinii 
pneumonia (PCP). PCP is normally not seen among healthy young men, but exclusively found in severely 
immunocompromised patients. The first reports described an epidemic of community-acquired 
Pneumocystis pneumonia, in most cases combined with oral thrush in previously healthy homosexual men, 
as well as chronic ulcerating perianal herpes infections (Gottlieb 1981a and b, Masur 1981, Siegal 1981). 
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PCP was later determined to be AIDS-related. In 1983, two years following the initial description of AIDS, 
HIV-1 was isolated as the AIDS-causing agent. 
 
The first known individual cases of HIV in Sub-Saharan Africa can also be -dated back to the 1980s: 
Tanzania declares that the first three cases were reported in 1983 (National AIDS Control Programme-
NACP: National Guidelines for the Management of HIV and AIDS, Third Edition, Dar es Salaam 2008). The 
first case of HIV in Kenya was identified in 1984 (K’Oyugi BO, Muita J. UNICEF, 2002). Malawi's first AIDS 
case was reported in 1985 (Malawi, National AIDS Commission, 2003), and in Mozambique the first case of 
HIV/AIDS was noted in 1986 (Mozambique, Ministry of Health, 2008). 
 
Figure 2. Adult HIV prevalence (%) in Africa between 1988 and 2003 (Source: Avert 2012) 
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As reaction to the occurrence of HIV/AIDS many African countries started to implement AIDS strategies and 
created National AIDS Councils or Committees to coordinate the countries efforts against the rising 
epidemic in the 1980s. These first responses to HIV/AIDS in Africa were absolutely insufficient, both from 
the African and western countries. The efforts of the first years consisted most of all in prevention and 
education programs, often without a real political will and chronically underfinanced. 
In the 1990s the epidemic spread at a tremendous speed, despite the prevention campaigns that showed, if 
any, only minimal effect. In 1998 70% of the newly infected people lived in Sub-Saharan Africa. 
 
The first years of medical efforts against HIV/AIDS were characterized by treatment failures and 
disappointments. In 1985 the first diagnostic antibody test was developed and clinical trials started with 
NRTIs, the first being AZT.The most important result obtained with the initial use of NRTIs was the 
demonstration that the treatment of HIV-infected pregnant women substantially decreased HIV 
transmission to the newborn. 
 
The breakthrough in the developed world came in 1995 and 1996 with two new fundamental insights: 
A, At the 11th International AIDS Conference ("One World, One Hope") in Vancouver, Canada, David Ho and 
colleagues presented pioneering data that explained the dynamics of HIV replication and the pathogenesis 
of the HIV infection on the hitherto completely misunderstood kinetics of HIV (Ho 1995 a and b, Perelson 
1996). They showed that the HIV infection, even during the clinically latent phases of the disease, is 
characterized by a high viral turnover with continuous high-level virus replication, that viral load is 
predictive of the subsequent risk of disease progression and death, and the molecular, functional and 
clinical impact of drug resistance to antiretroviral drugs (Vella 2012). 
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B, Julio Montaner et al. (NVP, AZT, ddI), Roy Gulick et al. (AZT, 3TC, IND) and Martin Markowitz et al. (AZT, 
3TC, RTV) published results about the efficacy of "triple-drug therapies". These data showed that triple 
combinations of antiretroviral drugs could result in undetectable plasma HIV RNA for longer periods and 
sustained improvements in CD4 cell counts. 
 
These two insights – the better understanding of the dynamics of the HIV infection and the discovery of a 
sustainable effective treatment - are considered as milestones in the history of medicine and the beginning 
of the ART era. After the years in which the inescapable fate of people with HIV/AIDS was death, a period of 
enormous optimism started in northern America and Europe. An inevitably fatal disease had been turned 
into a chronic manageable although not (yet) curable disease. 
 
In 1996 Brazil - as the first developing country - began its national ARV distribution. The Joint United 
Nations Programme on HIV/AIDS (UNAIDS) started in 1996 to advocate for global action on the epidemic, 
and to coordinate HIV/AIDS efforts across the UN system 
 
Despite the big success of HAART in the USA and western Europe, in the late 90s and still in the first years 
of the new millennium ART treatment in developing countries was viewed as impossible, at least outside 
some pilot projects, because it was considered as too expensive and too complex for African countries with 
low infrastructural and educational levels. 
 
In 1998 the South African NGO Treatment Action Campaign (TAC) started to fight for the access to 
antiretroviral treatment for South Africans. It was one of the first grassroots movements that pushed for 
the right to treatment in Africa. TAC and other civil society organizations played an important role in the 
13th International AIDS Conference ("Breaking the Silence ") at Durban, South Africa in 2000, the first 
International AIDS Conference in a developing nation. This Conference was a big push for the international 
awareness of the global pandemic and the scandal, that antiretrovirals had been available only in the 
developed countries but not in the poor world. The civil society campaigned for lower prices of ARVs and 
for local production and distribution of generic AIDS drugs. First AIDS treatment programs showed an 
unexpected success (for example from Médecins Sans Frontières in South Africa and the DREAM Program 
of the Community of Sant’Egidio in Mozambique, Malawi and eight other African countries) and 
contributed to change the political will in Western and African countries to work for the access to 
treatment. 
In 2000 the USA and the UN Security Council each declared HIV/AIDS a security threat, and the UN 
Millennium Development Goals included reversing the spread of HIV/AIDS, malaria and TB as one of eight 
key goals. 
In 2001, 20 years after the first AIDS case was reported, the United Nations General Assembly convened a 
first ever special session on HIV/AIDS (UNGASS). The World Trade Organization (WTO) at Doha (Qatar) 
announced the Doha Agreement that allowed developing countries to buy or manufacture generic 
medications in order to tackle health crises such as HIV/AIDS. Now the generic drug manufacturers, mostly 
in India, started to produce discounted, generic forms of antiretroviral drugs, and exported them to African 
countries. Several major pharmaceutical manufacturers agreed to offer reduced drugs prices in developing 
countries. 
In 2002, HIV became the leading cause of death worldwide among people aged 15 to 59 years. This and the 
growing conviction that activities to combat the HIV-pandemic had to start, global financing institutions had 
been installed: 
 In 2002 the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) started to operate and 
approved the first round of grants. 
 In 2003 US President George W. Bush announced PEPFAR, the President's Emergency Plan for AIDS 
Relief: a five-year $15 billion initiative to address HIV/AIDS, tuberculosis, and malaria primarily in hard 
hit countries. PEPFAR started in 2004 the first round of funding. PEPFAR 1 was followed by a second 
PEPFAR round from 2008 to 2013 amounting to $48 billion).  
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 The World Health Organization (WHO) announced the "3 by 5" Initiative that aimed to bring AIDS-
treatment to 3 million people by 2005. 
 
Another breakthrough came in 2003 when fixed-dose combination therapies became available that 
reduced the number of pills per day from 10–15 to as few as two. The price went down to 150 to 250 US$ 
per year for the first line regimens. 
In Malawi antiretroviral drugs (ARVs) were first made available by the public sector in 2003. In 2004, after 
having received a grant from the Global Fund to Fight AIDS, TB and Malaria, the government announced a 
five-year plan to make ARVs widely available in the public sector and began to distribute them to hospitals 
and clinics around the country.  
 
In the following years big efforts have been made to improve access to prevention, antiretroviral 
treatment, PMTCT and care in sub-Saharan Africa. According to UNAIDS (UNAIDS. World AIDS Day Report; 
2011. UNAIDS. Report on the Global AIDS Epidemic; 2010), at the end of 2010 34 million people were living 
with HIV, an increase of 5.4 million from 28.6 million in 2001, as a result of continuing new infections, 
people living longer with HIV, and general population growth. New HIV infections have declined by more 
than 20% since their peak in 1997, and declined by 15% between 2001 and 2010. Nevertheless, there were 
about 2.7 million new infections in 2010 or more than 7.000 new HIV infections per day. 
UNAIDS declared at the International AIDS Society's 2012 Conference (Turning the tide together) that the 
number of worldwide AIDS-related deaths fell to 1,7 million last year from some 1,8 million in 2010. AIDS 
deaths peaked at 2.3 million in 2005. 
The decline has been supported by more access to medications that help more people live with the disease. 
According to WHO data Sub-Sahara Africa has a 62% coverage rate of people eligible for treatment able to 
access treatment An estimated eight million people in lower-income countries receive antiretroviral drugs. 
UNAIDS estimated that in sub-Saharan Africa 31% fewer people died from AIDS-related causes in 2011 
compared with 2005. 
These big achievements should not lead to a false optimism that the HIV-epidemic is already under control. 
Urgent efforts in resource limited settings must be undertaken to improve access to HIV tests and medical 
services including ART, in order to increase the number of people who know their HIV-status and as a 
consequence can take the necessary measures and, if they are HIV-positive, to receive medical assistance. 
After all the number of people who receive ART included in a comprehensive package of a high level 
services must be increased. 
Secondly for those already in ART, in many cases the quality of the offered medical services must be 
improved by: 
 Systems for adherence monitoring and measures to improve adherence and retention rates 
 Access to a complete diagnostic including viral load and resistance testing 
 Introduction of state-of–the-art ART regimens, with access to modern ARVs like boostered PIs, Entry- 
and Integrase inhibitors that are not included in local guidelines in resource limited settings  
 Participation of HIV-positive patients as activists in the medical services, in order to better support 
patients e.g. with adherence problems, and to work against the widespread stigmatization of people 
living with HIV/AIDS 
 Inclusion of “African parameters” in the national guidelines like malnutrition and anemia as parameters 
for the decision when to start ART. 
 
1.4 The DREAM Program 
This thesis is based on an operational research within the DREAM Program (Drug Resource Enhancement 
against AIDS and Malnutrition) of the Community of Sant’Egidio, a faith-based organization based in Italy 
and many other countries in Europe, Africa, America and Asia. 
DREAM follows a holistic approach to the treatment of HIV/AIDS in Sub-Saharan Africa. It combines both 
prevention and antiretroviral treatment, similar to the one in developed countries, being convinced that 
individuals in Africa have the right to the same standard of care available in developed countries. 
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DREAM was launched in February 2002 in Mozambique by the Community of Sant’Egidio. Today the 
DREAM Program is present in 10 Sub-Saharan African countries: Mozambique, Malawi, Tanzania, Kenya, 
the Republic of Guinea, Guinea Bissau, Nigeria, Angola, the Democratic Republic of Congo and Cameroon. 
DREAM is a Public Health Program with the aim to offer high-quality medical services to as many people as 
possible.  
 
The key elements of the DREAM approach are: 
 A high standard of care associated with a high standard of laboratory diagnostics 
 Care free-of-charge to maximize access to services 
 Focus on the individual receiving care (humanistic approach) 
 Data processing with electronic medical records, in order to minimize errors and to improve 
retention in care by easier and faster identification of missed appointments and prompt access to 
medical information by caretakers. 
 
DREAM main activities are: 
 Voluntary counseling and testing (VCT), Provider-initiated HIV Testing (PIHT) 
 Antiretroviral therapy (ART) 
 Prevention of mother-to-child-transmission (PMTCT) 
 Inclusion of HIV-positive persons as activists 
 Health education 
 Installation of biomolecular laboratories for the measurement of CD4 T lymphocyte count, viral 
load, hematology and biochemistry parameters 
 Home based care 
 Provision of nutritional support to patients in need 
 
DREAM is supporting various public partners and from the church (mission hospitals, catholic 
congregations) in the implementation and the running of day hospitals for people living with HIV/AIDS. 
DREAM is working according the relative local guidelines, all DREAM Centers are approved by the local 
health authorities. The staff in the DREAM Centers are all locals. Currently 33 AIDS Centers are active. Since 
the beginning of DREAM in February 2002 the centers provided HIV care to more than 108.000 persons all-
in-all, more than 82.000 patients have taken antiretroviral treatment (cumulative data, end of august 
2012). 
Currently nearly 58.000 patients with HIV/ADS are under assistance, among them nearly 5.900 children 
under the age of 15. 43.900 are taking ART at present (4.500 children under 15 years). 
More than 17.000 children were born in PMTCT. Only 2-3% of the children are HIV-positive (Palombi 2007). 
Without the interventions of DREAM, most of all ART, up to 40% would have been HIV-infected during 
pregnancy, delivery and breastfeeding time. 
The 20 laboratories process over 50.000 patient specimens per year, for a cumulative total of 450.000 
laboratory tests processed to date including hematology, biochemistry, CD4 cell counts and HIV-1 viral load 
determination. 
 
1.5 Adverse effects 
The World Health Organization (WHO) defines adverse effects (AEs) or adverse drug reactions (ADRs) as 
“harmful, unintended reactions to medicines that occur at doses normally used for treatment” (WHO 2008, 
Fact sheet N°293). According the WHO Fact sheet “the majority of adverse drug reactions are preventable. 
In some countries ADR-related costs, such as hospitalization, surgery and lost productivity, exceed the cost 
of the medications. No medicine is risk free. Vigilant assessment of the risks and benefits of medicines 
promotes patient safety. … Preventing and detecting adverse effects from medicines is termed 
pharmacovigilance. Vigilant assessment of the risks and benefits of medicines needs to be applied 
throughout the life cycle of a medicine - from the pre-approval stage to the taking by patients. Global 
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information-sharing on adverse effects strengthens drug safety in countries and can translate into timely 
policy decisions that safeguard patient safety when problems emerge.” 
 
Edwards et al. classify six types of adverse drug reactions (Edwards 2000): 
 dose-related (augmented) 
 non-dose-related (bizarre) 
 dose-related and time-related (chronic) 
 time-related (delayed) 
 withdrawal (end of use) 
 failure of therapy (failure) 
 
1.5.1 Adverse effects of the antiretroviral therapy (ART) 
ART can be considered as a generally well tolerated drug treatment, given the fact that patients in ART take 
three drugs every day for many years (lifelong). But as any drug treatment also ART may be complicated by 
non-serious and serious adverse effects. The unwanted consequences may be health problems due to side 
effects and adherence problems, treatment changes or even discontinuation of treatment. 
 
The tolerance of antiretroviral treatment improved in the last years with the introduction of newer 
antiretrovirals. In the first years after 1996, when HAART became possible, at least 25% of the patients 
changed the initial combination in the first year due to adverse effects (d'Arminio Monforte 2000, Yuan 
2006). From 2003 to 2007 the change rate in the first year was slightly lower with 20% (Cicconi 2010). New 
and better tolerated drugs were able to further reduce the percentage of treatment changes or 
discontinuation in the first year of HAART in the last few years (Carr 2009). 
 
There is a lack of comprehensive and high-quality data about ART-related adverse effects in sub-Sahara-
African settings, and in general from developing countries.  
A study from rural Uganda (Forna 2007) reported that 39.9% of the patients developed an ART-related 
clinical toxicity; 13.3% of the toxicities were categorized as severe. The most common adverse effects were 
peripheral neuropathy (36%; 9% severe) and rash (6%; 2% severe), followed by 2% hypersensitivity reaction 
and <0.5% acute hepatitis, anemia, acute pancreatitis, or lactic acidosis. The ART used was d4T+3TC+NVP 
(96%) or EFV (4%). The limitation of this study was that the evaluation was not based on laboratory 
parameters but only on clinical symptoms reported in questionnaires. 
A pharmacovigilance study from South Africa (Dube 2012) reported that almost 50% of the cohort 
(1,374/2,815) “reported various medical conditions that could have been HIV and/or ARV-related. … The 
four most common adverse effects experienced by the 678 patients that changed ARV medicines due to 
ARV-related toxicity, were polyneuropathy (24.0%, 163/678), lipodystrophy (23.9%, 162/678), neuropathy 
(10.6%, 72/678), and suspected lactic acidosis (3.8%, 26/678).” The primary reason for regimen changes 
was drug-related toxicity (76.1%, 678/891). The used ART regimens were d4T-based (91.8%) or AZT-based 
(4.9%) or TDF-based (2.9%), each with 3TC and NVP (11.1%) or EFV (88.5%). A limitation of the study is that 
the adverse effects are not well defined. 
 
The definitions of adverse effects of ART according to laboratory parameters and clinical manifestations are 
unfortunately not standardized. According to an evaluation of the “reporting of adverse events in 
randomized controlled trials of highly active antiretroviral therapy” from Chowers et al., “AE reporting was 
nearly always selective”, due to a “large variability and a lack of standardization in the reporting of AEs” 
(Chowers 2009). 
Reporting of adverse effects of ART is variable and selective regarding 
 the severity grade of the AE: the severity of AEs reported ranged from all mild AEs to only those 
that led to discontinuation 
 an occurrence threshold of the AEs: The minimal frequency of occurrence used for reporting AEs 
seemed arbitrary (or chosen), ranging from none to AEs appearing in >20% of the study population 
 attribution to study drugs. 
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This variability precludes the possibility of comparing or compiling AEs reported in different HAART trials. 
Chowers at el. suggest following the CONSORT guidelines for reporting on harms in randomized trials 
(Moher 2001). 
 
1.5.2 Review of the literature 
A Medline research (http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed) with the MeSH terms* 
"Antiretroviral Therapy, Highly Active/adverse effects"[Mesh] produced 2378 hits (accessed 9 April 2012); 
these hits contain 11 meta-analysis, 619 reviews and 61 systematic reviews. 
If the MeSH term "Africa South of the Sahara" is added to this Medline query (09.04.2012), resulting from a 
research with the terms "Antiretroviral Therapy, Highly Active/adverse effects"[Mesh] AND "Africa South of 
the Sahara"[Mesh], only 84 hits are produced. These 84 hits include no meta-analysis, 7 reviews and 1 
systematic review. 29 (35%) of the articles are Free Full Text and so easily available for medical staff in 
resource limited settings. 
21 articles (25%) are published in journals that are difficult to find and to access, mainly African or exotic 
journals. 3 (4%) of the publications are in French.  
 
In many of these publications toxicity or adverse effect is not the main topic. Furthermore, the publications 
are addressing mostly quite specific questions, e.g. anemia in children with in utero exposure to maternal 
ART.  
 
If Medline queries are done with "Antiretroviral Therapy, Highly Active”, "Africa South of the Sahara" and 
more specific terms like “hepatotoxicity”, “myelotoxicity” or “lactic acidosis”, more articles can be found. 
But the number of hits remains always small, and some of the publications are of limited quality and 
published in exotic journals. 
 
The numbers show that clinical trials and researches about adverse effects of ART are done mostly in high-
income countries. There is a big discrepancy between the knowledge about side effects of antiretroviral 
drugs in industrialized countries and in sub-Saharan Africa. To my knowledge, no systematic evaluation of 
adverse effects of HAART (hepatotoxicity, anemia) in a big cohort from sub-Saharan Africa has been 
published up to now.  
 
* MeSH (Medical Subject Headings) is the controlled vocabulary thesaurus of the US National Library of Medicine (NLM)  
    and is used for indexing articles for PubMed. 
 
1.6 ART related hepatotoxicity 
ART related hepatotoxicity is a relevant adverse effect that complicates the management of HIV-infected 
patients. It may increase the morbidity and mortality of treated HIV-infected patients, lead to modifications 
of the administered ART combination, increase medical costs and alter the prescription patterns. 
A brief review summarizes the risk factors, mechanism and clinical symptoms, the diagnosis and 
monitoring, as well as data from sub-Saharan studies of ART related hepatotoxicity. More detailed 
information is given elsewhere (e.g. Núñez 2005, Núñez 2010). 
 
1.6.1 Risk factors for hepatoxicity 
Described risk factors for a severe liver damage are 
 elevated aminotransferases before initiation of ART (Wit 2002, Servoss 2006). Hepatotoxicity is more 
frequent in patients with a pre-existing liver dysfunction (Soriano 2008) 
 coinfection with chronic active or reactivated hepatitis B, C (Núñez 2001, Sulkowski 2002, Servoss 2006) 
or D, and with parasitosis (amoebiasis, schistosomiasis) 
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 the concurrent administration of hepatotoxic drugs (Núñez 2001, Servoss 2006, Kovari 2010). In African 
settings where TB/HIV coinfection is frequent, antituberculosis drugs, especially isoniazid, rifampicin and 
pyrazinamide, are often used hepatotoxic drugs. 
 the administration of NVP, protease inhibitors, high doses of ritonavir (>600 mg/day), and prolonged 
AZT or d4T exposure (Núñez 2001, Servoss 2006, Kovari 2010) 
 factors including alcohol abuse, older age, female sex, thrombocytopenia, renal insufficiency, high HIV 
RNA levels, increased body mass index, and non-black ethnicity (Núñez 2001, Wit 2002, Servoss 2006, 
Kovari 2010) 
 an increase in CD4 cell counts of >50 cells/µl after HAART initiation was associated with an almost two-
fold increased risk of severe GPT (ALT) elevation in one study (Sulkowski 2002). 
 
There are conflicting data whether a good immune status with higher CD4 cell counts in ART naïve patients 
starting NVP based ART is a risk factor for severe liver toxicity. Actually it is not recommended to start NVP 
in females with CD4 cell counts > 250 cells/μl and males with CD4 > 400 cells/μl. Virologically suppressed 
patients switching to NVP seem not to have a significantly higher risk (Mallolas 2006, De Lazarri 2008). See 
also 1.8.2.1 Nevirapine (NVP). 
 
1.6.2 Mechanisms and clinical manifestation of hepatotoxicity 
There is no uniform and internationally accepted definition of clinical drug hepatotoxicity. But 
aminotransferase elevation reflecting hepatocellular injury is commonly used to define and monitor 
hepatotoxicity. 
 
Low-grade elevations of liver enzymes are frequent. They may occur under every ARV combination, but are 
mostly asymptomatic and resolve often spontaneously. Severe liver damage is reported in up to 10% of the 
cases (Price 2010), but liver failure is rare (Núñez 2005, Núñez 2010). Hepatotoxicity is associated with 
lactic acidosis, hepatic steatosis, myopathy, pancreatitis, peripheral neuropathy and lipoatrophy. Severe 
grades of ART-related hepatotoxicity may require discontinuation of the antiretrovirals, for example, when 
there is liver decompensation, hypersensitivity reaction or lactic acidosis. 
 
Hepatotoxic reactions may occur at different time points for different drug classes: NNRTIs often cause a 
hypersensitivity reaction within the first 12 weeks; NVP associated allergic and hepatotoxic reactions are 
described under 1.8.2.1 Nevirapine (NVP). 
NRTIs lead to hepatic steatosis (probably caused by mitochondrial toxicity) which usually occurs after more 
than 6 months on treatment (Montessori 2003). PIs can lead to hepatotoxicity at any stage during the 
course of treatment, most frequently in patients on boosted atazanavir, indinavir (IND) and tipranavir 
(Sulkowski 2004). There are case reports about liver failure on darunavir, IND, lopinavir, ritonavir, 
tipranavir, atazanavir, EFV, and nelfinavir (NLF). 
 
Drug induced liver injury may be caused by four mechanisms: Hypersensitivity reactions, mitochondrial 
toxicity, direct liver cell stress, and the immune reconstitution inflammatory syndrome (IRIS). 
 
Hypersensitivity reactions 
Hypersensitivity reactions are idiosyncratic reactions of the host, not related to the dose of the drug, and 
are immune-mediated. They are typical for NNRTIS, after all NVP, and for Abacavir (ABC), but also for some 
PIs and the CCR5-Inhibitor maraviroc and usually occur within the first 4-6 (-12) weeks of treatment. 
Hepatotoxic reactions are most frequent due hypersensitivity reactions under NVP. They occur normally in 
the first 18 weeks vary from asymptomatic aminotransferase elevations, skin rash to fatal liver failure. Fatal 
liver failure is not described for the administration of a single dose of NVP. Single-dose NVP is a scheme 
that was promoted for PMTCT; it is still used despite the existence of more effective regimens (Bjornsson 
2006) 
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Mitochondrial toxicity (see also 1.7) 
An unfortunate effect of NRTIs is the dose-dependent inhibition of the mitochondrial polymerase-gamma 
which may cause mitochondrial toxicities. Long-term mitochondrial toxicity may include lactic acidosis and 
hepatic steatosis which may evolve to acute liver failure and carry a high mortality. 
The most serious mitochondrial toxicities are lactic acidosis and pancreatitis. 
 
Direct liver cell stress 
PIs (boostered atazanavir, IND, tipranavir) may at any time cause a symptomatic hepatitis due to direct liver 
cell damage (Sulkowski 2004). 
 
Immune reconstitution inflammatory syndrome (IRIS) 
IRIS is associated with an increased cytolytic activity against liver cells infected by hepatitis virus and thus 
may cause liver damage. It mostly occurs in the first two months after initiating ART. 
 
1.6.3 Hepatotoxicity data from sub-Saharan Africa 
There are not many studies investigating ART induced hepatotoxicity in sub-Saharan cohorts. The results of 
these studies are sometimes difficult to interpret and compare because of a “large variability and a lack of 
standardization in the reporting of AEs” (Chowers 2009). Table 1 shows the characteristics and differences 
of available African literature (Sanne 2005, Hoffmann 2007, Weidle 2008, Chu 2010, Moore 2010, Ocama 
2010, Kalyesubula 2011, Ugiagbe 2012). 
Elevations of liver enzymes according to the grading of the AIDS Clinical Trials Group Criteria are generally 
used to monitor hepatotoxicity. Hepatotoxicity (or severe hepatotoxicity) is usually defined as a grade 3 or 
4 elevation in GOT (AST) or GPT(ALT); one study included also grade 2 in the definition of hepatotoxicity 
(Kalyesubula 2011). Sometimes the ULN is not defined. All studies are measuring GOT/GPT in biweekly to 
monthly rhythms up to three months, and then thereafter every 3 or 6 months. 
 
The studies look for early hepatotoxicity, i.e. in the first few months after initiating ART. The observed 
percentages of early occurring liver enzyme elevations vary from 1.0-2.0% (Chu 2010) to 17% in a NVP arm 
(Sanne 2005). This variability is most likely influenced by the different ART regimens used, especially the 
percentage of patients taking NVP-based combinations; also the duration of the observational period, that 
varies from 3 months (Sanne 2005) to 12 months (Hoffmann 2012), may contribute. 
 
The clinical impact of elevated liver enzymes is normally modest, unspecific, and cannot be easily attributed 
to hepatotoxicity. Among the observed clinical symptoms are rash, nausea/vomiting, abdominal pain and 
jaundice. But the data are conflicting: Two studies looked for jaundice but did not diagnose it (Moore 2010, 
Ugiagbe 2012), while Kalyesubula et al. identified jaundice as “the main differentiating physical sign 
between patients with no transaminitis in comparison to those with moderate to severe transaminitis” 
(Kalyesubula 2011). 
Similar to that, the identified risk factors for hepatotoxicity are varying from “no risk factor could be 
identified” (Chu 2010) to a considerable number of laboratory parameters (Sanne 2005). 
The variability in the clinical manifestations and the risk factors can be explained by the fact that in a trial 
only those facts and changes can be observed and identified for which the patients are screened. 
An interesting observation is that the authors draw different conclusions regarding the necessity of a 
frequent routine measurement of transaminases: Kalyesubula et al., Moore at al. and Chu et al. are skeptic 
whether frequent routine monitoring of GOT (AST)/GPT(ALT) should be recommended, while Sanne et al. 
and Ugiagbe et al. advocate clearly for it. 
 
Despite the differences in quality and the observed variability, some concrete conclusions can be drawn: 
 ART induced early liver toxicity grade 3-4 occurs in 1-17% of the patients. Most of the 
transaminases elevations are asymptomatic (94% according Ugiagbe 2012). The overall morbidity 
due to hepatotoxicity is minimal, but moderate to severe symptoms may occur. 
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 Monthly monitoring of GOT/GPT in the first three months of ART and afterwards trimonthly, in 
combination with a close monitoring of clinical symptoms, is recommendable. 
 Literature describes important risk factors for ART induced hepatotoxicity. According to the African 
literature especially patients in concurrent TB-treatment, with a low BMI (BMI<18,5) and in NVP-
based regimens must be observed closely. Three of the four first-line antituberculosis agents are 
known hepatotoxins: isoniazid, rifampicin, and pyrazinamide. 
 The data in resource limited settings, whether sex-dependent CD4 cell count is predictive of NVP-
associated hepatotoxicity, are conflicting. There are studies, also in pregnant women with higher 
CD4 cell counts, which do not prove this association (Sanne 2005).  
 
1.7 Mitochondrial toxicity 
NRTIs inhibit dose-dependent the mitochondrial polymerase-gamma (responsible enzyme for DNA 
synthesis). This may cause a mitochondrial RNA depletion and mitochondrial damage (Montessori 2003). 
Long-term mitochondrial toxicities include lactic acidosis, myopathy, pancreatitis, peripheral neuropathy, 
and lipoatrophy. 
Lactic acidosis and hepatic steatosis may develop into acute liver failure and carry a high mortality. Lactic 
acidosis is a very rare but life-threatening complication. Clinical manifestations of lactic acidosis may be 
intensified breathing and drowsiness. 
According data from the United States, approximately 0.1% to 0.4% of patients develop the syndrome of 
lactic acidosis; the incidence has been reported to be 1.3–3.9 cases per 1000 person-years (Ogedegbe 
2003).  
There are studies, all from South Africa, that report higher rates of lactic acidosis compared with rates in 
developed countries: incidence rate 19 cases per 1 000 person-years (Geddes 2006); incidence rate 10.6 
cases per 1000 patient-years (Bolhaar 2007); 2.0% developed moderate to severe symptomatic 
hyperlactatemia, with 1.0% diagnosed with lactic acidosis (Wester 2007). The higher incidences and rates in 
the South African studies may partially be explained by the fact that often more women participate in ART 
programs, also through PMTCT services, and the still widespread use of d4T. 
 
The onset of mitochondrial toxicity requires prolonged time: NRTI related lactic acidosis and hepatic 
steatosis occur usually after 6 months of ART. According to the data of Ogedegbe et al. the median duration 
of exposure to NRTIs was 9 months (range, 3–20 months). 
Female gender, pregnancy, NRTIs, prolonged ART duration, obesity, reduced creatinine clearance, and low 
baseline CD4 cell count have been shown to be risk factors for the development of lactic acidosis. 
Disturbances in lipid and sugar metabolism seem to contribute to the steatohepatitis syndrome. They can 
be caused by all or several members of the three antiretroviral classes NRTIs, NNRTIs and PIs (Barbaro 
2006). 
The role of each specific NRTI in the development of lactic acidosis is difficult to determine because the 
patients might have been exposed to several NRTIs. The dideoxynucleosides, the so-called “d-drugs” ddI, 
d4T and formally ddC (manufacturing and distribution of ddC was stopped in 2006) have the highest 
potential for mitochondrial toxicity with stronger ability to inhibit mitochondrial DNA synthesis in vitro and 
in vivo (Moyle 2002, Montessori 2003). The risk of lactic acidosis under AZT, ABC and 3TC is much less 
(Garrabou 2009). Lactate levels do not need to be monitored routinely, as increases are not predictive and 
may lead to unnecessary changes in treatment (Brinkman 2001). 
In the developed world cases of lactic acidosis with acute hepatitis and hepatic steatosis are likely in decline 
because d-drugs have been displaced by NRTIs that are less toxic for the mitochondria. The preferred NRTI 
combination currently includes tenofovir, which does not affect mitochondrial DNA content or level of 
mitochondrial enzymes in liver cells, and emtricitabine, which has a low potential for mitochondrial toxicity. 
In Africa d4T is still used, even if d4T based first line regimens are no longer a preferred first-line WHO 
option. The actual Malawian guidelines still recommend d4T as standard first line combination (Malawi 
Guidelines 2011). 
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1.8 Hematologic disorders, myelotoxicity 
HIV infection itself may cause pancytopenia. 30–40 % of untreated HIV-patients show an anemia, 
neutropenia or thrombopenia. Anemia is a key aspect in this thesis, because it is clinically the most relevant 
HIV- and ART-associated blood disorder and so of special relevance. 
 
1.8.1 Neutropenia 
Neutropenia may occur as a direct consequence of HIV infection or drug therapy. The frequency of 
neutropenia at some time during HIV infection is 20%–34% (Murphy 1987, Hermans 1995). Moderate 
reductions in neutrophil count are common in HIV infection, but they are rarely severe and rarely 
associated with infection. Most episodes of neutropenia are associated with concomitant potentially 
myelosuppressive drug therapy. Other causes of neutropenia in HIV infection include the presence of 
opportunistic infections or malignancies affecting bone marrow function, which was rare in this cohort, and 
the possible presence of HIV-related myelodysplasia. The duration of neutropenia is, in general, short 
(Moore 2001). Neutropenia occurs frequently in people with HIV infection but is associated with a 
(surprisingly) low complication rate (Moore 2000). 
Neutropenia is the most frequent side effect of cotrimoxazole in sub-Saharan African HIV-infected adults. It 
seems that neutropenia is more frequent in patients receiving cotrimoxazole in sub-Saharan African or 
American African adults than in Caucasian adults (Huët 2000). Moore et al. report that in a British cohort of 
HIV-positive patients, 62% of the patients who took Cotrimoxazole developed a neutropenia; 56% of 
patients under 3TC and 40% under AZT became neutropenic (Moore 2001). 
 
1.8.2 Anemia and HIV 
Persons with HIV infection or AIDS are more likely than the general population to develop anemia. Anemia 
is the most common hematologic abnormality in HIV infected persons. It has a significant impact on clinical 
outcomes and quality of life. Anemia may cause fatigue, tiredness, headache, exertional dyspnoea, 
tachycardia and vertigo.  
 
1.8.2.1 Prevalence 
In literature, the prevalence of anemia in HIV disease varies considerably. A systematic review reports a 
prevalence from 1.3% to 95%, depending on several factors like the stage of HIV disease, sex, age, 
pregnancy status, and injection-drug use as well as the definition of anemia used (Belperio 2004). Pooled 
data from 10 large European and North-American cohorts showed a prevalence of anemia of 35% of HIV-
positive patients before commencing ART: 25% had a mild anemia, 9 % a moderate and 1% a severe anemia 
(Harris 2008). 
Data from resource limited settings show higher rates of anemia in HIV-positive, still ART-naïve patients: In 
cohorts from Ethiopia, Tanzania and Nigeria 52.6% respectively 77.4% respectively 69.17% of ART-naïve 
patients where anemic (Adane 2012, Johannessen 2011, Omoregie 2009). Explanations are that patients 
from African settings have generally a more advanced immunodeficiency, and that the prevalence of 
anemia is higher also in the general HIV-negative population due to widespread micronutrient deficiencies 
and diet-related insufficient iron intake, the higher burden of infectious diseases like Malaria, TB and 
parasitosis, and higher prevalence of beta-thalassemia and sickle cell anemia. 
 
1.8.2.2 Pathogenesis, risk factors, management of HIV-related anemia 
The pathogenesis of HIV-associated anemia is complex and multifactorial. Anemia in patients with HIV can 
be related to anemia of chronic disease, malabsorption, insufficient dietary intake including general 
malnutrition, bleeding, haemolytic anemia (i.e. malignancies, infections, splenomegaly, and immune 
dysfunction), and changes in erythropoietin synthesis and/or bone marrow suppression. Suppression of the 
bone marrow in HIV-infected patients may be initiated in several ways. These include an action of HIV itself 
(infection of the progenitor of the red blood cell synthesis in late-stage disease), direct pathogenic 
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involvement of the bone marrow (neoplasms infiltrating the bone marrow, atypical mycobacteriosis), or 
myeolsuppressive drugs (cotrimoxazole, ganciclovir, pyrimethamine, AZT, cytostatic drugs). 
 
Risk factors are female gender, older age, advanced HIV infection (Harris 2008). In a Tanzanian cohort, 
female gender, clinical AIDS, TB, low BMI, were significantly associated with anemia (Johannessen 2011). 
Risk factors for anemia in a Rwandan cohort where lower body mass index, the use of AZT, lack of ART, and 
an advanced AIDS-disease with opportunistic diseases (oral candidiasis, pulmonary tuberculosis, 
cryptococcal meningitis, Pneumocystis jiroveci pneumonia) and a CD4 cell count under 200 cells/μL 
(Masaisa 2011). 
 
The management of anemia includes the correction of the underlying cause(s), blood transfusion or the 
administration of iron or erythropoietin. AZT must be discontinued in severe cases. Blood transfusion is the 
treatment of choice in acute or severe, symptomatic anemia, but may directly activate HIV expression and 
trigger transfusion-related immunosuppression. 
A Cochrane review provided evidence that erythropoietin “compared with placebo does not reduce 
mortality, does not reduce transfusion requirements, did not increase hemoglobin levels, and did not 
improve quality of life in HIV-infected patients with anemia. … Therefore prescription of this intervention 
for treating anemia in patients with AIDS is not justified“ (Martí-Carvajal 2011).  
The usually practiced treatment of anemia in sub-Saharan African health centers is iron substitution and/or 
AZT discontinuation. 
 
1.8.2.3 Malaria associated anemia 
Anemia is a common complication for all types of malaria. The majority of malarial infections are associated 
with some degree of anemia. During their blood stages of infection the Plasmodium species induce anemia. 
Malarial anemia is capable of causing severe morbidity and mortality especially in children and pregnant 
women infected with Plasmodium falciparum. The severity of malaria associated anemia depends upon 
patient-specific characteristics (age, innate and acquired resistance, co-morbidities etc.) as well as parasite-
specific characteristics (species, drug-resistance phenotype etc.). Plasmodium falciparum causes the most 
severe anemia, with a significant risk of death (Menendez 2000): Sheehy et al. report a mortality rate of 
severe malarial anemia of over 13% (Sheehy 2011); Haldar et al. say that “severe malarial anemia caused by 
P falciparum is responsible for approximately a third of the deaths associated with disease” (Haldar 2009). 
Malarial anemia is multi-factorial and caused by a variety of pathophysiologic mechanisms. It involves 
increased removal of circulating erythrocytes as well as decreased production of erythrocytes in the bone 
marrow (Haldar 2009.). It may be aggravated by co-morbidities like other parasitic infections, iron, folate 
and Vitamin B12 deficiency, or anemia associated with anti-malarial drugs (Ghosh 2007). 
 
1.8.2.4 Association between anemia and AIDS progression 
Anemia generally worsens with HIV disease progression. Studies from industrialized and developing 
countries show a strong, statistically significant and graded association of the severity of anemia 
respectively hemoglobin (HB)-levels with rates of progression to AIDS and death. The association of anemia 
with AIDS progression and mortality is independent of CD4 cell count or viral load (VL) at baseline and other 
prognostic factors for short- and long-term prognosis (Mocroft 1999, Etard 2006, Marazzi 2008, May 2010, 
Russel 2010), even in patients whose HB levels improved after the beginning of ART (Harris 2008). In the 
EuroSIDA cohort, patients with severe anemia at baseline had 13 times greater risk of death during the first 
year of ART than patients with normal hemoglobin levels (Mocroft 1999). In a cohort from Rwanda 
(Masaisa 2011), HB levels of HIV-negative patients did not differ from those of patients with asymptomatic 
HIV infection (8% vs. 9%). But a significant increase of the anemia prevalence in the different WHO HIV-
disease stages could be observed: The prevalence of anemia among HIV-positive patients by clinical HIV 
stage (I, II, III, and IV) was 9%, 26%, 40%, and 88%, respectively. 
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Some authors propose that HB could be considered as an “African parameter” for the decision when to 
start ART, additional to CD4 cell count and VL (Marazzi 2008), or in settings where VL or CD4 cell count are 
not available (Obirikorang 2009). 
Some studies express the increase of risk of death per 1g/dl reduction in HB with estimates ranging from 
14% to 57% increase in risk (Moyle 2002). But these data are conflicting. Harris et al. found that the 
relationship between disease progression and levels of HB is not linear (Harris 2008). 
It is uncertain whether the association between anemia and mortality is causal or whether anemia acts as a 
surrogate marker of underlying disease.  
 
1.8.2.5 Anemia and ART 
The use of ART is associated with a significant increase in HB concentrations and a decrease in the 
prevalence of anemia (Belperio 2004). Recovery from anemia reduces the risk of disease progression to 
approximately the same level as seen among patients who never had anemia. Data from both industrialized 
and developing countries show that HIV-associated anemia can be reversed by ART in the majority of 
individuals: The pooled data from 10 large European and North-American cohorts show that the prevalence 
of any type of anemia declined from 35% before starting ART to 26% after 6 months (Harris 2008). Cohorts 
from Tanzania, Rwanda and two from Uganda showed significant HB increases of 2.5g/dL after 12 months 
(Johanessen 2011) respectively 1.4 g/dl after 8 months (Masaisa 2011), 1.5g/dl after 12 months (Forna 
2009), and 2.9g/dL after 6 months (Kiragga 2010) in patients who started ART. 
 
But even if many patients who were anemic at the time of ART initiation had a significant HB increase over 
the initial 6 to 12 months of ART, more than one third of the patients did not reach normal HB levels while 
on ART (Johanessen 2011). According Johanessen et al., predictors of persistent anemia are a low mean cell 
volume (MCV) and an AZT-containing initial regimen. MCV is the diagnostic marker for microcytic anemia. 
Iron deficiency is the most common cause of microcytic anemia. 
 
1.8.2.6 AZT-associated anemia 
Even if ART in general tends to improve HIV-associated anemia and reduces the percentage of anemic 
patients, some ARVs may have a myelosuppressive effect and cause anemia. Because multiple drug 
combinations are standard today, it is difficult to identify the role of each drug in HIV-associated anemia. 
The potential of AZT to provoke anemia is well described. AZT is the ARV with the highest myelosuppressive 
potential. AZT-associated anemia is due to red cell hypoplasia or aplasia. AZT has been found to inhibit HB 
synthesis and globin gene transcription (Weidner 1992). 
 
5 to 10% of patients taking AZT develop anemia and granulocytopenia – usually during the first 3 months of 
therapy, but sometimes even after years of treatment (Carr 2001). Studies in industrialized countries 
comparing AZT-based regimens with non AZT-based combinations report higher anemia rates in the AZT-
arms. AZT-associated anemia grade 2-4 occurs in 5% of the patients within 48 weeks (AZT+3TC+EFV), in 
comparison to 2% in patients on ABC+3TC+EFV (de Jesus 2004) and <1% in patients taking TDF+FTC+EFV 
(Gallant 2006). More patients in the AZT+3TC-arm than in the TDF+FTC arm had adverse events resulting in 
discontinuation of ART (9% vs. 4%), with anemia as the leading reason (6% vs. 0%) (Gallant 2006). 
The increased risk of anemia associated with AZT has been well documented in the pre-ART era (Richman 
1987, Volberding 1990). Some authors presume that the detrimental effect of AZT in HB could be more 
modest in the context of ART combinations: Harris et al. report mean HB at 6 months 0.2g/dl lower in 
patients on regimens without AZT compared with patients on AZT-containing ART (Harris 2008), and 
Huttner and colleagues observed a difference of 0.5-0.8g/dl (Huttner 2007). 
AZT-associated anemia is more common in patients with more advanced HIV disease and possibly those 
receiving other myelosuppressive drugs.  
Tseng et al. (Tseng 1998) suggest that the combination of AZT/3TC could increase the risk of anemia, but 
this could not be confirmed by others (Harris 2008). 
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1.8.2.7 Literature from sub-Saharan Africa 
Found articles from sub-Saharan Africa show considerable differences in quality and methodology. Table 2 
shows the characteristics and differences of some African literature about anemia in HIV-positive patients 
(Moh 2005, Obirikorang 2009, Omoregie 2009, Johannesse 2011, Masaisa 2011, Ogoina 2012). These 
differences bias the comparison of data. As noted already regarding ART-induced hepatotoxicity, there is a 
big need to standardize the definition and grading of anemia (Chowers 2009). Also different follow-up 
periods and different, sometimes not even specified (Obirikorang 2009, Omoregie 2009, Masaisa 2011) ART 
regimens make a comparison of prevalence data nearly impossible: 
 While two studies use WHO definition of anemia with 4 grades (Moh 2005, Omoregie 2009), two 
studies distinguish only “anemic” and “non-anemic” (Obirikorang 2009, Masaisa 2011). One study does 
not use HB as diagnostic parameter to measure anemia but hematocrit (PCV) (Ogoina 2012). 
Given the strong and graded association of the severity of anemia with rates of progression to AIDS 
and death, a grading in four HB levels is necessary in order to get better information about the 
individual risk of anemic patients. 
 Future studies should report exactly the used ART combinations and stratify HB levels according to ART 
combinations. 
 
The available data confirm that there is a relatively high prevalence of anemia in HIV-positive Africans, and 
that ART has a positive effect on low HB levels and anemia prevalence. The influence of different ART 
combinations is not yet satisfactory clarified. AZT plays an important role, but more data about AZT-
associated anemia and its clinical implications in African settings are needed. Questions resulting from sub-
Saharan experiences should be answered: Do we need a special anemia grading for African populations? Do 
“African conditions” like low BMI, TB or Malaria influence prevalence and incidence of anemia? 
 
1.9 Antiretroviral drugs 
The actually approved antiretroviral drugs (ARVs) can be subdivided into five different classes: 
 Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
 Protease inhibitors (PIs) 
 Entry inhibitors (coreceptor antagonists and fusion inhibitors) 
 Integrase inhibitors 
 
Actual ART-guidelines from WHO and sub-Saharan African countries foresee only the use of NRTIs, NNRTIs 
and PIs. (Boostered) PIs are usually reserved for 2nd line combinations. 
In order to have more options for 1st line and 2nd combinations and to prepare future 3rd line and salvage 
combinations, there is urgent need to introduce modern PIs like darunavir, atazanavir and tipranavir, to 
increase the access to and availability of modern NRTIs (tenofovir, emtricitabine) and NNRTIs (etravirine, 
delavirdine, rilpivirine), and to insert Entry and Integrase inhibitors in the treatment possibilities. 
In short, the modernization of treatment options in African settings requires the following steps: 
 Realization of clinical trials to evaluate the significance of newer drugs in resource limited settings 
 Updating of national guidelines, in order to create the legal precondition to use more modern drugs 
 Creation of the necessary infrastructures for the production, trading and distribution of modern 
drugs. This means the establishment of the legal and commercial background through both the 
local governments and administrations and the pharmaceutical industry 
 Sufficient laboratory capacities 
 Financial security to implement modern ART combinations and to maintain the procurement of 
ARVs 
 
Below the main characteristics of ARVs drugs are summarized that are predominantly used in resource-
constrained regions and in the cohort of this thesis, focusing on adverse effects. 
 18 
1.9.1 Nucleoside reverse transcriptase inhibitors (NRTIs) 
The target of the nucleoside reverse transcriptase inhibitors (NRTIs), also referred to as nucleoside analogs 
(“nukes”), is the HIV enzyme reverse transcriptase. Acting as alternative substrates, they compete with 
physiological nucleosides, differing from those only in a minor modification in the ribose molecule. The 
incorporation of nucleoside analogs induces the abortion of DNA synthesis because phosphodiester bridges 
can no longer be built to stabilize the double strand. 
Nucleoside analogs are pro-drugs. They are converted to the active metabolite only after endocytosis by 
phosphorylation to triphosphate derivatives. Only this triphosphate is effective. 
 
1.9.1.1 Zidovudine (Azidothymidine, AZT) 
AZT is a synthetic thymidine analog (3-azido-3-deoxythymidine); the 3-hydroxy group of thymidine has 
been replaced by an azido group. AZT was first synthesized in 1964 as a potential anti-cancer agent, and its 
antiretroviral activity was discovered later. AZT was the first approved antiretroviral drug in 1987. 
AZT is a potent inhibitor of the in vitro replication and cytopathic effect of HIV. It interferes with retroviral 
DNA polymerase (reverse transcriptase) and inhibits viral replication. AZT is converted intracellularly into 
Zidovudine monophosphate, diphosphate and triphosphate. The triphosphate form interferes with reverse 
transcriptase thus inhibiting viral replication (Yarchoan 1986). The azido group substitution makes 
phosphodiester linkages impossible and terminates chain synthesis of DNA. HIV is 100 times more 
susceptible to inhibition by AZT than the DNA polymerase of mammalian cells (Elwell 1987, Furman 1986). 
 
Very early studies that tested AZT monotherapy, showed a significant survival benefit in very 
immunocompromised patients (Fischl 1987) or a significant reduction of the risk for progression (Fischl 
1990 a, Volberding 1990). Even at that time, it was becoming apparent that AZT monotherapy showed no 
long-term benefit but considerable myelotoxicity at higher doses (Fischl 1990 b). 
In the nineties, the combination of AZT and 3TC was one of the most frequently used backbones in HIV 
therapy. AZT has been tested in numerous clinical studies and offers more experience than any other 
antiretroviral agent. But many guidelines from developed countries do not list AZT as first line drug in 
treating naïve patients any more for several reasons: 
The Gilead 934 study showed the inferiority of AZT (+3TC+EFV) in comparison to TDF (+FTC+EFV): After 144 
weeks, fewer patients on AZT than on TDF had a viral load less than 400 copies/ml (58% vs. 71%) (Gallant 
2006). This difference was in large part attributed to the fact that more patients on AZT withdrew due to 
adverse events (11% vs. 5%), in particular severe AZT-associated anemia. AZT remains the most widely used 
myelosuppressive drug in HIV patients (see also 1.7.2.4 AZT-associated anemia). 
Other side effects leading to discontinuation were gastrointestinal complaints such as nausea, usually 
occurring within the first few weeks of treatment. Moreover, a significant reduction in fat tissue of the 
extremities while on AZT was observed (Arribas 2008). 
Another disadvantage is that AZT needs to be taken twice daily as opposed to most HIV compounds, 
thereby disqualifying it as being part of once-daily combinations. However, currently AZT remains a 
component of some ART regimens and transmission prophylaxes as it proves to be valuable especially with 
regard to resistance. Lack of neurotoxicity and a good CNS penetration are additional advantages. 
 
1.9.1.2 Stavudine (d4T) 
Stavudine is a synthetic thymidine nucleoside analogue (2',3'-dideoxynucleoside analogue). The chemical 
name of d4T is 2',3'-didehydro-2',3'-dideoxythymidine. It is structurally similar to other nucleoside 
analogues used in AIDS treatment such as AZT, ddI and zalcitabine (Sandstrom 1993). 
Like AZT, d4T enters cells via nonfacilitated diffusion and is subsequently phosphorylated by cellular 
enzymes to monophosphate, diphosphate, and triphosphate forms. d4T triphosphate is responsible for 
antiviral effects through potent and selective inhibition of HIV reverse transcriptase (Ho 1989, Sandstrom 
1993). AZT and d4T have similar affinity for human nuclear DNA polymerases (Zhu 1991). In vitro studies 
with a combination of d4T and AZT have demonstrated that AZT inhibits the phosphorylation of d4T, 
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whereas d4T has no effect on the phosphorylation of AZT (Ho 1989). This suggests that a clinical 
combination of these agents would offer no advantage over AZT alone. 
The in vitro activity of d4T is similar against HIV-1 and HIV-2. The drug has also shown activity against AZT-
resistant HIV-1. In contrast to AZT, d4T lacks significant activity against hepatitis B virus (Sandstrom 1993). 
d4T was the second thymidine analog to be introduced after AZT. It is just as effective as AZT (Spruance 
1997).Nowadays, d4T is hardly ever used in industrialized countries, mainly due to its long-term toxicities in 
comparison to other NRTIs. 
d4T is the NRTI that is most often associated with mitochondrial toxicity, which results in relatively high 
rates of peripheral neuropathy and lipoatrophy, as well as in lactic acidosis and pancreatitis (McComsey 
2004, John 2001, Shah 2003, Mauss 2002). Despite of many disadvantages and recommendations from 
WHO, d4T is unfortunately still a widely used ARV in resource limited settings. So the actual Malawian ART 
guidelines recommend as first-line combination for adults still d4T 30mg +3TC 150mg +NVP 200mg twice 
daily (Malawi Guidelines 2011). 
 
Peripheral neuropathy 
10% to 21% persons exposed to d4T developed peripheral neuropathy (Moyle 1998, Scarsella 2002). 
Although symptoms usually resolve after prompt discontinuation of d4T therapy, symptoms in a subset of 
patients may persist. In the DREAM Program patients with persisting d4t-associated peripheral neuropathy 
receive – depending on severity - analgesics for ten to fourteen days (diclofenac 50mg 2-3 times daily or 
ibuprofen 400mg 3x4 times daily) or pyridoxine 50-200 mg daily (or Vitamin B Complex if pyridoxine is not 
available) or amitriptyline 25 – 75 mg daily. Gabapentin 300 to 1200 mg taken three times daily did not 
show a clinical benefit and was no longer used after one year (it was expensive and difficult to find in 
Malawi and Mozambique). 
Studies from sub-Saharan Africa report peripheral neuropathy rates from 6.7% in 24 weeks in a cohort from 
Cameroon (Laurent 2004) to 56% in a Malawian cohort (van Oosterhout 2005). Possible explanations for 
this wide range may be e.g. short follow-up periods, different and insensitive screening tools; in the 
Malawian cohort only a fixed drug combination with 40mg d4T was available and, therefore, also used for 
patients with a body weight below 60kg.  
 
Lipodystrophy and metabolic complications 
The prevalence of d4T-associated lipodystrophy in western studies is 50%–63% (i.e. Bernasconi 2002). 
However, many of these studies included patients who also received protease inhibitors (PIs), which 
independently cause lipodystrophy. d4T associated lipodystrophy commonly presents as lipoatrophy (i.e., 
fat loss in the cheeks, arms, and buttocks). Although AZT may cause lipodystrophy, d4T is more strongly 
associated with it (van der Valk 2004). 
Risk factors for developing lipodystrophy are a low CD4 cell count before starting ART and a low BMI 
(Lichtenstein 2003). Also ethnic variability affects the incidence of lipodystrophy. White race may be an 
independent risk factor for the development of lipodystrophy (Mallal 2000, Lichtenstein 2003). 
In studies from developed countries, of all the NRTIs d4T has been most strongly associated with 
dyslipidemia and hyperglycemia. Numerous studies showed that substitution of d4T with other NRTIs, 
particularly ABC or TDF, had positive effects on lipoatrophy and other metabolic disorders (Carr 2002, 
Moyle 2003, Libre 2006). 
 
Lactic acidosis 
Although lactic acidosis is quite unusual, there are studies and case reports from developing countries that 
highlight concerns about timely diagnosis of life-threatening d4T-induced lactic acidosis (Geddes 2006, 
Bolhaar 2007, Wester 2007). See also 1.6 Mitochondrial toxicity. 
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1.9.1.3 Lamivudine (3TC) 
Lamivudine, also a synthetic dideoxynucleoside analogue, is the (-)-enantiomer of 2'-deoxy-3'-thiacytidine 
of racemic 2'-deoxy-3'-thiacytidine. It was chosen for clinical use because it has similar or greater in vitro 
activity against HIV types 1 and 2 than the (+)-enantiomer and is associated with a substantially lower 
degree of cytotoxicity (Lisignoli 1993). The (-)-enantiomer displays higher affinity for human 2'-
deoxycytidine kinase than the (+)-enantiomer (Shewach 1993) 
As with other nucleoside analogues, the mechanism of antiviral activity of 3TC is related to its conversion 
intracellularly to the 5'-triphosphate derivative, which inhibits HIV reverse transcriptase; this metabolite is 
also incorporated as a chain terminator (Cammack 1992, Sandstrom 1993). 
3TC was licensed in Europe in August 1996 as the fifth NRTI. It is generally well-tolerated and a component 
of many ART combinations. Its main disadvantage is its rapid development of resistance, and a single point 
mutation (M184V) is sufficient to compromise its effectiveness. Resistance is likely to develop already after 
only a few weeks (Eron 1995). But the M184V point mutation does have advantages: it improves the 
susceptibility of AZT-resistant viruses in some patients and impairs viral fitness. The reverse transcriptase 
substitution M184V is a fitness reducing NRTI resistance that reduces HIV replicative capacity by 
approximately 10%. There may be a therapeutic benefit continuing with 3TC as part of an ART combination 
in patients with resistant HIV-1 (e.g. in salvage therapy), despite the presence of M184V mutations and 3TC 
resistance. The aim is to conserve the M184V mutation and thus reduce the replicative capacity of HIV, 
especially when not all the other agents in the regimen are active (Miller 2002). 
The antiviral efficacy of 3TC is the same as that for FTC (Rousseau 2003, Benson 2004). Once-daily dosing is 
possible although the half-life of 3TC is less than that of FTC (DeJesus 2004). 
Another advantage of 3TC is its efficacy against hepatitis B viruses, useful in co-infected patients. 
 
1.9.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) were first described in 1990. As with the 
nucleoside analogs, the target enzyme is reverse transcriptase. However, NNRTIs bind directly and 
noncompetitively to the enzyme at a position near to but distinct from the substrate binding site for 
nucleosides. The resulting complex blocks the catalyst-activated binding site of the reverse transcriptase. 
This in turn can bind fewer nucleosides, slowing down polymerization significantly. In contrast to NRTIs, 
NNRTIs do not require intracellular phosphorylation for antiviral activity. The activity does not compete 
with template or nucleoside triphosphates. NNRTIs have no activity against reverse transcriptase from 
other retroviruses, including HIV-2, and are inactive against all four human DNA polymerases alpha, beta, 
gamma, or delta. 
Hypersensitivity reactions are typical for NNRTIs, not dose related and symptoms resolve usually after 
stopping the drug. They occur within the first 4 to 12 weeks (Joshi 2011). 
 
1.9.2.1 Nevirapine (NVP) 
NVP is a dipyridodiazepinone derivative, structurally similar to the benzodiazepines and tricyclic 
antidepressants (Hargrave 1991). It binds directly to HIV reverse transcriptase (RT) and blocks RNA-
dependent and DNA-dependent polymerase activities by causing disruption of the enzyme's catalytic site. 
NVP was the first licensed NNRTI in 1997. In early randomized studies NVP performed similar to indinavir 
(van Leeuwen 2003) and better than nelfinavir (Podzamczer 2002); more recent studies showed that the 
virological efficacy was comparable to boosted atazanavir (Soriano 2011) and to boosted lopinavir 
(McIntyre 2010). 
Once-daily dosing of NVP (400mg OD) is possible according to the pharmacokinetics of NVP. It is safe for 
patients with suppressed viraemia, and at least as efficient as NVP administered twice daily (2x200mg) (van 
Leth 2004, Calmy 2009). 
The risk that HIV-1 develops a resistance against NVP is high; the resistance can develop very rapidly. Once 
it occurs, it almost always indicates resistance to the entire class of NNRTIs. One point mutation (K103N) is 
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enough to eliminate the entire drug class. Resistance has even been described in mothers who took a single 
dose of NVP for the prevention of mother to child prevention (PMTCT) (Eshleman 2002). 
 
In the long run NVP is usually well-tolerated. Some studies showed favorable lipid changes compared to 
other drugs (Van der Valk 2001, van Leth 2004). Lipid profiles improved even when EFV was replaced by 
NVP (Parienti 2007). Whether these positive effects will have clinical relevance over time and really help to 
prevent cardiovascular events remains to be seen. 
Typical adverse effects of NVP are allergy manifesting in skin reactions (rash, Stevens-Johnson syndrome), 
and hepatotoxicity. 
 
NVP-associated allergic reactions 
NVP may cause a skin rash in 15 to 30% of the patients, leading to discontinuation in about 5% of the cases. 
Rash occurs less frequently during EFV and etravirine therapy, where patients discontinue the drug only 
rarely due to rash (Carr 2001).  
NVP associated allergic reaction is reversible and systemic, and occurs typically as an erythematous, 
maculopapular, pruritic and confluent rash, distributed mainly over the trunk and arms. Fever may precede 
the rash. Further symptoms include myalgia (sometimes severe), fatigue and mucosal ulceration. The 
allergy usually begins in the second or third week of treatment. Women are more often and more severely 
affected (Bersoff-Matcha 2001). Severe reactions such as Stevens Johnson Syndrome, toxic epidermal 
necrolysis (Lyell’s syndrome) or anicteric hepatitis are rare. 
A NVP-associated rash usually precedes evidence of liver damage and implies greater subsequent risk for 
the occurrence of hepatotoxicity In the case of an isolated rash or isolated transaminases elevation (up to 
severe=grade 3), treatment can be continued but, it is recommended to stop treatment if a rash occurs 
together with even a slight elevation of transaminases (>2- fold ULN). 
ART should be immediately discontinued when signs and symptoms of severe skin or hypersensitivity 
reactions develop (mucous membrane involvement, blisters, exfoliation, transaminases > 5 times the upper 
limit of normal or fever > 39°C). Approximately 50% of NNRTI allergies resolve with continuation of therapy. 
Antihistamines may be helpful. Prophylactic treatment with glucocorticosteroids or antihistamines has no 
protective effect (Montaner 2003, The Grupo Estudio 2004). Following a severe allergic reaction, the drug 
responsible for the reaction should never be given again. 
 
NVP-associated hepatotoxicity 
Liver toxicity occurs more often on NVP than on other antiretroviral drugs, typically within the first two 
months of treatment. Clinically asymptomatic and symptomatic liver toxicity, including rapidly occurring 
fatal liver failure have been observed (Bjornsson 2006). In clinical trials, mostly conducted in resource-rich 
countries, NVP- associated hepatotoxicity ranges from 8–18% (van Leth 2004, Stern 2003). A review of 
cohort studies from Western countries reports that around 10% of all NVP-treated patients developed 
elevated transaminases levels; almost two-thirds (6.3% of NVP-treated patients) of these elevations were 
asymptomatic, 4.9% were symptomatic (Dieterich 2004). 
NVP associated hepatotoxicity in Africa appears to be lower (1–2%) (Hahn 2007, Meyssonnier 2008, Calmy 
2006), although these studies may underrepresent the risk of hepatotoxicity because of limited 
transaminases monitoring (Chu 2010). 
Serious and fatal liver toxicity has been reported even during post-exposure prophylaxis (PEP), but not after 
single-dose NVP (McKoy 2009). Hepatic toxicity may occur even after several months. 
Symptomatic hepatotoxicity depends on different risk factors like female gender, a body mass index lower 
than 18.5 (Sanne 2005) or chronic hepatitis C (Torti 2007). 
 
There are conflicting data whether there is an increased risk of hepatic toxicity in patients with good 
immune status prior to initiation of ART: A retrospective analysis of the Boehringer Ingelheim database 
(Boehringer Ingelheim is the manufacturer of Viramune©, the original product of NVP tablets and NVP 
suspension) showed a higher risk for females with CD4 cell counts > 250 cells/μl and males with CD4 cell 
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counts > 400/μl. Women with CD4 cell counts above 250/μl have a 12-fold elevated risk (11% versus 0.9%). 
In men there is an increased risk above 400 cells/μl (6.3% versus 1.2%) (Sanne 2005, Kappelhoff 2005). 
Other studies could not confirm these findings (Manfredi 2006). If there is an increased risk, it seems to be 
particular to ART-naïve patients. Virologically suppressed patients switching to NVP do not seem to have a 
significantly higher risk (Mallolas 2006, De Lazarri 2008). Initiating NVP in antiretroviral-experienced 
patients with high CD4 cell counts was well tolerated provided that there is no detectable viremia 
(Kesselring 2009). For pregnant women, data are inconsistent. 
These findings lead to a special warning in the product information of Viramune© tablets and suspension 
not to give NVP to females with CD4 cell counts > 250 cells/μl and males with CD4 cell counts > 400/μl with 
a VL> 50 copies/ml.  
The actual WHO ART-Guidelines 2010 do not give the all-clear regarding the increased risk for patients with 
higher CD 4 counts, stating that “the panel found that there was limited evidence to cause concern but still 
urged caution in the use of NVP in women with CD4 cell counts of >250 cells/mm3 or in those with 
unknown CD4 cell counts. Close clinical monitoring (and laboratory monitoring if feasible) during the first 
12 weeks of therapy is recommended when NVP is initiated in women with a CD4 cell count of 250−350 
cells/mm3” (WHO Guidelines 2010). This is reflected in the national African guidelines. 
 
The incidence of NVP associated rash can be reduced through a desensitization regimen (Barreiro 2001). In 
the first 14 days after initiation of ART, the recommended starting dose for NVP is 200 mg daily. After the 
14-day lead-in period, the full dose of NVP 200mg twice daily can be taken. During the first three months 
on NVP-based ART, monthly monitoring of transaminases is recommended. 
 
1.9.2.2 Efavirenz (EFV) 
The benzoxazinone efavirenz acts through noncompetitive inhibition of HIV-1 reverse transcriptase.  
EFV was the third NNRTI to be approved, and the first for which it could be shown that NNRTIs were at least 
as effective as and maybe even better than PIs in untreated or only slightly treatment-experienced 
patients. In many guidelines, EFV is among the preferred first-line drugs for treating-naïve patients.  
EFV can be used once daily, is generally well tolerated but is more costly and currently in resource limited 
settings less widely available than NVP. 
Its primary toxicities are related to the central nervous system (CNS) and possible, but not proven 
teratogenicity, if received during the first trimester of pregnancy (but not in the second and third 
trimesters), and rash. Rash is generally mild and self-resolving and usually does not require the 
discontinuation of therapy. 
Neuropsychiatric disorders are the most concerning adverse effects associated with EFV with regard to 
tolerability and adherence. CNS side effects include dizziness and numbness, vivid dreams or nightmares. 
After four weeks of treatment with EFV, Fumaz and colleagues report, 66% of patients complaining about 
of dizziness, 48% of abnormal dreams, 37% of somnolence and 35% of insomnia (Fumaz 2002). The side 
effects probably correlate with high plasma levels (Marzolini 2001). EFV disrupts sleep architecture (Gallego 
2004). Black African patients in particular seem to have a genetic predisposition: due to a variant of hepatic 
enzyme CYP2B6 they may experience slower clearance of EFV from plasma and increased neurotoxicity 
(Haas 2004, Wyen 2008). Additional research clarifying the influence of ethnicity on EFV plasma levels may 
lead to dose adjustments, which may decrease rates of neurotoxicity in particular populations. 
 
While neurotoxic adverse effects typically resolve after 2−4 weeks, they can also persist for months. In such 
cases, EFV should be replaced. EFV should be avoided in patients with a history of severe psychiatric illness 
EFV is the NNRTI of choice in individuals with TB/HIV co-infection who are receiving rifampicin-based TB 
therapy.  
 
EFV is associated with teratogenicity, but data on EFV safety in first trimester pregnancy are conflicting. 
There is concern that EFV may increase the risk of central nervous system birth defects. Reports from 
animal studies and subsequent retrospective case reports of several human infants with first trimester 
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exposure to EFV who were born with neural tube defects (myelomeningocele), led the United States Food 
and Drug Administration (FDA) to classify EFV as a Class D drug (‘evidence of human fetal risk’) and 
recommend against using it during first trimester pregnancy. But data on EFV safety in first trimester 
pregnancy are conflicting. Prospective reports from the Antiretroviral Pregnancy Registry (Antiretroviral 
Pregnancy Registry Steering Committee 2009) and cohort studies (Townsend 2009, Ford 2011) have found 
no evidence of an increased incidence for overall congenital abnormalities among infants born to pregnant 
women who received EFV in the first trimester compared with rates among the general population. 
In June 2012, the WHO revised their recommendations about the use of EFV during early pregnancy (WHO 
2012. Technical update on treatment optimization) and made it possible to use EFV also during pregnancy: 
“Review of the available data and programmatic experience provides reassurance that exposure to EFV in 
early pregnancy has not resulted in increased birth defects or other significant toxicities. In addition, new 
evidence suggests that EFV is clinically superior to NVP, as it provides better long-term viral suppression, 
has fewer adverse events and less risk of resistance. Finally, the cost of EFV has decreased considerably, 
and it is now increasingly available as part of once-daily fixed-dose combinations. Based on the available 
data, program experience and a public health perspective, this interim guidance provides further support 
for the use of EFV as part of the World Health Organization (WHO) strategy to optimize and simplify first-
line treatment, including among pregnant women and those of reproductive age.” 
 
1.9.3 Comparison of AZT-vs. d4T and NVP- vs. EFV-based regimens 
In the following, in particular developments are described in the past editions of the ART guidelines and 
recommendations from WHO. Since the mandate of WHO is to design health recommendations, its 
guidelines are usually of notable relevance for developing countries and are observed and realized in the 
long run. In order to understand the choices of certain ARVs and ART regimens in African AIDS treatment 
guidelines, a short analysis of the evolution of first line combinations in the past editions of the WHO ART 
guidelines (WHO Guidelines 2002, 2003, 2006 and 2010) is necessary. 
 
1.9.3.1 Comparison of AZT- vs. d4T-based regimens 
Since the roll-out of ARV medicines in Sub-Saharan Africa countries began, the national African ART-
guidelines recommended a first-line ARV regimen consisting in 2 NRTIs and 1 NNRTI for all patients 
initiating ART. The class of protease inhibitors (PIs) should be reserved for second-line treatments. 
This was in accordance with the WHO guidelines that focused on first-line therapy with two NRTI and one 
NNRTI, simplified drug regimens with fixed-dose combinations, easy to use and to prescribe at the primary 
level by doctors and nurses. The first edition of the WHO ART-guidelines in 2002 had still recommended 
AZT/3TC/EFV or AZT/3TC/NVP (WHO Guidelines 2002) The second set of WHO guidelines, released in 2003, 
preferred d4T to AZT: “The choice between d4T and ZDV should be made at the country level on the basis 
of local considerations but it is recommended that both drugs be available. …. However, the initial need for 
less laboratory monitoring might, at present, favor d4T as the nucleoside of choice for the majority of 
patients in ART programs in settings with severe resource limitations where rapid scaling-up is intended.” 
(WHO Guidelines 2003). 
The third revision of the WHO guidelines in 2006 recognized the critical role of d4T-containing regimens 
due to its low cost, limited need for laboratory monitoring, initial tolerability and widespread availability. 
However, they recommended that countries should plan to move away from d4T. 
Since 2007 the WHO recommends to use d4T “at the dose of 30 mg twice daily for all adult and adolescent 
patients regardless of body weight” (WHO Addendum to 2006 guidelines) 
Only in the 2009 edition of the ART guidelines the WHO recommended to “progressively phase out the use 
of Stavudine as a preferred first-line therapy option and move to less toxic alternatives such as Zidovudine 
(AZT) and Tenofovir (TDF)” (WHO Rapid advice 2009). The WHO guidelines valid from 2010 recommend as 
first line combination finally only AZT- or TDF-based regimens: AZT or TDF + 3TC or FTC + EFV or NVP (WHO 
Guidelines 2010). The latest set of WHO guidelines state that “in resource-limited settings, d4T continues to 
play a critical role in the scaling up of ART, where approximately 56% of HIV regimens still contain d4T” 
despite knowledge of their toxicity profiles (WHO, UNAIDS and UNICEF, Progress report 2009). WHO 
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Guidelines 2010 recommend: “While progressive reduction in the use of d4T is occurring, it may be 
retained as an interim measure if plans are initiated to monitor and manage toxicity. In certain situations, 
d4T may be retained as a backup drug, such as when TDF and AZT are contraindicated.” 
Important reason for the continuing use of d4T are the quite low costs of fixed dose combinations with d4T 
compared to FDCs with AZT or TDF. 
Unfortunately boosted protease inhibitors continue to be preserved for second line combinations. 
 
The objectives of the thesis reflect points of this ongoing process about the definition of first-line regimens 
for resource-limited settings. Studies and guideline developing committees investigate and discuss the 
composition of the NRTI-backbone and the choice of the NNRTI, which is the significance of the NRTIs AZT, 
d4T and FTC/3TC and the NNRTIs NVP and EFV. The actual WHO ART Guidelines 2010 say that their 
“systematic review did not find any evidence from RCTs, non-randomized trials or observational studies 
from resource-limited settings that clearly indicated the superiority of regimens based on AZT, d4T or TDF 
or the superiority of either EFV or NVP, in triple-drug antiretroviral regimens for treatment-naive patients. 
… As current evidence suggests that the recommended regimens are comparable in terms of efficacy, 
countries should select one of them as the preferred option for most patients initiating ART, on the basis of 
factors related to acceptability and feasibility, such as: 
 numbers of individuals needing to start ART according to 2010 and 2015 targets; 
 numbers of individuals starting ART who have HIV/TB co-infection or chronic active HIV/HBV co-
infection; 
 anemia (due to malaria, malnutrition, intestinal parasites, repeated pregnancies or other causes); 
 pregnant women or women of reproductive age; 
 predicted expenditure per person needing ART (based on selected national start criteria); 
 availability of FDC; 
 in-country cost of the drug regimens; 
 decisions by countries on laboratory requirements to monitor toxicities; 
 training needs for the introduction and management of the regimens; 
 countries may need to use modeling to assist in decision-making” 
 
So the issue of drug induced toxicities is crucial in this decision process. Consequently this thesis respects 
two important aspects of ART in sub-Saharan Africa: 
 Up to now, the first line combinations in the period of enrolment are still mainly either d4T-based 
or AZT-based. Because of that the subjects of the cohort are stratified in patients using a d4T- or an 
AZT-based regimen. In addition to the NRTI-backbone usually an NNRTI is given, mainly NVP, but 
also EFV. 
 Among the most important adverse effects associated with the used ARVs are liver injury and 
myelotoxicity. Thus the evaluation of the “d4T-based” and “AZT-based arm” is focused on 
hepatotoxicity and anemia. 
 
1.9.3.2 Comparison of NVP- vs. EFV-based regimens 
In developed countries where various treatment options with comparable antiretroviral efficacy are 
available, the individualization of ART is practiced, that means that the most appropriate antiretroviral 
combination for an individual patient is chosen according to his personal characteristics, wishes and health 
conditions. For the choice of the first line regimen besides clinical efficacy also his life conditions are taken 
into account, the individual tolerability, the expected adherence, possible drug interactions and other 
personal risks. This means that there is no general valid “best third component” beneath the NRTI-
backbone. 
NNRTIs have an equal or superior antiretroviral potency compared to PI combinations, measured by the 
number of patients with viral load below the limit of detection. NNRTIs have performed well in numerous 
randomized studies: EFV-based regimens were superior to unboosted PIs such as indinavir or nelfinavir 
(Robbins 2003) and at least equivalent to lopinavir/r (Riddler 2003), atazanavir or raltegravir. 
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A disadvantage of NNRTI combinations is that HIV-resistance occurs faster on NNRTIs than on PIs, especially 
in patients with insufficient adherence, and the rapid development of cross-resistance between the 
different NNRTIS. This is due to the low resistance barrier of NNRTIS. Resistance upon virologic failure is 
generally more frequent on NNRTIs than on PIs (Gupta 2008). 
Especially in West African countries where HIV 2 is more diffused, it must be considered that NNRTIs are 
not active against HIV2. 
 
Relating to ART in developing countries, since the first edition of WHO guidelines in 2002, there is a 
discussion about the third component beneath the NRTI-backbone of first line regimens. Only the WHO 
Guidelines 2002 offered the possibility of boostered PIs or NFV as third component. The WHO Guidelines 
2002 and 2006 offered also the possibility of triple NRTI combinations with ABC (2002 and 2006) or TDF 
(2002), as alternative first-line regimens “in situations where NNRTI options provide additional 
complications (e.g. women who have CD4 counts between 250 and 350 cells/mm3, viral hepatitis 
coinfection, TB coinfection, severe reactions to NVP or EFV, and HIV-2 infection)” (WHO Guidelines 2006). 
The WHO Guidelines 2010 preserve PIs for second- line treatment. All WHO guidelines (2002, 2003, 2006, 
2010) offered the choice between the two NNRTIs NVP and EFV as third component. 
The actual ART guidelines in Mozambique and Malawi recommend NVP as preferred NNRTI component and 
EFV as alternative, especially for patients on concurrent TB treatment and pregnant women with higher 
CD4 cell counts after the first trimester (TDF 300mg +3TC 300mg +EFV 600mg). (Boostered) PIs are only 
intended for second line combinations. 
 
A systematic review of the WHO Guidelines 2010 “did not find any evidence from RCTs, non-randomized 
trials or observational studies from resource-limited settings that clearly indicated the superiority of … 
either EFV or NVP, in triple-drug antiretroviral regimens for treatment-naive patients. Six RCTs, which 
compared NVP to EFV, found no differences in efficacy (Ayala 2004, Manosuthi 2009, Nuñez 2002, Sow 
2006, van den Berg-Wolf 2008, van Leth 2004). One RCT reported that EFV was less likely than NVP to be 
associated with the development of antiretroviral resistance (van den Berg-Wolf 2008). The EFV toxicity 
review showed consistent reports of self-limiting or tolerable CNS adverse events and uncertainties about 
teratogenic risk in humans. In the important outcome (as distinct from the predetermined critical outcomes 
of mortality, disease progression and adverse events) of ARV resistance, EFV may be superior to NVP 
(Bannister 2008).” 
A review of the Cochrane Database of Systematic Reviews identified seven randomized controlled trials 
that compared EFV and NVP as part of a three-drug combination. This review also showed “that both drugs 
are equally effective in suppressing HIV infection but cause different side effects. Based on limited data, it 
appears that EFV is slightly less likely to cause side effects and more likely to prevent death than NVP” 
(Mbuagbaw 2010). 
More recent cohort data, however, suggest the clinical superiority of EFV over NVP in terms of suppression 
of viral load and length of time to treatment failure (Bock 2010, HIV-CAUSAL Collaboration 2012, Tang 
2012). In a modeling study, the potentially superior virological efficacy of EFV was translated into a 1.6-year 
life expectancy gain for women of childbearing age on EFV compared with those on NVP (Hsu 2011). 
 
In sub-Saharan Africa NVP was always the preferred NNRTI in first line regimens for adults and adolescents 
who had no limiting health conditions. In short, the reasons for the favored position of NVP or for opting 
for EFV can be summarized like that: 
 NVP is generally better available than EFV. 
 Since the first years of ART in sub-Saharan Africa, NVP is available in fixed-dose combinations that 
allow taking triple combinations in one tablet (both d4T+3TC+NVP and AZT+3TC+NVP). Only for a 
few years there have been EFV-containing fixed-dose combinations (TDF+3TC+EFV), which permit 
the even simpler once daily administration. 
 The costs for NVP containing combinations are generally lower than for EFV containing 
combinations. 
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 NVP is (still) the preferred NNRTI option in women of childbearing potential or who are pregnant 
because of the suspected teratogenicity of EFV. 
 EFV is the NNRTI of choice in patients with TB/HIV co-infection under rifampicin-based TB 
treatment. 
 NVP is associated with a higher incidence of rash, Stevens-Johnson syndrome, and hepatotoxicity 
compared to EFV (van Leth 2004), while EFV should be avoided in persons with a history of severe 
psychiatric illness, due to its CNS related side effects. 
 NVP may be inferior to EFV due to a higher risk in developing antiretroviral resistance (van den 
Berg-Wolf 2008). 
 
The actual trend seems to be that NVP is losing significance and EFV is used more frequently because of the 
increasing availability of fixed-dose combinations containing EFV that enable once daily administration, the 
decline of the costs for EFV, the actual WHO approval of EFV for pregnant women and those of 
reproductive age (WHO 2012. Technical update on treatment optimization), and the recent data about the 
clinical superiority of EFV over NVP. It is desirable that this development will soon be reflected in African 
ART guidelines. 
 
1.9.3.3 Recommendations for first-line ART regimens in Mozambique and Malawi 
In public health services in Mozambique and Malawi ARVs were first available in 2003, at the beginning 
only in few centers and for few patients. When the period of enrolment for the thesis started (01.01.2006), 
the national guidelines of Mozambique and Malawi recommended as first line regimen d4T+3TC+NVP 
(Malawi Guidelines 2003, Mozambique Guidelines 2006).  
Until 2007 the d4T dosages depended on the body weight: 
30mg d4T bid for patients less than 60kg 
40mg d4T bid for patients with 60kg and above 
 
In the case of intolerances or adverse effects the older local guidelines (Malawi Guidelines 2003, 
Mozambique Guidelines 2006) recommended switching to an alternative first line regimen (or to a second 
line combination): 
 In case of severe peripheral neuropathy due to d4T, d4T is replaced by AZT 
 In case of hepatotoxicities or severe skin reactions NVP is substituted by EFV  
 
Actual recommendations for first line regimen in Mozambique: 
Since June 2010 d4T is no longer recommended as starting combination for first line ART (but is only used 
as alternative first line combination) in Mozambique. Since then AZT is used as first line NRTI.  
 
As ART first line regimen for adults aged 15 years or older the actual ART guidelines recommend AZT 300mg 
+ 3TC 150mg + NVP 200mg twice daily. The alternative first line combination is d4T 30mg + 3TC 150mg + 
NVP 200mg. 
Pregnant women start ART with AZT 300mg + 3TC 150mg + NVP 200mg bid (HB>8g/dL) or d4T 30mg +3TC 
150mg +NVP 200mg bid (HB<8g/dL). The first line combination for patients on TB treatment or NVP 
intolerance is AZT 300mg +3TC 150mg +ABC 300mg bid (Mozambique Guidelines 2010/2011). 
 
Actual recommendations for first-line regimen in Malawi 
The actual set of the Malawian ART guidelines recommends as standard first-line combination for adults 
aged 15 years or older, who initiate ART, d4T 30mg + 3TC 150mg + NVP 200mg twice daily. Here the 
Malawian guidelines are not following the current WHO guidelines (WHO guidelines 2010). 
Children under 15 years should take AZT 300mg + 3TC 150mg + NVP 200mg as starting regimen. The 
recommended first-line starting combination for pregnant and lactating women and for adults on TB 
treatment is TDF 300mg + 3TC 300mg + EFV 600mg once daily (Malawi Guidelines 2011). 
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2. Objectives of the thesis 
The objective of this thesis is to evaluate characteristics of adverse effects in patients starting a first line 
regimen in sub-Sahara-African settings. The focus is on two of the most important ART related adverse 
effects, hepatotoxicity and anemia, in d4T-based and AZT-based regimens. 
The aim is to draw concrete conclusions from the cohort data collected under real-world conditions in real-
world settings, which help to implement medical services for people living with HIV/AIDS including ART in 
African settings. 
 
The relevant questions of this thesis concern 
A, Prevalence of hepatotoxicity and anemia: 
 Do d4T-based combinations induce more hepatotoxicity than AZT-based combinations? 
 Do NVP-based combinations induce more hepatotoxicity than EFV-based combinations? 
 Do AZT-based combinations induce more anemia than d4T-based combinations? 
 
B, Risk factors of hepatotoxicity and anemia: 
 Which risk factors for hepatotoxicity and anemia can be identified under d4T-based and AZT-based 
combinations? 
 Which differences between the risk factors for hepatotoxicity and anemia can be identified, each 
under d4T-based and AZT-based combinations? 
 
Accordingly the specific aims of the research are: 
A, Calculation and comparison of hepatotoxicity and anemia prevalence within a period of 12 months after 
the initiation of d4T-based and AZT-based ART regimens 
 
B, Identification and comparison of risk factors for hepatotoxicity and anemia within a period of 12 months 
after the initiation of d4T-based or AZT-based regimens, by analyzing the “d4T-based arm” and the “AZT-
based arm” according to the following potential risk factors: 
 Type of ART combination (d4T-based versus AZT-based regimen) 
 Immunological status (CD4 cell count) 
 Virological status (VL) 
 Nutritional status (BMI) 
 Choice of the NNRTI component beneath the NRTI backbone 
 Anemia 
 Sex  
 Malaria after the start of ART (only analyzed for anemia) 
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3. Methods 
3.1 Study Design 
The study design is a multicenter retrospective observational study. 
 
This thesis is an Operational Research within the Public Health Program DREAM. The data are not collected 
under conditions of a clinical trial, but in AIDS Treatment Centers that reflect the reality of African health 
centers and African patients. This thesis wants to find out which adverse effects can be observed under 
conditions of an “African reality”, in order to give a picture as realistic as possible. 
So the results and conclusions of this analysis are supposed to offer concrete facts and options for action 
that are useful for the medical staff of African health centers and AIDS-treatment sites. 
 
There is no control group of HIV-positive patients not yet on ART. This is due to the concept of the DREAM 
Program that is a program only for people living with HIV/AIDS, and can be considered as a limitation of the 
thesis. 
  
3.2 Study population 
The study population consists in HIV-1 infected adolescents and adults that are under assistance in four 
AIDS-treatment centers of the DREAM Program in Mozambique and in three DREAM centers in Malawi: 
 The centers in Mozambique are the Centro para a Criança (Maputo), in Machava (quarter of Matola 
near Maputo), in Benfica (quarter of Maputo), and in Manga Chingussura (quarter of Beira). 
 The Malawian centers are in Blantyre, Mthengo wa Ntenga (near Lilongwe) and Balaka. 
 
The DREAM Program is a Public Health Program under real-world conditions in real-world settings. There 
are no inclusion or exclusion criteria that may select sub-groups of the population. No HIV-positive patient 
is excluded a priori. Every person that decides to be tested for HIV is welcome and can receive medical 
assistance, if the result of the HIV test turns out to be positive. Because of that the cohort is very similar to 
the normal population found in African AIDS-Treatment Centers. 
 
The seven AIDS-treatment sites are all fully integrated in the respective national health-system. The 
Community of Sant’Egidio has specific agreements and memoranda with the Ministries of Health in 
Mozambique and Malawi that are regulating the implementation of centers for ART and all other activities, 
including operational research.  
 
3.3 Inclusion/exclusion criteria 
Patients that met the following criteria are enrolled: 
 HIV positive serostatus  
 Age 15 years or older  
 No pregnancy throughout the duration of the study period 
 ART-naïve patients with the indication to start ART according immunological, virological, clinical 
criteria 
 At least 12 months of follow-up after initiation of ART 
 
3.4 Enrolment and patient follow-up 
The period of enrolment was from 01.01.2006 to 31.08.2011. The period of Follow-up was 12 months 
starting from the day of enrolment (=initiation of ART). The follow-up ended on 31.08.2012. 
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3.5 DREAM treatment protocol for adults or children older than 6 years 
3.5.1 HIV antibody test and start of assistance 
Patients are self-referred or transferred from surrounding health institutions to the DREAM center. 
At the first visit, an HIV antibody test is performed. Before and after the HIV test the patients receive a pre-
test and a post-test counseling. In the case of a positive result of the HIV antibody test, the patient is 
invited in the post-test counseling to become a regular patient of the DREAM center, and to start the 
assistance. Normally the patients accept to start assistance. Immediately at the first visit, a patient file is 
opened, the personal data are inserted and a blood sample is taken in order to measure 
  Baseline biochemistry parameters 
  Baseline CD4 cell count 
  Baseline Plasma HIV RNA (VL, branched DNA) 
  Baseline BMI (if BMI<18.5 patients receive monthly nutritional support until a BMI value 
  above 18.6 will be reached) 
 
The patient continues assistance with fortnightly, later monthly and then three-monthly appointments until 
he has to start ART. 
 
3.5.2 Indications to start ART 
 WHO clinical stage 3 or 4 or 
 CD4 cell count less than 200 cells/µl or 
 CD4 cell count between 200 and 350 cells/µl and viral load higher than 55.000 copies/ml (until 
2008) respectively 100.000 copies/ml (since 2008). 
The protocol modification that patients with CD4 counts 200-350 cells/µl do start ART only at VL > 
100.000 copies/ml was implemented in the second half of 2008. 
 
3.5.3 Protocol after commencing ART during the 12 months of follow-up 
Start of ART Pre-ART parameters: CD4 cell count 
     Plasma HIV RNA (VL, branched DNA), if in the last 3 months  
     VL was measured this value is used as pre-ART VL 
     Biochemistry 
     Hemogram 
     BMI 
 
1 week  Medical check (done by a nurse) 
2 weeks Medical examination (done by a clinical officer or medical doctor), hemogram 
3 weeks Medical examination  
1 month Hemogram, transaminases, medical examination 
2 months Hemogram, transaminases, medical examination 
3 months CD4 cell count, hemogram, transaminases, medical examination 
6 months Hemogram, transaminases, medical examination 
  Until the end of 2010 also 6 months after ART initiation a CD4 cell count and a VL was  
  measured 
7 months Medical check 
9 months CD4 cell count, hemogram, transaminases, medical examination 
11 months Medical check 
1 year  VL, hemogram, biochemistry parameters 
13 months Medical examination 
  Evaluation of the therapeutic success: VL>50c/ml is considered as therapeutic failure 
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After 1 year CD4 cell count every 6 months (until end of 2010 every 3 months) 
  VL once a year (until end of 2010 every 6 months) 
  Hemogram every 3 months 
  Biochemistry parameters every 3 months 
 
The following laboratory tests are performed as a routine for all patients in the AIDS Centers of DREAM. 
The same techniques were used at all participating laboratories. The used instruments are described in 
table 3. 
 
Hemogram: White blood cell count (WBC) 
  Red blood cell count (RBC) 
  Hemoglobin (HB) 
  Platelet count, Thrombocytes (PLT) 
  Lymphocytes (LYM) 
 
Biochemistry: Albumin 
  Blood sugar, nonfasting (Glyc, nonfasting) 
  Creatinin 
  Direct Bilirubin, Conjugated Bilirubin (BILD) 
  Total Bilirubin (BILT) 
  GOT (AST) 
  GPT (ALT) 
 
3.5.4 Home based care 
An outreach program run by community activists and nurses provides patient support at home. Patients in 
precarious conditions get a home visit and, if the difficulties persist, are taken in home-based-care service: 
 patients with severe health problems (but not admitted to a hospital) 
 severely malnourished patients 
 patients with serious adherence problems 
 patients missing regularly appointments 
 
If there is no contact with the patient for more than 3 months he is declared as lost-to-follow-up (LTFU). 
 
3.6 ART regimens 
Two arms in the cohort with different antiretroviral first-line regimens are compared: 
d4T-based and AZT-based regimens, each in combination with another NRTI (usually 3TC) and a NNRTI 
(usually NVP, but also EFV). 
 
In the first month after ART initiation the patients receive from the pharmacy of the DREAM center a 
quantity of antiretroviral tablets sufficient for two weeks. After that they get tablets for 1 month 
(exceptions with quantities for 3-4 months are possible, for example because of long travels). 
 
d4T-based ART: 
d4T 30mg BID (until 2007 patients with a body weight > 60kg received 40mg BID) 
3TC 150mg BID 
NVP 200mg BID (the first 14 days are a lead-in period with only NVP 200mg OD) 
 
AZT-based ART: 
AZT 300mg BID 
3TC 150mg BID 
NVP 200mg BID (the first 14 days are a lead-in period with only NVP 200mg OD) 
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Sub-Sahara African countries usually use fixed dose combinations of two or three active ingredients. 
Virtually all products are Indian generics, produced in India from big manufacturers like Cipla Ltd. (Mumbai, 
India), Ranbaxy Ltd. (Gurgaon, India), Aurobindo Ltd. (Hyderabad, India), Hetero Drugs Ltd. (Hyderabad, 
India): 
d4T 30mg/3TC 150mg/NVP 200mg (i.e. Triomune 30©, Virolans © 
AZT 300mg/3TC 150mg/NVP (i.e. Duovir N©, Zidolam N©, Zidovex-LN©, Virocomb-N©) 
d4T 30mg/3TC 150mg + EFV 600mg 
AZT 300mg/3TC 150mg + EFV 600mg 
 
Usually only drugs that are prequalified from WHO (http://apps.who.int/prequal/), this means that fulfill 
unified standards of good quality and safety, are distributed by the governmental distributors. 
 
3.7 Laboratory evaluations 
For the evaluations during the 12 months follow-up after initiation of ART the following laboratory 
parameters were used: 
A, CD4 cell count: Pre-ART 
 
B, Plasma HIV RNA (VL): Pre-ART 
 
C, HB:   Pre-ART 
   1, 2, and 3 months after initiation of ART 
   Thereafter every 3 months 
 
D, GOT:   Pre-ART 
   1, 2, and 3 months after initiation of ART 
   Thereafter every 3 months 
 
As pre-ART parameters the latest parameters were taken that have been measured prior to the initiation of 
ART (parameters measured several weeks before the commencement of ART until the starting day of ART). 
The values at month 1, 2, 3, 6, 9, 12 have been measured in these spaces of time: 
Month 1: 28 days after initiation ART, 14 days before and 14 days after that date 
Month 2: 56 days (8 weeks) after initiation ART, 14 days before and 14 days after that date 
Month 3: 84 days (12 weeks) after initiation ART, 14 days before, 30 days after that date 
Month 6: 168 days (24 weeks) after initiation ART, 30 days before and 30 days after that date 
Month 9: 252 days (36 weeks) after initiation ART, 30 days before and 30 days after  
Month 12: 336 days (48 weeks) after initiation ART, 30 days before and 30 days after that date 
 
3.8 Classification of adverse effects 
In this thesis abnormal laboratory findings were graded according to the AIDS Clinical Trials Group Division 
of AIDS, Table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; 
Clarification August 2009 
(www.mtnstopshiv.org/sites/default/files/attachments/DAIDS_AE_GradingTable_ClarificationAug2009_Fin
al_[1].pdf; accessed 16 September 2012). See Table 4, Grading of laboratory parameters measured in the 
DREAM Program. 
The table of the AIDS Clinical Trials Group Division of AIDS was chosen for this thesis because it is widely 
used in the literature about ARV related toxicities. It does not distinguish between patients living in 
developed and developing settings or between Africans and Caucasian, but it was used in the researches 
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for the actual ART guidelines of WHO (WHO Guidelines 2010) in order to define the criteria for “serious 
adverse events”. 
 
Hepatotoxicity was defined as 
Mild and moderate hepatotoxicity (grade 1+2) GOT 1.1-5.0 U/l x ULN Males 62.5-250 U/l 
Females 44-175 U/l 
Severe and potentially life threatening 
hepatotoxicity (grade 3+4) 
GOT >5.1 U/l x ULN Males > 250 U/l 
Females > 175 U/l 
 
Anemia was defined as 
Mild and moderate anemia (grade 1+2) HB 7.5-10.0 g/dl 
Severe and potentially life threatening anemia 
(grade 3+4) 
HB < 7.5 g/dl 
 
For reasons of clarity of the statistical evaluation, grades 1+2 and 3+4 of abnormal hepatotoxicity and 
anemia parameters were combined. 
 
3.9 Analysis of prevalence of hepatotoxicity and anemia under d4T-and AZT-based combinations 
Laboratory parameters indicating hepatotoxicity (GOT) and anemia (HB) were analyzed through 
 comparison of hepatotoxicity and anemia prevalence under d4T-based and AZT-based 
combinations and the 
 identification of statistically significant risk factors for increase of hepatotoxicity and anemia 
prevalence in d4T-based and AZT-based regimens 
 
For the analysis the cohort was stratified in two arms with patients whose initiating ART regimen was d4T-
based (“d4T-based arm”) or AZT-based (“AZT-based arm”). 
 
The analysis was carried out in two ways: 
A, Comparison of hepatotoxicity and anemia prevalence, and identification of risk factors for prevalence 
increase in patients without pre-ART hepatotoxicity respectively pre-ART anemia under d4T-based and AZT-
based combinations (chapter 4.2). Only patients without hepatotoxicity respectively anemia before the 
start of ART were included in order to show directly ART-associated effects. The evaluation was done by 
univariate and multivariate analysis. 
 
B, Comparison of hepatotoxicity and anemia prevalence, and identification of risk factors for prevalence 
increase separately in the “d4T-based” and the “AZT-based arm” by univariate analysis (chapter 4.3). In 
these analyses all patients of the cohort (patients with and without pre-ART hepatotoxicity and anemia) 
were included in order to identify risk factors in a “real world” cohort typical for African settings. 
 
Among the most important risk factors described in literature for developing hepatotoxicity and anemia are 
 
Risk factors for hepatotoxicity 
 Good immune status prior to initiation of ART (females: CD4 cell count > 250 cells/μl; males: CD4 
cell count > 400/μl) (Sanne 2005, Kappelhoff 2005) 
 High VL before start of ART (Núñez 2001, Wit 2002, Servoss 2006, Kovari 2010) 
 Use of NVP (e.g. Bjornsson 2006, van Leth 2004, Stern 2003, Dieterich 2004) 
 Low BMI (Sanne 2005) or increased BMI (Núñez 2001, Wit 2002, Servoss 2006, Kovari 2010) 
 Female sex (Núñez 2001, Wit 2002, Servoss 2006, Kovari 2010) 
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Risk factors for anemia 
 Advanced AIDS-disease (low CD4 cell count, increased VL) (Harris 2008, Masaisa 2011) 
 Low BMI (Johannessen 2011, Masaisa 2011) 
 Use of AZT (e.g. Richman 1987, Volberding 1990, Carr 2001, de Jesus 2004, Gallant 2006) 
 Anemia before the initiation of ART 
 Malaria (Menendez 2000, Ghosh 2007, Haldar 2009, Sheehy 2011) 
 
According to that, rates of patients with hepatotoxicity and anemia (prevalence) in the “d4T-based arm” 
and the “AZT-based arm” were analyzed in different ways concerning the following risk factors (pre-ART 
parameters): 
 
Pre- ART parameters, potential risk factors Subgroups (see chapter 4.3) 
Type of ART combination d4T-based vs. AZT-based arm  
Low or medium or high CD4 
cell count 
CD4<250 cells/μl vs. 
CD4 251-399 cells/μl vs. 
CD4>400 cells/μl 
Subgroup “CD4 pre-ART” 
Increased VL VL<100,000 copies/ml vs. 
VL>100,000 copies/ml 
Subgroup “VL pre-ART” 
Use of NVP NVP-containing vs. EFV-containing 
regimen 
Subgroup “NNRTI” 
Low or high BMI BMI<18.5 vs. BMI>18.5 Subgroup “malnutrition pre-ART” 
Low HB HB<7.5 g/dl vs. HB 7.5-10 g/dl Subgroup “anemia pre-ART” 
Sex (only multivariate analysis 
of hepatotoxicity) 
Female vs. male sex  
Malaria events after the start 
of ART (only multivariate 
analysis of anemia) 
“No malaria after the start of ART” vs. “at 
least once malaria after the start of ART 
(cumulative malaria)” 
 
Table 5. Analyzed risk factors (pre-ART parameters) 
 
3.10 Statistical analysis 
SPSS v.Win 19.0 (SPSS Inc., Chicago, Illinois, USA) was used for statistical data analysis. Relative risk (RR) 
ninety-five percent confidence intervals and p-values were calculated. To assess the impact of risk factors 
on the development of hepatotoxicity and anemia in the “d4T-based” and “AZT-based arm”, data were 
dichotomized according to pre-ART CD4 cell counts, VL, BMI and HB in order to generate relative risks for 
each strata. 
 
The software of the DREAM Program is designed for HIV care and can be used in Portuguese, Italian, 
English, and French. It includes a comprehensive patient registration and arrival/flow system and utilizes 
form-based templates. The software is able to manage the social and medical data of each individual 
patient. Medical diagnoses are listed based on ICD-9/10 codes in both short and comprehensive lists.  
Furthermore, the DREAM software connects the clinical department, the pharmacy and the laboratory in a 
data network: 
 It permits the clinical staff to have immediate access to the necessary clinical data of each patient and 
to easily review his clinical history. 
 Prescriptions and drug supplies to the patients are linked with a register of available stocks, 
consumptions and inventories. 
 It provides an electronic system for requests of laboratory parameters and the saving of these values. 
DREAM software is able to create reports based on patient demographics, ICD codes, and prescriptions 
and supplies of drugs and nutritional support. 
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 It assists the administrative, pharmaceutical and laboratory staff in the procurement of drugs and 
laboratory reagents via the creation of data of actual stocks and consumptions of the products. 
 
This network and the quick access to the patient data reduces paperwork and facilitates the analysis of data 
for the daily work of the staff of the AIDS Center, and in the creation of data and statistics for clinical trials. 
The data for this thesis are analyzed in a blinded fashion with removal of patient names. 
 
 
Figure 3. Form for the prescription of laboratory parameters 
(DREAM Software, Copyright 2002-2020, Community of Sant’Egidio) 
 
 
Figure 4. Form with laboratory parameters, patient with the internal ID number BF002242 
(DREAM Software, Copyright 2002-2020, Community of Sant’Egidio) 
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Figure 5. “Dashboard”: Form with the most important parameters at a glance 
(DREAM Software, Copyright 2002-2020, Community of Sant’Egidio) 
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4. Results 
4.1 Description of the cohort 
Computerized data of all HIV-positive, ART-naïve, non-pregnant patients older than 15 years, who started 
ART in four Mozambican and three Malawian centers run by the DREAM program, was retrospectively 
evaluated. The follow-up period was 12 months and started at the day of the initiation of ART. The cohort 
consists of 10,567 patients, 6824 (64.6%) of them are female and 3743 (35.4%) male. 
The 10,567 patients were stratified in patients on a d4T-based regimen (“d4T-based arm”, n= 8231, 77.9%), 
on an AZT-based regimen (“AZT-based arm”, n= 2306, 21.8%) and on other, non-d4T/AZT-based, regimens 
(n= 30, 0.3%). The 30 patients on non-d4T/AZT-based combinations were excluded from further evaluations 
because of the small number. They took the following combinations: 14 patients TDF+3TC+EFV, 7 
TDF+3TC+LPVr, 4 TDF+3TC+NVP, 2 ABC+3TC+NVP, 1 ABC+3TC+EFV, 1 TDF+ABC+LPVr, and 1 TDF+ABC+NVP  
While the majority of patients at the four Mozambican AIDS-treatment centers come from urban settings, 
two of the three Malawian centers are located in very rural settings (Mthengo wa Ntenga and Balaka). Even 
though the social conditions and educational levels of the patients were not used as parameters in the 
study, it should be considered that most of the patients are from low social classes, are mainly poor and do 
have a low educational level, no matter whether they are living in urban slums or rural settlements. 
 
As pre-ART parameters were available CD4 cell counts of 8711 patients (82.4%), VL of 7952 patients 
(75.3%), BMI of 6659 patients (63.0%), and HB of 9131 patients (86.4%). GOT pre-ART values were available 
from 8381 patients (79.3%), among them 1302 (grade 1+2: 1273; grade 3+4: 29) in the “d4T-based arm” 
and 251 (grade 1+2: 242; grade 3+4: 9) in the “AZT-based arm”. 
The average pre-ART values of the cohort were CD4 cell count 217 cells/μl, VL 92,552 copies/ml, BMI 20.9, 
GOT 38.6 U/l and HB 10.9 g/dl. 
 
To 10,297 patients (97.4%) was prescribed a NNRTI as third component of the starting ART combinations. 
Among them 10,043 (97.5%) started a NVP-containing and 254 (2.5%) an EFV-containing combination. 270 
patients did not take a NNRTI additional to the NRTI-backbone: 210 of them took ABC, 25 IND, 30 LPVr, 3 
NLF and 2 TDF as third component. ddI was prescribed to 1 patient instead of 3TC (AZT+ddI+LPVr). 
The very low number of patients, which initiated with EFV as NNRTI, unfortunately hampered a statistically 
valid comparison of NVP vs. EFV as potential risk factors for increased hepatotoxicity and anemia 
prevalence. 
 
More details of the cohort are shown in tables 6 and 7. 
 
CD4 count VL BMI GOT HB 
< 250 5402 (62.0%) < 100,000 5737 (72.1%) < 18.5 2035 (30.6%) Non-
pathologic 
6828 (81.5%) Non-
pathologic 
5922 (64.9%) 
251 - 399 2662 (30.6%) > 100,000 2215 (27.9%) > 18.5 4624 (69.4%) Grade 1+2 1515 (18.1%) Grade 1+2 2599 (28.5%) 
> 400 647 (7.4%)     Grade 3+4 38 (0.5%) Grade 3+4 610 (6.7%) 
Total 8711 (82.4%)  7952 (75.3%)  6659 (63.0%)  8381 (79.3%)  9131 (86.4%) 
Table 7. Available pre-ART values in the cohort 
 
4.2 Comparison of ART-associated hepatotoxicity and anemia prevalence, and identification of 
       risk factors for prevalence increase  
 
As described in literature, general hepatotoxicity prevalence is elevated in sub-Sahara settings because liver 
enzyme elevations are quite frequent due to multiple reasons (pre-existing liver dysfunction, coinfection 
with hepatitis B, C or D, parasitosis, concurrent administration of hepatotoxic drugs, alcohol abuse and 
other reasons). Anemia prevalence is higher too compared to developed countries because of the 
 37 
widespread malnutrition, insufficient iron intake, Malaria, TB and parasitosis, beta-thalassemia, sickle cell 
anemia and other reasons. 
 
In the following, hepatotoxicity and anemia prevalence under d4T-based and AZT-based combinations are 
compared, and statistically significant risk factors for prevalence increase in patients without pre-ART 
hepatotoxicity respectively pre-ART anemia are identified. In order to identify as correctly as possible the 
influence of the ART regimen on the development of hepatotoxicity and anemia prevalence, only patients 
were included in this research who did not have increased GOT and HB values before starting ART and in 
that way the increased “background” hepatotoxicity and anemia was deducted. Hence only prevalence of 
ART-associated hepatotoxicity and anemia was analyzed. 
The research was done both with univariate and multivariate analysis: 
The univariate analysis was made with the variable “d4T-based” vs. “AZT-based arm”. The following 
variables were included in the multivariate analysis: 
 
Pre- ART parameter, potential risk factor Variables 
Type of ART combination  d4T- vs. AZT based arm 
Low or medium or high CD4 cell count CD4<250 cells/μl vs. 
CD4 251-399 cells/μl vs 
CD4>400 cells/μl 
Increased VL VL<100.000 copies/ml vs. 
VL>100.000 copies/ml 
Low or high BMI BMI<18,5 vs. BMI>18,5 
Low HB HB<7,5 vs. 
HB 7,5-10.0 vs. 
HB >10,0 
Sex (only analyzed for hepatotoxicity) Female sex vs. male sex 
Malaria events after the start of ART 
(only analyzed for anemia) 
“no malaria after the start of ART” vs. 
“at least once malaria after the start 
of ART (cumulative malaria)” 
Table 8. Variables of the multivariate analysis 
 
4.2.1 Malaria prevalence during the 12 months follow-up 
Malaria infection by Plasmodium species is associated with a reduction in HB levels, frequently leading to 
anemia (see 1.8.2.3 Malaria associated anemia). 
The prevalence of malaria during the 12 months follow-up shows that malaria is a frequent disease in the 
cohort. A considerable effect of malaria in developing anemia can be assumed (see 1.8.2.5 Malaria 
associated anemia). Because of that, the impact of malaria associated anemia was considered in the 
multivariate analysis of anemia prevalence. 
 
 Prevalence of malaria 
in the cohort 
Month 1 5.5% 
Month 2 1.7% 
Month 3 1.5% 
Month 6 2.9% 
Month 9 2.4% 
Month 12 1.6% 
Table 9. Malaria prevalence 
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4.2.2 Comparison of ART-associated hepatotoxicity prevalence in the d4T- and AZT-based arm 
The prevalence of mild and moderate elevated GOT values (hepatotoxicity grade 1+2) before starting ART 
in the complete cohort was 18.1% (1515/8386). The prevalence of severe and potentially life-threatening 
GOT elevations (hepatotoxicity grade 3+4) before the commencement of ART was low and amounted to 
0.5% (38/8386). 
 
4.2.2.1 Univariate analysis of ART-associated hepatotoxicity prevalence 
The rates of hepatotoxicity grade 1+2 declined from 13.5% after the first month to 10.8% after 3 months, 
peaked in month 6, and remained at 9.6% in month 9 and 10.0% in month 12. The peak in month 6 is due 
to an exceptional high prevalence in the “d4T-based arm" in month 6. 
The rate of hepatotoxicity 3+4 decreased from 2.0% in month 1 to 0.8% in month 2, and remained at a low 
level below 1% until month 12. 
For the complete 12-months follow-up period, the prevalence of hepatotoxicity grade 1+2 was higher in the 
“d4T-based” than in the “AZT-based arm”. The prevalence of hepatotoxicity grade 1+2 was higher in the 
“d4T-based arm” between 3.1% (month 12) and 5.5% (month 1 and 9) than in the “AZT-based arm” (the 
high prevalence in the d4T-base arm in month 6 is probably an outlier). Even 12 months after the initiation 
of ART the rate of GOT-elevations grade 1+2 in both arms was still quite high (d4T-based arm: 10.7%, AZT-
based arm: 7.6%), and it would be interesting to check whether the prevalence would continue to decrease 
also during the second year of ART. 
In both arms the rates of hepatotoxicity grade 3+4 descended quickly in the first 2 to 3 months and then 
remained at low levels (0.2%-0.5%). A general higher prevalence due to d4T could not be confirmed; on the 
contrary the prevalence after 1, 2, 9 and 12 months was slightly higher in the “AZT-based arm”. The 
differences were not statistically significant. 
The prevalence of both hepatotoxicity strata in month 12 were lower than before starting ART. This could 
be related to an improvement of the general health condition, AIDS-disease or coinfections like TB. 
 
 
Figure 6 (see table 10 for data) 
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Figure 7 (see table 10 for data) 
 
During all months of the follow-up a d4T-based combination was a statistically significant risk factor for 
higher prevalence of hepatotoxicity grade 1+2 compared to AZT-based combinations. d4T-based 
combinations were in no month a statistically significant risk factor for higher prevalence of hepatotoxicity 
grade 3+4 compared to AZT-based combinations: 
 
 Hepatotoxicity grade 1+2 Hepatotoxicity grade 3+4 
Month 1 RR 1.06, CI 95%: 1.04-1.09 Non-significant 
Month 2 RR 1.05, CI 95%: 1.03-1.08 Non-significant 
Month 3 RR 1.06, CI 95%: 1.04-1.08 Non-significant 
Month 6 RR 1.13, CI 95%: 1.10-1.15 Non-significant 
Month 9 RR 1.06, CI 95%: 1.03-1.09 Non-significant 
Month 12 RR 1.04, CI 95%: 1.01-1.07 Non-significant 
Table 11. Relative risks for increased prevalence of ART-associated hepatotoxicity 1+2: AZT-based vs. d4T-
     based combinations 
     Relative risks for increased prevalence of ART- associated hepatotoxicity 3+4: AZT-based vs.  d4T-
     based combinations 
 
4.2.2.2 Multivariate analysis of ART-associated hepatotoxicity prevalence 
4.2.2.2.1 Prevalence of ART-associated hepatotoxicity 1+2 
The multivariate analysis showed these statistically significant, independent risk or protective factors for 
increased prevalence of ART-associated hepatotoxicity 1+2: 
 
Month 1 d4T- vs. AZT based RR 1.68, CI 95%: 1.23-2.29, p=0.001 
Pre-ART BMI  RR 0.78, CI 95%: 0.61-0.99, p=0.040 
Female vs. male  RR 1.59, CI 95%: 1.26-1.99, p=0.000 
Month 2 d4T- vs. AZT based RR 1.58, CI 95%: 1.07-2.34, p=0.021 
Pre-ART BMI  RR 0.64, CI 95%: 0.48-0.85, p=0.002 
Pre-ART HB >10 g/dL RR 1.31, CI 95%: 1.06-1.60, p=0.010 
Female vs. male  RR 1.92, CI 95%: 1.44-2.55, p=0.000 
Month 3 d4T- vs. AZT based RR 2.11, CI 95%: 1.43-3.11, p=0.000 
Pre-ART BMI  RR 0.68, CI 95%: 0.52-0.88, p=0.003 
Pre-ART HB >10 g/dL RR 1.22, CI 95%: 1.02-1.47, p=0.033 
Female vs. male  RR 1.92, CI 95%: 1.48-2.49, p=0.000 
Month 6 d4T- vs. AZT based RR 4.27, CI 95%: 2.73-6.69, p=0.000 
Female vs. male  RR 2.25, CI 95%: 1.75-2.88, p=0.000 
Month 9 d4T- vs. AZT based RR 2.53, CI 95%: 1.57-4.07, p=0.000 
Month 12 Female vs. male  RR 2.02, CI 95%: 1.40-2.91, p=0.000 
Table 12. Multivariate analysis of risk factors for increased hepatotoxicity 1+2 prevalence 
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Female sex was statistically significant associated with increased risk for higher hepatotoxicity prevalence 
1+2 until month 12 compared to male sex, and being on a d4T-based regimen until month 9 compared to 
AZT-based combinations. 
Not being malnourished (BMI>18.5) before the start of ART was a statistically significant protective factor 
against higher hepatotoxicity 1+2 prevalence until month 3, and being anemic (HB<10 g/dl) before the start 
of ART was a statistically significant risk factor also until month 3. The factors “d4T-based combination”, 
“pre-ART BMI”, “pre-ART HB” and “female sex” are independently associated with the risk of increased 
hepatotoxicity 1+2 prevalence. 
It must be noted that during the follow-up in the multivariate analysis the pre-ART CD4 count and pre-ART 
VL were at no point statistically significant associated with increased hepatotoxicity 1+2 prevalence. 
 
4.2.2.2.2 Prevalence of ART-associated hepatotoxicity 3+4 
The multivariate analysis could not find statistically significant associations between hepatotoxicity 3+4 
prevalence and the variables during the 12 months follow-up. Severe or life-threatening hepatotoxicities 
are rare events, the rates of hepatotoxicity 3+4 were <1% in month 3 and later. 
 
4.2.3 Comparison of ART-associated anemia prevalence in the d4T- and AZT-based arm 
Before starting ART the prevalence of mild and moderately decreased HB values (anemia grade 1+2) was 
32.5% (3052/6403) in the complete cohort. The prevalence of severely and potentially life-threatening 
decreased HB values (anemia grade 3+4) was 7.4% (699/9403). Even if data from other trials about this 
topic cannot easily be compared due to different anemia definitions and study designs, our data seem to be 
quite consistent with other studies from developing countries (Marazzi 2008, Masaisa 2011, Ogoina 2012). 
 
4.2.3.1 Univariate analysis of ART-associated anemia prevalence 
The rate of anemic patients grade 1+2 (who were not anemic before starting ART) was 13.5% after 1 
month. The pre-ART prevalence was 32.5%; this confirms that there is a high “background anemia” in HIV-
positive persons who have not yet started ART. The prevalence decreased during the complete 12 months 
follow-up and reached 3.0% after 12 months. The rate of anemia grade 3+4 decreased continuously too 
from 3.2% in month 1 until 0.5% in month 12; it remained below 1% from month 6 to 12. This confirms the 
expected quick and permanent association of ART with recovery from anemia and decrease of anemia rates 
(Belperio 2004, Harris 2008, Forna 2009, Kiragga 2010, Johanessen 2011, Masaisa 2011). 
 
During the complete follow-up anemia 1+2 prevalence was higher in the “AZT-based arm” than in the “d4T-
based arm”. Anemia 3+4 prevalence was increased in the “AZT-based arm” compared to the “d4T-based 
arm” in all months except for month 1 (3.1% vs. 3.2%). This confirms the expected anemia inducing effect 
of AZT.  
 
 
Figure 8 (see table 13 for data) 
 41 
 
Figure 9 (see table 13 for data) 
 
In the univariate analysis an AZT-based combination was a statistically significant risk factor for higher 
prevalence of anemia grade 1+2 during all months of the follow-up, and in month 2, 3 and 6 for higher 
prevalence of anemia grade 3+4, compared to d4T-based combinations: 
 
 Anemia grade 1+2 Anemia grade 3+4 
Month 1 RR 1.49, CI 95%: 1.27-1.75 Non-significant 
Month 2 RR 2.23, CI 95%: 1.80-2.77 RR 1.88, CI 95%: 1.25-2.83 
Month 3 RR 2.06, CI 95%: 1.64-2.59 RR 3.02, CI 95%: 2.01-4.55 
Month 6 RR 1.58, CI 95%: 1.17-2.14 RR 3.00, CI 95%: 1.70-5.29 
Month 9 RR 1.69, CI 95%: 1.18-2.44 Non-significant 
Month 12 RR 2.49, CI 95%: 1.58-3.95 Non-significant 
Table 14. Relative risks for increased prevalence of ART-associated anemia 1+2 (only patients with pre-ART 
     HB>10g/dL): AZT-based vs. d4T-based combinations 
     Relative risks for increased prevalence of ART- associated anemia 3+4 (only patients with pre-ART 
     HB>7.5 g/dL): AZT-based vs. d4T-based combinations 
 
4.2.3.2 Multivariate analysis of ART-associated anemia prevalence 
4.2.3.2.1 Prevalence of ART-associated anemia 1+2 
Statistically significant, independent risk factors for increased prevalence of ART-associated anemia 1+2 
were the following according to the multivariate analysis: 
 
Month 1 d4T- vs. AZT based RR 1.89, CI 95%: 1.50-2.39, p=0.000 
Pre-ART VL  RR 1.32, CI 95%: 1.05-1.66, p=0.016 
Pre-ART BMI  RR 0.58, CI 95%: 0.46-0.72, p=0.000 
Malaria (cumulative) RR 1.81, CI 95%: 1.20-2.73, p=0.005 
Month 2 Pre-ART BMI  RR 0.65, CI 95%: 0.46-0.91, p=0.011 
Malaria (cumulative) RR 2.87, CI 95%: 2.07-3.99, p=0.000 
Month 3 Malaria (cumulative) RR 2.53, CI 95%: 1.79-3.56, p=0.000 
Month 6 Malaria (cumulative) RR 2.01, CI 95%: 1.29-3.13, p=0.002 
Month 9 Malaria (cumulative) RR 2.05, CI 95%: 1.20-3.51, p=0.009 
Month 12 Malaria (cumulative) RR 2.15, CI 95%: 1.25-3.68, p=0.005 
Table 15. Multivariate analysis of risk factors for increased anemia 1+2 prevalence 
 
The fact of having had malaria at least once after the initiation of ART was a statistically significant risk 
factor for an increased prevalence of anemia 1+2 in all months of the follow-up, always more than 2 fold 
except month 1. Hence cumulative malaria was the most important independent risk factor. A good 
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nutritional status (BMI>18.5) was a statistically significant protective factor against increased prevalence of 
anemia 1+2 in month 1 and 2. Receiving an AZT-based combination and a high VL before starting ART 
(VL>100.000 c/ml) were statistically significant risk factors only in the first two months. 
The factors “AZT-based combination”, “pre-ART BMI”, “pre-ART VL” and “cumulative malaria” are 
independently associated with the risk of increased anemia 1+2 prevalence. 
As in the case of hepatotoxicity 1+2 prevalence, pre-ART CD4 count was never statistically significant 
associated with increased anemia 1+2 prevalence and a high pre-ART VL only in the first month of follow-
up. 
 
4.2.3.2.2 Prevalence of ART-associated anemia 3+4 
This multivariate analysis included patients without pre-ART anemia and also with pre-ART anemia 1+2. The 
following statistically significant, independent risk factors for increased prevalence of ART-associated 
anemia 3+4 were identified: 
 
Month 1 No statistically significant factors 
Month 2 d4T- vs. AZT based RR 3.03, CI 95%: 1.73-5.30, p=0.000 
Pre-ART BMI  RR 0.45, CI 95%: 0.26-0.76, p=0.003 
Pre-ART HB >7.5 g/dL RR 0.18, CI 95%: 0.11-0.32, p=0.000 
Malaria (cumulative) RR 3.40, CI 95%: 1.13-10.25, p=0.030 
Month 3 d4T- vs. AZT based RR 2.56, CI 95%: 1.34-4.87, p=0.004 
Pre-ART HB >7.5 g/dL RR 0.19, CI 95%: 0.10-0.34, p=0.000 
Month 6 d4T- vs. AZT based RR 4.51, CI 95%: 1.91-10.64, p=0.001 
Pre-ART HB >7.5 g/dL RR 0.22, CI 95%: 0.92-0.50, p=0.000 
Malaria (cumulative) RR 3.11, CI 95%: 1.51-6.41, p=0.002 
Month 9 No statistically significant factors 
Month 12 No statistically significant factors 
Table 16. Multivariate analysis of risk factors for increased anemia 3+4 prevalence 
 
Only in month 2, 3 and 6 statistically significant, independent factors could be identified. An AZT-based 
combination was in month 2, 3 and 6 a statistically significant risk factor for increased anemia 3+4 
prevalence. A pre-ART anemia 1+2 and cumulative malaria after the start of ART were in two months 
(month 2, 3 respectively 2, 6) statistically significant associated with increased anemia 3+4 prevalence, 
whilst a pre-ART BMI>18.5 protected against higher anemia 3+4 prevalence in months 2 and 3. Cumulative 
malaria increased anemia 3+4 prevalence in month 2 and 6 more than 3 fold, an AZT-based regimen in 
month 2, 3, and 6 between 2.56 and 4.51 fold. 
Not being anemic or having only anemia 1+2 before the initiation of ART (pre-ART HB >7.5 g/dL) was a 
statistically significant protective factor against increased anemia 3+4. This “protective effect” can be 
explained with the fact that patients with anemia 3+4 had been filtered out before the analysis; the 
“significant protection” means that non or mildly to moderately anemic patients developed less anemia 
3+4 during ART than patients with anemia 3+4. In fact a significant protective effect of pre-ART anemia 
could not be observed in the univariate analyis of the subgroup “anemia pre-ART” that included also 
patients with anemia before the start of anemia (but in this analysis also a risk-enhancing effect could not 
be observed). 
 
Multivariate analysis confirms the role played by AZT-based combination in the development of anemia 3+4 
until six months after the beginning of ART. 
The factors “AZT-based combination”, “pre-ART BMI”, “pre-ART HB” and “cumulative malaria” are 
independently associated with the risk of increased anemia 1+2 prevalence. 
Like in the other multivariate analysis, pre-ART CD4 count pre-ART VL were not statistically significant 
associated with increased anemia 3+4 prevalence. 
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4.3 Comparison of overall hepatotoxicity and anemia prevalence and identification of risk  
        factors for prevalence increase separately in the d4T- and AZT- based arm 
 
In order to identify and compare the risk factors “low/high CD4 cell count”, “high VL”, “low BMI”, “NVP-
containing combination” and “low HB” and their influence on prevalence in d4T-based and AZT-based 
regimens during the 12 months follow-up, the “d4T-“ and “AZT-based arm” were stratified into the five 
subgroups “CD4 pre-ART”, “VL pre-ART”, “NNRTI”, “malnutrition pre-ART” and “anemia pre-ART” (see 3.9 
and tables 6 and 7). In these analyses all patients of the cohort (patients with and without pre-ART 
hepatotoxicity and anemia) were included in order to identify risk factors in a “real world” cohort typical for 
African settings. 
In the following, statistically significant factors for increased risk or protection against hepatotoxicity and 
anemia prevalence are identified separately in the “d4T-based” and the “AZT-based arm” by univariate 
analysis (see table 17). Hepatotoxicity and anemia prevalence under d4T-based and AZT-based 
combinations are compared in the five subgroups. 
 
4.3.1 Subgroup “CD4 pre-ART” 
4.3.1.1 Evaluation of hepatotoxicity prevalence in the d4T-based and the AZT-based arm 
During the 12 months follow-up, GOT values were available from 21.5% (month 9) to 81.1% (pre-ART) of 
the patients in the subgroup “CD4 pre-ART” of the “d4T-based arm”, and in the “AZT-based arm” from 
29.3% (month 12) to 71.2% (pre-ART). 
 
Pre-ART prevalence of hepatotoxicity grade 1+2 differed between the three CD4 strata. Patients with low 
CD4 cell count (CD4<250 cells/µl) before starting ART had the highest average prevalence, while average 
prevalence of less immunosuppressed patients was lower: 
Average pre-ART prevalence of hepatotoxicity grade 1+2: 22.0% (pre-ART CD4<250 cells/μl) 
        11.8% (pre-ART CD4 251-399 cells/μl) 
        9.1% (pre-ART CD4>400 cells/μl) 
 
Average pre-ART prevalence of hepatotoxicity grade 3+4: 0.7% (pre-ART CD4<250 cells/μl) 
        0.3% (pre-ART CD4 251-399 cells/μl) 
        0.3% (pre-ART CD4>400 cells/μl) 
 
In both arms the prevalence of hepatotoxicity 1+2 and 3+4 usually increased in month 1 (only in the “AZT-
based arm” in the pre-ART CD4>400 stratum hepatotoxicity grade 3+4 peaked in month 2). Interestingly in 
the groups of patients with low CD4 count rates, hepatotoxicity grade 1+2 prevalence (and also in the 
group with CD4 251-399 cells/µl in the “AZT-based arm”) did not peak but descended immediately from the 
pre-ART maximum. This shows that in both arms shortly after initiation of ART hepatotoxicity increased, 
mostly grades 3+4 and in the “d4T-based arm”. 
In all three CD4 strata in both arms the rates of hepatotoxicity 1+2 and 3+4 declined during follow-up. 
Despite the reduction of hepatotoxicity grade 1+2 and 3+4 during the follow-up, the rates were always 
higher in the “d4T-basd arm”. The prevalence reduction of hepatotoxicity grade 1+2 was less in the “d4T-
based arm”. 
In the “d4T-based arm” the average prevalence of hepatotoxicity grade 1+2 in the CD4 strata after 12 
months was 14.3% and in the “AZT-based arm” 9.2%. It would be interesting to check whether the rates 
would continue to decrease in the second year of ART. 
The univariate analysis identified only once a higher CD4 cell count as a statistically significant risk factor for 
higher prevalence of hepatotoxicity: In the “d4T-based arm”, pre-ART CD4 251-399 cells/µl increased 
statistically significant in month 1 1.01-fold the risk of increased hepatotoxicity grade 3+4 prevalence in 
comparison to CD4<250 cells/µl (CI 95%: 1.00-1.03). 
 
Summary: The pre-ART prevalence of hepatotoxicity grade 1+2 and 3+4 were higher in patients with 
CD4<250 cells/µl (22.0% and 0.7%) than in less immunosuppressed patients. In most CD4 strata in both 
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arms the prevalence of hepatotoxicity grade 1+2 and 3+4 increased in month 1 or 2, but hepatotoxicity 
grade 1+2 prevalence did not increase in highly immunosuppressed patients (CD4<250) whose background 
liver enzyme elevation had already been particularly high before starting ART. 
In general the hepatotoxicity prevalence decreased during follow-up, but prevalence of hepatotoxicity 
grade 1+2 was always higher in the “d4T-based arm” than in the “AZT-based arm”. 
In the “d4T-based arm”, pre-ART CD4 251-399 cells/µl was a statistically significant risk factor for increased 
hepatotoxicity grade 3+4 in month 1. At no other month a higher pre-ART CD4 cell count was a statistically 
significant risk factor. 
 
 
Figure 10 (see table 18 for data) 
 
 
Figure 11 (see table 19 for data) 
 
4.3.1.2 Evaluation of anemia in the “d4T-based” and the “AZT-based arm” 
In the “d4T-based arm”, HB values were available from 34.3% to 71.2% of the patients, and in the “AZT-
based arm” from 31.4% (month 12) to 83.8% (pre-ART). 
 
Pre-ART prevalence of anemia grade 1+2 and 3+4 differed between the three CD4 strata. Patients with low 
CD4 cell count (CD4<250 cells/µl) before starting ART had the highest average, while prevalence in less 
immunosuppressed patients was lower: 
Average pre-ART prevalence of anemia grade 1+2: 30.8% (pre-ART CD4<250 cells/μl) 
       21.9% (pre-ART CD4 251-399 cells/μl) 
       27.8% (pre-ART CD4>400 cells/μl) 
 
Average pre-ART prevalence of anemia grade 3+4: 6.2% (pre-ART CD4<250 cells/μl) 
       2.4% (pre-ART CD4 251-399 cells/μl) 
       3.4% (pre-ART CD4>400 cells/μl) 
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In the “AZT-based arm” in all three CD4 strata prevalence of anemia 1+2 and 3+4 increased after 1 month 
and declined during the follow-up. In the “d4T-based arm” prevalence of anemia grade 1+2 and 3+4 peaked 
only in the group with high CD4 counts (>400 cells/µl). This shows the anemia inducing effect of AZT shortly 
after the start of ART. 
In both arms and in all three CD4 strata the rates of anemia grade 1+2 and 3+4 declined due to the general 
anemia reducing effect of ART. But prevalence of anemia grade 1+2 was always higher in the “AZT-based 
arm” during the complete follow-up after initiation of ART, with highest prevalence for patients with 
CD4<250 cells/µl. This was less pronounced for anemia grade 3+4. 
In the “d4T-based arm” the average prevalence of anemia grade 1+2 was 7.6% after 12 months and in the 
“AZT-based arm” 9.6%. It would be interesting to check whether the rates would continue to decrease in 
the second year of ART. 
 
Summary: The average pre-ART prevalence of anemia grade 1+2 and 3+4 was higher in patients with 
CD4<250 cells/µl (30.8% and 6.2%) than in less immunosuppressed patients. 
In the “AZT-based arm” in all three CD4 strata the prevalence of anemia 1+2 and 3+4 peaked in month 1 
and declined during the follow-up. There was a general decrease of anemia prevalence in both arms and all 
pre-ART CD4 strata, but anemia grade 1+2 rates were always higher in the “AZT-based arm”. Rates of 
anemia grade 1+2 were higher in patients with CD4<250 cells/µl than in less immunosuppressed patients. 
At no measuring point pre-ART CD4 251-399 cells/µl or CD4>400 cells/µl were statistically significant risk 
factors for higher anemia prevalence. 
The data show that AZT-based combinations induce higher anemia grade 1+2 and 3+4 prevalence than d4T-
based combination. 
 
 
Figure 12 (see table 20 for data) 
 
 
Figure 13 (see table 21 for data) 
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4.3.2 Subgroup “VL pre-ART” 
4.3.2.1 Evaluation of hepatotoxicity in the “d4T-based” and the “AZT-based arm” 
In the “d4T-based arm”, GOT values were available from 19.4% (month 9) to 74.6% (pre-ART) of the 
patients, and in the “AZT-based arm” from 26.3% (month 12) to 62.1% (pre-ART). 
 
Pre-ART prevalence of hepatotoxicity grade 1+2 differed between the VL strata. Average pre-ART 
prevalence of hepatotoxicity 1+2 and 3+4 were higher in both arms in patients with high pre-ART VL 
(VL>100.000 copies/ml) than in patients with lower pre-ART VL: 
Average pre-ART prevalence of hepatotoxicity grade 1+2: 
 27.2% (pre-ART VL>100.000 copies/ml) 
 13.6% (pre-ART VL<100.000 copies/ml) 
 
Average pre-ART prevalence of hepatotoxicity grade 3+4: 
 0.7% (pre-ART VL>100.000 copies/ml) 
 0.4% (pre-ART VL<100.000 copies/ml) 
 
The typical elevation of GOT shortly after starting ART could be observed in both arms. In the groups with 
VL<100.000 copies/ml prevalence of hepatotoxicity grade 1+2 and 3+4 peaked in both arms in month 1, 
and in the group with high VL only the rates of grade 3+4 hepatotoxicity (month 1). 
The rates of hepatotoxicity grade 1+2 and 3+4 decreased during follow-up. But rates of hepatotoxicity 
grade 1+2 remained higher during nearly the complete follow-up for patients with high VL (except of the 
rates after month 9 and 12 in the “AZT-based arm”). The prevalence of hepatotoxicity grade 1+2 was also 
always higher in the “d4T-based arm”. This could not be observed to such an extent for hepatotoxicity 
grade 3+4. 
In the “d4T-based arm” the average prevalence of hepatotoxicity grade 1+2 after 12 months was 14.4% and 
in the “AZT-based arm” 7.2%. It would be interesting to check whether the rates would continue to 
decrease in the second year of ART. 
 
A pre-ART VL>100.000 copies/ml was a statistically significant risk factor for increased hepatotoxicity 1+2 
prevalence only in the “d4T-based arm” in month 1, 2 and 3 in comparison to VL<100.000 copies/ml: 
 
/ = No statistically significant factor. For complete list of RRs see table 17 
 AZT-based arm d4T-based arm 
 Hepatotoxicity 1+2 Hepatotoxicity 3+4 Hepatotoxicity 1+2 Hepatotoxicity 3+4 
Month 1 / / RR 1.04, CI 95%: 1.01-1.08 / 
Month 2 / / RR 1.03, CI 95%: 1.00-1.07 / 
Month 3 / / RR 1.04, CI 95%: 1.01-1.07 / 
 
In the “AZT-based arm” or regarding hepatotoxicity grade 3+4 prevalence in the “d4t-based arm”, a high 
pre-ART VL was never a statistically significant risk factor. 
 
Summary: The average pre-ART prevalence of hepatotoxicity grade 1+2 and 3+4 was higher in patients with 
VL>100.000 copies/ml (27.2% and 0.7%) than in patients with lower VL. Prevalence of hepatotoxicity grade 
1+2 was higher in patients with high VL than with low VL and in patients in the “d4T-based arm” in 
comparison to the “AZT-based arm”. The results were less pronounced for hepatotoxicity grade 3+4, 
probably due to the low number of patients with hepatotoxicity grade 3+4.  
A high VL before starting ART increased statistically significant only in the first 3 month of d4T-based 
combination the risk for increased hepatotoxicity grade 1+2 prevalence (never in the “AZT-based arm” and 
regarding hepatotoxicitiy 3+4 in the “d4T-based arm”). 
The data show the hepatotoxicity inducing effect of d4T in comparison to AZT especially a few months after 
starting ART in patients with high VL. 
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Figure 14 (see table 22 for data) 
 
 
Figure 15 (see table 23 for data) 
 
4.3.2.2 Evaluation of anemia in the “d4T-based” and the “AZT-based arm” 
In the “d4T-based arm”, HB values were available from 31.6% to 76.9% (pre-ART) % of the patients, and in 
the “AZT-based arm” from 28.3% (month 12) to 64.8% (pre-ART). 
 
Pre-ART prevalence of anemia grade 1+2 and 3+4 differed between the pre-ART VL strata. Pre-ART anemia 
prevalence (all grades) was higher in patients with high pre-ART VL (VL>100.000 copies/ml) than in patients 
with lower pre-ART VL: 
Average pre-ART prevalence of anemia grade 1+2: 
 33.5% (pre-ART VL>100.000 copies/ml) 
 24.9% (pre-ART VL<100.000 copies/ml) 
 
Average pre-ART prevalence of anemia grade 3+4: 
 6.6% (pre-ART VL>100.000 copies/ml) 
 3.9% (pre-ART VL<100.000 copies/ml) 
 
In the “AZT-based arm” in both VL strata prevalence of anemia 1+2 and 3+4 increased after 1 or 2 months 
and declined during the follow-up. In the “d4T-based arm” prevalence of anemia grade 1+2 peaked only in 
the group with low VL. This shows the anemia inducing effect of AZT shortly after the start of ART. 
In both arms and in all VL strata the rates of anemia grade 1+2 and 3+4 declined due to the general anemia 
reducing effect of ART. But prevalence of anemia grade 1+2 and 3+4 was always higher in the “AZT-based 
arm” during the complete follow-up after initiation of ART.  
 
In the first months of ART the prevalence of anemia grade 1+2 and 3+4 was higher for patients with high 
pre-ART VL. In the “d4T-based arm” the rates of anemia (all grades) were no longer higher for high pre-ART 
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VL after month 3, whilst in the “AZT-based arm” this effect could be observed later on (month 9 for grade 
1+2, month 6 for grade 3+4). 
 
A high pre-ART VL was a frequent risk factor for developing anemia, interestingly especially for anemia 1+2 
in the “d4T-based arm: 
 
/ = No statistically significant factor. For complete list of RRs see table 17 
 AZT-based arm d4T-based arm 
 Anemia 1+2 Anemia 3+4 Anemia 1+2 Anemia 3+4 
Month 1 / RR 1.13, 
CI 95%: 1.05-1.21 
RR 1.04, 
CI 95%: 1.01-1.07 
RR 1.02, 
CI 95%: 1.00-1.03 
Month 2 RR 1.20, 
CI 95%: 1.05-1.37 
/ / / 
Month 3 / RR 1.07, 
CI 95%: 1.00-1.14 
/ / 
Month 6 / / RR 1.82, 
CI 95%: 1.18-2.82 
/ 
Month 9 / / RR 1.90, 
CI 95%: 1.09-3.33 
/ 
Month 12 / / RR 4.79, 
CI 95%: 1.50-15.37 
/ 
 
Summary: The average pre-ART prevalence of anemia grade 1+2 and 3+4 was higher in patients with 
VL>100.000 copies/ml (33.5% and 6.6%) than in patients with lower VL. AZT induced after 1-2 months after 
the initiation of ART increased anemia rates. There was a general decrease of anemia prevalence in both 
arms and all pre-ART VL strata, but anemia grade 1+2 and 3+4 rates were (nearly) always higher in the 
“AZT-based arm”. 
It is remarkable that a high pre-ART VL was more frequently a statistically significant risk factor for higher 
anemia 1+2 prevalence (and in month 1 for anemia 3+4) in the “d4T-based arm” than in the “AZT-based 
arm”. In the AZT-based arm a high pre-ART VL was only in the first three months of ART (anemia 1+2: 
month 2, anemia 3+4: month 1 and 3) statistically significant associated with higher anemia prevalence. 
The picture given by the univariate analysis is not clear; in every case a high pre-ART VL is a frequent risk 
factor for increased anemia prevalence in both arms during follow-up. 
 
 
Figure 16 (see table 24 for data) 
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Figure 17 (see table 25 for data) 
 
4.3.3 Subgroup “NNRTI” 
Due to the very low number of patients, which started an EFV-containing ART (n=254, 2.5%), it was not 
possible to evaluate the hepatotoxic effect of NVP in comparison to EFV. This is a limitation of the study. 
 
4.3.4 Subgroup “malnutrition pre-ART” 
4.3.4.1 Evaluation of hepatotoxicity in the “d4T-based” and the “AZT-based arm” 
In the “d4T-based arm”, GOT values were available from 16.1% (month 9) to 62.1% (pre-ART) of the 
patients, and in the “AZT-based arm” from 18.6% (month 12) to 43.9% (pre-ART). 
 
Pre-ART prevalence of hepatotoxicity grade 1+2 and 3+4 differed between the BMI strata. In both arms pre-
ART prevalence of hepatotoxicity 1+2 and 3+4 were higher in patients with malnutrition (pre-ART 
BMI<18.5) before starting ART than in patients with no malnutrition before ART (pre-ART BMI>18.5). The 
pre-ART prevalence of hepatotoxicity was: 
Average pre-ART prevalence of hepatotoxicity grade 1+2: 28.1% (pre-ART BMI<18.5) 
        13.9% (pre-ART BMI>18.5) 
 
Average pre-ART prevalence of hepatotoxicity grade 3+4: 0.6% (pre-ART BMI<18.5) 
        0.4% (pre-ART BMI>18.5) 
 
The expected increase of hepatotoxicity rates after starting ART could only be observed for hepatotoxicity 
grade 3+4 after 1 or 2 months (both arms), while hepatotoxicity grade 1+2 peaked only in the “AZT-based 
arm” for the BMI>18.5 group. 
 
In general the rates of hepatotoxicity grade 1+2 and 3+4 decreased during follow-up.  
The rates of hepatotoxicity grade 1+2 were higher for malnourished patients (BMI<18.5) in both arms 
during the complete follow-up. The rates of hepatotoxicity grade 3+4 were only in the “d4T-based arm” 
during the follow-up, but not in the “AZT-based arm” (perhaps because of the lower patient number in the 
“AZT-based arm”). 
 
Despite the general decrease, the prevalence of hepatotoxicity grade 1+2 was always higher in the “d4T-
based arm” than in the “AZT-based arm”. This shows that d4T induces higher rates of hepatotoxicity 1+2 
during the complete follow-up than AZT. 
 
A pre-ART BMI>18.5 was only in the “d4T-based arm” (never in the “AZT-based arm”) and in the first three 
months of ART a statistically significant protective factor against increased hepatotoxicity grade 1+2 
prevalence: 
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/ = No statistically significant factor. For complete list of RRs see table 17 
 d4T-based arm 
 Hepatotoxicity 1+2 Hepatotoxicity 3+4 
Month 1 RR 0.95, CI 95%:0.91-0.98 / 
Month 2 RR 0.92, CI 95%:0.89-0.96 / 
Month 3 RR 0.94, CI 95%: 0.91-0.98 / 
 
Summary: The average pre-ART prevalence of hepatotoxicity grade 1+2 and 3+4 was higher in patients with 
BMI<18.5 (28.1% and 0.6%) than in non-malnourished patients. Prevalence of hepatotoxicity grade 1+2 was 
higher in patients with BMI<18.5 before starting ART than in patients with higher pre-ART BMI, and in 
patients in the “d4T-based arm” in comparison to the “AZT-based arm”. The results were less pronounced 
for hepatotoxicity grade 3+4, probably due to the low number of patients with hepatotoxicity grade 3+4.  
Only in the ”d4T-based arm” a BMI>18.5 before starting ART reduced statistically significant the risk for 
increased hepatotoxicity grade 1+2 prevalence in the first 3 months of follow-up. To be non-malnourished 
before starting ART protects only in the first 3 months of d4t-based combinations (not AZT-based) from 
hepatotoxicity grade 1+2. 
 
 
Figure 18 (see table 26 for data) 
 
 
Figure 19 (see table 27 for data) 
 
4.3.4.2 Evaluation of anemia in the “d4T-based” and the “AZT-based arm” 
In the “d4T-based arm”, HB values were available from 26.6% (month 12) to 64.6% (pre-ART) of the 
patients, and in the “AZT-based arm” from 19.8% (month 12) to 46.5% (pre-ART). 
 
Pre-ART anemia prevalence (all grades) was higher for malnourished patients (BMI<18.5) in both arms than 
in patients with BMI>18.5: 
Average pre-ART prevalence of anemia grade 1+2:  40.9% (pre-ART BMI<18.5) 
       24.1% (pre-ART BMI>18.5) 
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Average pre-ART prevalence of anemia grade 3+4: 9.4% (pre-ART BMI<18.5) 
       3.4% (pre-ART BMI>18.5) 
 
In the “AZT-based arm” in both BMI strata prevalence of anemia 1+2 and 3+4 increased after 1 or 2 months 
and declined during the follow-up. In the “d4T-based arm” only prevalence of anemia grade 1+2 peaked in 
month 1 in the group with higher BMI. This confirms the anemia inducing effect of AZT shortly after the 
start of ART. 
In both arms and in both BMI strata the rates of anemia grade 1+2 and 3+4 declined due to the general 
anemia reducing effect of ART. But prevalence of anemia grade 1+2 and 3+4 was always higher in the “AZT-
based arm” and for patients with BMI<18.5 during the complete follow-up after initiation of ART (with few 
exceptions for hepatotoxicity grade 3+4).  
In the “AZT-based arm” the average prevalence of anemia grade 1+2 after 12 months was 13.6% and in the 
“d4T-based arm” 7.6%. It would be interesting to check whether the rates would continue to decrease in 
the second year of ART. 
 
A pre-ART BMI>18.5 was only in the first 3 months of ART and after all in the “d4T-based arm” a statistically 
significant protective factor especially against increased anemia prevalence: 
 
/ = No statistically significant factor. For complete list of RRs see table 17 
 AZT-based arm D4T-based arm 
 Anemia 1+2 Anemia 3+4 Anemia 1+2 Anemia 3+4 
Month 1 / RR 0.86, CI 0.79-0.95 RR 0.89, CI 95%: 0.86-0.93 RR 0.98, CI 95%: 0.97-0.99 
Month 2 / / RR 0.93, CI 95%: 0.90-0.96 RR 0.98, CI 95%: 0.97-0.99 
Month 3 / RR 0.91, CI 95%: 0.83-0.99 RR 0.97, CI 95%: 0.94-0.99 / 
 
Summary: The average pre-ART prevalence of anemia grade 1+2 and 3+4 was higher in patients with 
BMI<18.5 (40.9% and 9.4%) than in non-malnourished patients. 
AZT-based combinations induced anemia grade 1+2 and 3+4 in month 1 and 2 after the initiation of ART. 
There was a general decrease of anemia prevalence in both arms and both pre-ART BMI strata, but anemia 
grade 1+2 and 3+4 rates were (nearly) always higher in the “AZT-based arm” and in malnourished patients. 
A pre-ART BMI>18.5 was only in the first 3 months of ART and especially in the “d4T-based arm” a 
statistically significant protective factor. 
 
 
Figure 20 (see table 28 for data) 
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Figure 21 (see table 29 for data) 
 
4.3.5 Subgroup “anemia pre-ART” 
4.3.5.1 Evaluation of hepatotoxicity in the “d4T-based” and the “AZT-based arm” 
In the “d4T-based arm”, GOT values were available from 22.3% (month 9) to 81.1% (pre-ART) of the 
patients, and in the “AZT-based arm” from 30.9% (month 12) to 72.0% (pre-ART). 
 
Pre-ART prevalence of hepatotoxicity grade 1+2 and 3+4 differed between the HB strata. The pre-ART 
prevalence of hepatotoxicity was: 
Average pre-ART prevalence of hepatotoxicity grade 1+2: 20.9% (pre-ART anemia grade 1+2) 
        25.2% (pre-ART anemia grade 3+4) 
Average pre-ART prevalence of hepatotoxicity grade 3+4: 0.8% (pre-ART anemia grade 1+2) 
        3.2% (pre-ART anemia grade 3+4 
 
The prevalence of hepatotoxicity grade 1+2 was higher in 11 from a total of 14 measuring points in both 
arms in patients with pre-ART anemia grade 3+4 than in patients with pre-ART anemia grade 1+2. 
Regarding hepatotoxicity grade 3+4 no clear trend can be observed, whether higher hepatotoxicity 
prevalence was attributed to patients with pre-ART anemia grade 1+2 or 3+4. This was probably due to the 
low number of patients with hepatotoxicity grade 3+4. 
 
In both arms no increase of hepatotoxicity grade 1+2 prevalence can be observed after starting ART with a 
peak in the first three months. The prevalence of hepatotoxicity grade 1+2 in the group of pre-ART anemia 
grade 3+4 of “AZT-based arm” seems to peak after month 2, but this is less pronounced. The prevalence of 
hepatotoxicity grade 1+2 decreased in both arms and both pre-ART anemia groups during the follow-up. 
For all hepatotoxicity grade 3+4 groups in both arms no peaks and no clear development of the prevalence 
can be observed due to low patient numbers. 
 
The rates of hepatotoxicity grade 1+2 were higher in patients with pre-ART anemia grade 1+2 in the “d4T-
based arm” than in the “AZT-based arm” during the complete follow-up. Because of the low number of 
patients with anemia grade 3+4 in the “AZT-based arm” and with hepatotoxicity grade 3+4 no trend of 
higher rates in other groups was distinguishable. 
 
Summary: The average pre-ART prevalence of hepatotoxicity grade 1+2 was higher in patients with anemia 
grade 3+4 (40.9% and 9.4%) than in patients with anemia grade 1+2. 
d4T seems to induce higher rates of hepatotoxicity than AZT, especially grade 1+2 in patients with pre-ART 
anemia 1+2. Rates of hepatotoxicity grade 1+2 decreased during the follow-up, with no peak in both arms a 
few months after starting ART. For prevalence of hepatotoxicity grade 3+4 no conclusions can be drawn 
because of the low number of patients. 
Pre-ART anemia 1+2 and 3+4 was no statistically significant risk factor for higher hepatotoxicity prevalence 
during the follow-up. 
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Figure 22 (see table 30 for data) 
 
 
Figure 23 (see table 31 for data) 
 
4.3.5.2 Evaluation of anemia in the “d4T-based” and the “AZT-based arm” 
In the “d4T-based arm”, HB values were available from 35.4% to 72.8% of the patients, and in the “AZT-
based arm” from 33.2% to 65.3%. 
 
In the “d4T-based arm” the prevalence of anemia grade 1+2 declined as expected immediately after 
starting ART. In the “AZT-based arm”, the prevalence of anemia grade 1+2 in the pre-ART anemia grade 1+2 
group declined also, but the values very always higher than in the corresponding group of the “d4T-based 
arm”. The curve of prevalence anemia grade 1+2 in the pre-ART anemia grade 3+4 group of the “AZT-based 
arm” showed an increase until month 3 and declined afterwards; 4 values of 7 measuring points were 
higher than in the corresponding group in the “d4T-based arm”. 
 
Summary: In most cases the anemia rates declined quickly during follow-up. The prevalence of anemia 
grade 1+2 was higher in the “AZT-based arm”. Pre-ART anemia 1+2 and 3+4 was never a statistically 
significant risk factor for higher anemia prevalence during the follow-up. 
The prevalence data of anemia grade 3+4 may be biased. 
 
 
Figure 24 (see table 32 for data) 
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Figure 25 (see table 33 for data) 
 
4.3.6 Key findings 
The curves confirmed in general the expected higher prevalence of hepatotoxicity in the “d4T-based arm”, 
especially of hepatotoxicity 1+2, compared to the “AZT-based arm”, and of anemia in the “AZT-based arm” 
compared to the “d4T-based arm”. The curves confirmed the hepatotoxicity-inducing effect of d4T-based 
combinations and the anemia-inducing effect of AZT-based combinations. 
 
Statistically significant factors were only VL (high pre-ART VL as a risk factor) and BMI (high pre-ART BMI as 
a protection factor). Pre-ART anemia was never and a high pre-ART CD4 count was only once statistically 
significant associated with an increased hepatotoxicity and anemia prevalence. 
 
“d4T-based” vs. “AZT-based arm” 
In the “d4T-based arm” were found 17 of 22 statistically significant associations with increased 
hepatotoxicity and anemia prevalence. In the “AZT-based arm” were identified only 5 of 22 statistically 
significant associations, all regarding prevalence of anemia (no regarding hepatotoxicity prevalence). 
 
15 of 22 statistically significant factors were found in the analyses of anemia prevalence, 10 of the 15 in the 
“d4t-based arm”. Only 7 of 22 statistically significant factors were found in the analyses of hepatotoxicity 
prevalence, all in the “d4t-based arm”.  
 
Hepatotoxicity prevalence 
Statistically significant factors could be identified only in the first 3 months of d4T-based ART regarding 
hepatotoxicity 1+2 prevalence (a high pre-ART CD4 count only once in month 1 in the “d4T-based arm” 
regarding hepatotoxicity 3+4). 
 
Anemia prevalence 
The majority of statistically significant factors could be identified in the first three months of ART, mainly in 
the “d4T-based arm”. After 3 months of ART there were only 3 of 15 statistically significant factors (three 
times high pre-ART VL in the d4T-based arm and regarding anemia 1+2).  
 
Pre-ART BMI 
A high pre-ART BMI was a statistically significant protection factor 
 only in the first 3 months of ART, mainly in the “d4T-based arm” (in the “AZT-based arm” only twice 
against anemia 3+4). 
 against increased hepatotoxicity 1+2 prevalence only in the “d4T-based arm” (never in the “AZT-
based arm”). 
 mainly against increased anemia prevalence (7 of 10) 
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Pre-ART VL 
A high pre-ART VL was a statistically significant risk factor 
 mainly in the first 3 month of ART (8 of 11) 
 mainly for increased anemia prevalence (8 of 11), especially anemia 1+2  
 mainly in the “d4T-based arm” (8 of 11) 
 
Pre-ART CD4 count 
Pre-ART CD4 count did not play an important role as risk or protection factor. A high CD4 cell count was 
only once identified as a statistically significant risk factor for higher prevalence of hepatotoxicity (in the 
“d4T-based arm” in month regarding hepatotoxicity 3+4 prevalence). 
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5. Discussion 
Evaluated were the prevalence of elevated liver-enzyme values (GOT) as indicator for hepatotoxicity and 
decreased hemoglobin (HB) values as indicator for anemia, and potential risk factors for developing 
hepatotoxicity and anemia under d4T-based and AZT-based regimens during a follow-up of 12 months in 
seven Mozambican and Malawian AIDS-treatment sites. Hepatotoxicity and anemia are among the most 
relevant d4T- and AZT-associated adverse effects: 
 Even if low-grade liver enzyme elevations are frequent, mostly asymptomatic and often resolve 
spontaneously, hepatotoxicity may be associated with severe, painful, adherence reducing and 
potentially life-threatening clinical manifestations such as lactic acidosis, hepatic steatosis, 
myopathy, pancreatitis, peripheral neuropathy and lipoatrophy. 
 Anemia is statistically significantly associated with AIDS progression and increased mortality. It is 
more frequent in African settings than in developed countries due to widespread malnutrition and 
insufficient iron intake, the higher burden of infectious diseases like Malaria, TB and parasitosis, 
higher prevalence of beta-thalassemia and sickle cell anemia, frequent use of AZT, and the fact that 
patients from African settings who are initiation ART have generally a more advanced 
immunodeficiency. 
 
In general the found prevalence of hepatotoxicity grade 1+2/3+4 and anemia grade 1+2/3+4 before starting 
ART coincided with the expected relatively high prevalence. The prevalence data confirmed that the overall 
“background hepatotoxicity 1+2” in HIV-positive persons who have not yet started ART is with 18.1% quite 
high, while the “background hepatotoxicity 3+4” is only 0.5% (table 7). The ART-associated hepatotoxicity 
1+2 and 3+4 prevalence without the “background hepatotoxicity” was 13.5% respectively 2% at month 1, 
decreased from month 1 to month 2, but remained then more or less at the same level (figures 6 and 7, 
table 10). The increase of hepatotoxicity 3+4 prevalence from “background hepatotoxicity” 0.5% to 2% at 
month 1 is probably due to the hepatotoxicity-inducing effect of ART; in particular NVP induces liver 
enzyme elevations in the first two months of ART. 
Also the overall “background anemia” in HIV-positive persons who have not yet started ART was high 
(anemia 1+2: 28.5%; anemia 3+4: 6.7%, table 7). The ART-associated anemia 1+2 and 3+4 without 
“background anemia” was 13.3% respectively 3.2% and decreased considerably during follow up due to the 
overall anemia-reducing effect of ART (figures 8 and 9, table 13). 
The prevalence curves during the 12-months follow-up (figures 6-9; tables 10, 13) corresponded in general 
with the expected elevated prevalence of hepatotoxicity in the “d4T-based arm”, especially of 
hepatotoxicity 1+2, compared to the “AZT-based arm”, and of anemia 1+2 and 3+4 in the “AZT-based arm” 
compared to the “d4T-based arm”. The prevalence of hepatotoxicity 1+2 was during the complete follow-
up higher in the “d4T-based” than in the “AZT-based arm”; the rates of hepatotoxicity 3+4 are difficult to 
interpret due to low number of cases. The prevalence of anemia 1+2 and 3+4 was during the complete 
follow-up (anemia 3+4 not in month 1) higher in the “AZT-based” than in the “d4T-based arm”. 
The curves confirmed the hepatotoxicity-inducing effect of d4T-based combinations and the anemia-
inducing effect of AZT-based combinations. They reflect the interaction between two effects: 
 The positive effect of ART, that reduces the immunosuppression and hence also other factors 
associated with hepatotoxicity and anemia (nutritional status, burden of infectious diseases and 
others), and leads to a reduction of anemia rates and less pronounced of hepatotoxicity rates. 
 The hepatotoxicity-inducing effect of d4T-based combinations and the anemia-inducing effect of AZT-
based combinations. 
 
A comparison of the data with other studies is difficult because of differences in study design and in 
defining and reporting of adverse effects, in particular different grading of laboratory parameters. 
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Risk factors 
Factors that are statistically significant associated with the risk of increased hepatotoxicity and anemia 
prevalence during follow-up in the “d4T-based arm” versus “AZT-based arm” were identified with 
univariate and multivariate analyses. Only patients of the cohort without hepatotoxicity respectively 
anemia before ART were included in these analyses in order to show directly ART-associated effects. 
(chapter 4.2). 
 
Univariate analyses showed that a d4T-based combination was during the complete follow-up a statistically 
significant risk factor for higher prevalence of hepatotoxicity 1+2 compared to AZT-based combinations, but 
never for hepatotoxicity 3+4. The multivariate analysis confirmed d4T-based combinations as a significant 
and independent risk factor at nearly all months of follow-up (not month 12), and showed that also female 
sex was statistically significant and independently associated with higher hepatotoxicity 1+2 prevalence 
during nearly the complete follow-up (not month 9). Like in the univariate analysis a d4T-based 
combination was never a risk factor for elevated hepatotoxicity 3+4 prevalence. 
 
In the univariate analysis AZT-based combination was a statistically significant risk factor for higher 
prevalence of anemia 1+2 during the complete follow-up, and for anemia 3+4 only at month 2, 3 and 6, 
compared to d4T-based combinations. The multivariate analysis confirmed AZT-based regimens as a risk 
factor for anemia 3+4 in month 2, 3 and 6, but showed - inconsistently with the univariate analysis – that 
AZT-based regimens were only at month 1 a significant risk factor for anemia 1+2. 
In the multivariate analysis cumulative malaria increased significantly about 2fold the risk for anemia 1+2 at 
all months, and for anemia 3+4 more than 3fold at months 2 and 6. Whilst in the univariate analysis AZT-
based combination was the dominating risk factor, it was cumulative malaria in the multivariate analysis. 
Malaria induced the development of anemia 1+2 during the first year of ART independently from the ART 
regimen and other factors. An AZT-based regimen, a high pre-ART VL and pre-ART malnutrition were only in 
the first one or two months statistically significant, independently associated with increased anemia 1+2 
prevalence. Obviously the influence of combinations with AZT, the clinical condition (with BMI as criteria) 
and the state of the AIDS disease (high pre-ART VL) are strong factors mainly at the beginning of ART, when 
the patient is still weak and ART has not yet developed its positive effects. 
The strong effect of malaria on increasing anemia 1+2 during at least 12 months of ART and increasing 
anemia 3+4 in the first six months was independent from the type of ART combination and must be taken 
very seriously. Cumulative malaria induces anemia 1+2 for a longer period than anemia 3+4. But in any case 
special attention must be paid to anemic patients on ART, especially under AZT-based combinations, who 
develop malaria. In the clinical praxis HB levels should be monitored closely. 
 
A bad nutritional status before starting ART may increase the risk for hepatotoxicity 1+2 and anemia 1+2 
and 3+4 in the first few months after starting ART, independently from the regimen: In the multivariate 
analysis a high pre-ART BMI was a significant protection factor against hepatotoxicity 1+2 until month 3, 
against anemia 1+2 in month 1 and 2, and against anemia 3+4 in month 2.  
The parameter “malnutrition” can be considered as a general symptom of a bad health condition due to 
multiple reasons. It seems that as long as the patients are still “weak” (malnourished) shortly after the 
beginning of ART, the pre-ART BMI is a significant factor. As soon as the health condition of the patients 
improve after few months due to ART and they are becoming stronger (less or no malnutrition), the 
remaining risk factors for higher prevalence of hepatotoxicity 1+2 are female sex and d4T-based 
combinations. 
The observation that a good nutritional status has a protective effect against hepatotoxicity 1+2 and 
anemia 1+2, independently from the ART regimen in the first few months of ART confirms the necessity to 
identify HIV-positive patients early, and that the patients should start medical services as soon as possible 
and not in an advanced stage of malnutrition and the HIV-infection. As long as their health condition is 
worse, the risk of developing hepatotoxicity and anemia is increased. 
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It must be underlined that in the multivariate analyses the stage of the AIDS disease before starting ART 
was irrelevant. Pre-ART CD4 count and pre-ART VL were never statistically significant associated with 
increased hepatotoxicity prevalence, and high pre-ART VL was only in the first month statistically significant 
associated with increased anemia 1+2 (never with increased anemia 3+4). These observations should be 
confirmed and deepened by further researches. 
 
In the comparison of statistically significant risk factors separately under d4T- and AZT-based combinations 
(chapter 4.3) relevant statistically significant factors were only high pre-ART VL and high pre-ART BMI 
(univariate analysis). Pre-ART anemia was never and a high pre-ART CD4 count was only once statistically 
significant associated with an increased hepatotoxicity and anemia prevalence. The most statistically 
significant associations were identified in the first 3 months of ART (19 out of 22 significant factors). 
17 out of 22 statistically significant associations with increased hepatotoxicity and anemia prevalence were 
identified under d4T-based regimens. In the “AZT-based arm” all five identified statistically significant 
associations were regarding prevalence of anemia (especially anemia 3+4) and in the first 3 months of ART. 
15 out of 22 statistically significant factors were found in the analyses of anemia prevalence, mainly in the 
“d4t-based arm”. All identified statistically significant factors regarding hepatotoxicity prevalence were 
identified in the “d4t-based arm”. 
The multivariate analysis confirmed that a high pre-ART BMI was as protection factor in the first 2 to 3 
months after the beginning of ART. But it could not confirm that a high pre-ART VL increased often (mainly 
in the “d4T-based arm”) significantly the risk for hepatotoxicity and anemia, as it was the case in the 
comparison of the risk factors. 
The multivariate analysis confirmed the protective effect of a good nutritional status before starting ART 
(high pre-ART BMI) in the first three months. 
Also in the comparison the pre-ART CD4 count was not a decisive factor, as well as pre-ART HB. 
 
Influence of the ART-combination 
Hepatotoxicity and anemia in HIV-positive patients have multiple reasons, among others also antiretroviral 
drugs. d4T may not be seen isolated as hepatotoxicity inducing drug but always the combination of d4T 
with other ARVs. In particular the NVP-associated hepatotoxicity in the first two months of ART is well 
described. Regarding hepatotoxicity d4T and NVP must be seen as a hepatotoxic combination. Also anemia 
is not only associated with AZT but may be caused from more ARVs that are given as combination. Deciding 
are the combinations of antiretroviral drugs. Hence in this study the adverse effects of triple ART 
combination were evaluated, mostly d4T/3TC/NVP and AZT/3TC/NVP.  
A limitation of the study was that the influence of the NNRTI especially on hepatotoxicity prevalence could 
not be evaluated. 
 
Limitations of the study 
This study had several limitations: 
 Despite the big number of patients enrolled in the cohort, the number of patients under EFV-containing 
regimens was too small in order to evaluate differences between NVP- and EFV containing regimens. 
95% of the patients started a NVP-containing regimen. Because of that valid statistical tests “NVP-
based” vs. “EFV-based combinations” were not possible. 
 The influence of tuberculosis and anti-TB drugs on hepatotoxicity and anemia was not evaluated. 
Reason is that the DREAM software during the period of enrolment and follow-up did not register 
statistics of TB cases. The actual used updated software version counts TB for statistical reasons. 
 Only GOT was analyzed as indicator for hepatotoxicity but not GPT. 
 Because the data collection was done in the health facilities under „real world conditions“ and not 
under the conditions of a clinical trial, for quite many patients of the cohort not all GOT and HB values 
were available during follow-up. Often had only a lower percentage of the patients that had been 
included in the cohort GOT and/or HB values at the measuring points. 
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 The number of patients with hepatotoxicity and anemia grade 3+4 was often small. This could have 
weakened the analyses of these infrequent adverse effects. 
 
Concrete conclusion 
 In literature is discussed, how frequently GOT and HB should be measured. According to the data of this 
study a monthly measurement of GOT and HB in the first three months of ART is recommendable, 
because of the increased incidence of elevated liver enzyme and HB levels especially in the first months 
after starting ART. Afterwards, measurement every quarter is sufficient. Intensive laboratory 
monitoring, at least during the first year of ART, may prevent severe toxicity. 
 The study showed the relevance of the above mentioned typical African parameters which influence the 
HIV-infection in patients in African settings, in particular malnutrition, malaria and an advanced AIDS 
disease before starting ART. The importance to measure viral load, that is often doubted, and BMI must 
be highlighted. Both parameters should be considered when ART is planned for an individual patient, 
and must be monitored regularly during ART. 
 In order to avoid frequent malaria-associated anemia, AIDS-treatments sites must monitor closely 
malaria events. Especially in anemic patients and in patients under AZT-based combinations. Malaria 
cases must be well monitored. All confirmed malaria must be treated. 
 d4T, AZT and NVP have a considerable risk of adverse effects. Less-toxic first-line drugs must be 
introduced quickly in African guidelines and markets. 
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Table 2. Sub-Saharan cohorts investigating anemia in HIV-positive persons 
 ART regimen Duration of follow-up 
 
Definition of anemia Prevalence, incidence 
Moh 2005 
Côte d’Ivoire 
 
Prospective cohort 
study 
 
n=498 
AZT+3TC+EFV 6 months after 
initiation of ART 
Grade 1: 9.5 – 10.5g/dl 
 
Grade 2: 8 – 9.4g/dl 
 
Grade 3: 6.5 – 7.9g/dl 
 
Grade 4: < 6.5 g/dl 
(WHO definition) 
During 6 months follow-up: 
9,6 cases of grade 3–4 
anemia/100 PY 
Obirikorang 2009 
Ghana 
 
Prospective case 
control comparative 
Study 
 
n=228 
Not specified; evaluated 
is anemia in HIV-positive 
patients 
Not specified (sic!) HB< 12 g/dl 
and 
haematocrit <37% 
Not specified 
Omoregie 2009 
Nigeria 
 
Cross-sectional study 
 
n=457 
Not specified; ART 
combinations contain 
AZT, d4T, NVP 
No follow-up, objective 
of the study was to do a 
snapshot evaluation of 
anemia in patients on 
ART vs. ART naïve 
patients 
Grade 1: 9.5 – 10.5g/dl 
 
Grade 2: 8 – 9.4g/dl 
 
Grade 3: 6.5 – 7.9g/dl 
 
Grade 4: < 6.5 g/dl 
(WHO definition) 
Patients on ART vs. ART naïve 
patients: 
51,15% vs. 69,17% 
Johannessen 2011 
Tanzania 
 
Prospective 
observational study 
 
n=838 
AZT or d4T+3TC+EFV or 
NVP 
12 months after 
initiation of ART 
Mild: 
10-12 g/dL (women) 
10-13 g/dL (men) 
 
Moderate: 
8-10 g/dL  
 
Severe: 
<8 g/dL 
Pre-ART anemia prevalence: 
77,4% 
 
Anemia prevalence after 12 
months follow-up: 38,2% 
Masaisa 2011 
Rwanda 
 
Cross-sectional study 
 
n=250 
D4T (AZT) + 3TC + NVP 
(EFV) 
8 months after 
initiation of ART 
Anemia: 
HB<11,5 mg/dL 
Pre-ART anemia prevalence: 
29% 
 
Anemia prevalence after 8 
months follow-up not 
specified. 
Mean + SD HB increased from 
10,9 + 1,6 g/dL at ART 
initiation to 12,3 + 1,5 g/dL 
after 8  months follow-up. 
Ogoina 2012 
Nigeria 
 
Retrospective cohort 
analysis of routinely 
collected medical 
records 
 
n=207 
Non-ART arm (n=152) vs. 
ART arm (n=55) 
1
st
 line combinations: 
AZT+3TC+NVP 
d4T+3TC+NVP 
AZT+3TC+EFV 
TDF+FTC+NVP or EFV 
 
2
nd
 line combinations 
with AZT/TDF/FTC/LPVr. 
During 4 years 
morbidity and mortality 
patterns of hospitalized 
adult HIV/AIDS patients 
in ART were examined 
Severe anemia: 
Hematocrit (PCV) < 24% 
 
Mild or no anemia: 
PCV ≥ 24% 
7,3% of the hospitalized 
HIV/AIDS patients on ART 
showed AZT-related severe 
anemia 
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Table 3. Laboratory instruments used in the Mozambican laboratories 
 
Viral load (HIV RNA) CD4 cell count Biochemistry Hematology 
Maputo Since 2006 to date: 
Siemens Sys340 (bDNA assay, 
detection limit 50-500.000 
copies RNA/ml), former Bayer 
Diagnostics  
 
Contemporaneously since 
2010 to date: 
Abbott m2000 RealTime 
System  
BD FacsCalibur Elitech Flexor EL200 
 
Since 2010: 
Spinreact Spinlab 180 
Clinical Analyzer 
Sysmex XS-1000i 
Beira Since 2006 to date: 
Siemens Sys340 (bDNA 
assay), former Bayer 
Diagnostics  
 
Contemporaneously since 
2010 to date: 
Abbott m2000 RealTime 
System 
BD FacsCalibur Elitech Flexor EL150 Sysmex KX-21N 
Quelimane VL done at Beira BD FacsCount Spinreact Spinlab 180 
Clinical Analyzer 
Sysmex KX-21N 
 
Laboratory instruments used in the Malawian laboratories 
 Viral load CD4 cell count Biochemistry Hematology 
Blantyre Until 2010: 
Siemens Sys340 (bDNA 
assay), former Bayer 
Diagnostics  
 
Since 2010 to date: 
Abbott m2000 RealTime 
System 
Beckman-Coulter 
EPICS-XL MCL flow 
cytometer  
(equipped with an 
Argon ion laser, 
488mm) 
Until 2009: 
HumaStar 180 
 
Since 2009: 
Spinreact Spinlab 180 
Clinical Analyzer 
 
Sysmex XS-1000i 
Mthengo wa 
Ntenga (near 
Lilongwe) 
Siemens Sys340 (bDNA 
assay), former Bayer 
Diagnostics 
Beckman-Coulter 
EPICS-XL MCL flow 
cytometer  
HumaStar 180 Sysmex KX-21N 
Balaka VL done at Blantyre BD FacsCount Spinreact Spinlab 180 
Clinical Analyzer 
Sysmex KX-21N 
 
Beckman-Coulter, Fullerton, CA, USA 
Becton Dickinson, Franklin Lakes, NJ, USA 
ELITech Group, Puteaux, France 
Human GmbH, Wiesbaden, Germany 
Siemens Healthcare, Erlangen, Germany 
Spinreact, Girona, Spain 
Sysmex Co, Kobe, Japan 
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Table 17. Statistically significant factors for increased risk or protection of hepatotoxicity and anemia prevalence 
      / = No statistically significant factors 
Hepatotoxicity prevalence: statistically significant factors for increased risk or protection 
 AZT-based arm d4T-based arm 
 Hepatotoxicity 1+2 Hepatotoxicity 3+4 Hepatotoxicity 1+2 Hepatotoxicity 3+4 
Month 1 / / VL>100.000 c/ml 
(RR 1.04, CI 95%: 1.01-1.08) 
 
BMI>18.5 
(RR 0.95, CI 95%:0.91-0.98) 
CD4 251-399 cells/μl 
(RR 1.01, CI 95%:1.00-1.03) 
Month 2 / / VL>100.000 c/ml 
(RR 1.03, CI 95%: 1.00-1.07) 
 
BMI>18.5 
(RR 0.92, CI 95%:0.89-0.96) 
/ 
Month 3 / / VL>100.000 c/ml 
(RR 1.04, CI 95%: 1.01-1.07) 
 
BMI>18.5 
(RR 0.94, CI 95%: 0.91-0.98) 
/ 
Month 6 / / / / 
Month 9 / / / / 
Month 12 / / / / 
 
Anemia prevalence: statistically significant factors for increased risk or protection 
 AZT-based arm d4T-based arm 
 Anemia 1+2 Anemia 3+4 Anemia 1+2 Anemia 3+4 
Month 1 / VL>100.000 c/ml 
(RR 1.13, CI 95%: 1.05-1.21) 
 
BMI>18.5 
(RR 0.86, CI 0.79-0.95) 
VL>100.000 c/ml 
(RR 1.04, CI 95%: 1.01-1.07) 
 
BMI>18.5 
(RR 0.89, CI 95%: 0.86-0.93) 
VL>100.000 c/ml 
(RR 1.02, CI 95%: 1.00-1.03) 
 
BMI>18.5 
(RR 0.98, CI 95%: 0.97-0.99) 
Month 2 VL>100.000 c/ml 
(RR 1.20, CI 95%: 1.05-1.37) 
/ BMI>18.5 
(RR 0.93, CI 95%: 0.90-0.96) 
BMI>18.5 
(RR 0.98, CI 95%: 0.97-0.99) 
Month 3 / VL>100.000 c/ml 
(RR 1.07, CI 95%: 1.00-1.14) 
 
BMI>18.5 
(RR 0.91, CI 95%: 0.83-0.99) 
BMI>18.5 
(RR 0.97, CI 95%: 0.94-0.99) 
/ 
Month 6 / / VL>100.000 c/ml 
(RR 1.82, CI 95%: 1.18-2.82) 
/ 
Month 9 / / VL>100.000 c/ml 
(RR 1.90, CI 95%: 1.09-3.33) 
/ 
Month 12 / / VL>100.000 c/ml 
(RR 4.79, CI 95%: 1.50-
15.37) 
/ 
 
 
 6
7
 
 
 
d
4
T-
b
as
e
d
 a
rm
: 
n
= 
8
2
3
1
 (
7
7
.9
%
) 
 
P
re
-A
R
T 
C
D
4
 <
2
5
0
 
P
re
-A
R
T 
C
D
4
 2
5
1
-3
9
9
 
P
re
-A
R
T 
C
D
4
 >
4
0
0
 
n
=p
re
-A
R
T 
C
D
4
<2
5
0
/2
5
1
-3
9
9
/>
4
0
0
 
(t
o
ta
l o
f 
C
D
4
 v
a
lu
e
s)
 
G
O
T 
G
ra
d
e
 1
+2
 
G
O
T 
G
ra
d
e
 3
+4
 
G
O
T 
G
ra
d
e
 1
+2
 
G
O
T 
G
ra
d
e
 3
+4
 
G
O
T 
G
ra
d
e
 1
+2
 
G
O
T 
G
ra
d
e
 3
+4
 
P
re
-A
R
T:
 n
=4
3
5
1
/2
0
0
3
/3
2
0
 (
6
6
7
4
) 
2
2
,5
%
 (
n
=
9
7
8
) 
0
,5
%
 (
n
=2
1
) 
1
3
,2
%
 (
n
=
2
6
5
) 
0
,2
%
 (
n
=5
) 
1
2
,2
%
 (
n
=
3
9
) 
0
,6
%
 (
n
=2
) 
M
o
n
th
 1
: n
=3
4
2
0
/1
5
8
5
/2
2
3
 (
5
2
2
8
) 
1
9
,6
%
 (
n
=
6
7
1
) 
1
,6
%
 (
n
=5
5
) 
1
8
,4
%
 (
n
=
2
9
1
) 
2
,8
%
 (
n
=4
5
) 
1
7
,0
%
 (
n
=
3
8
) 
1
,8
%
 (
n
=4
) 
M
o
n
th
 2
: n
=2
4
9
8
/1
2
1
7
/1
8
5
 (
3
9
0
0
) 
1
8
,0
%
 (
n
=
4
5
0
) 
0
,8
%
 (
n
=1
9
) 
1
5
,9
%
(n
=1
9
3
) 
0
,7
%
 (
n
=8
) 
1
4
,1
%
 (
n
=
2
6
) 
0
,5
%
 (
n
=1
) 
M
o
n
th
 3
: n
=3
2
0
6
/1
5
3
9
/2
1
0
 (
4
9
5
5
) 
1
6
,8
%
 (
n
=
5
3
9
) 
0
,7
%
 (
n
=2
4
) 
1
5
,6
%
 (
n
=
2
4
0
) 
0
,4
%
 (
n
=6
) 
1
5
,7
%
 (
n
=
3
3
) 
0
%
 (
n
=0
) 
M
o
n
th
 6
: n
=2
8
8
4
/1
4
3
0
/1
8
2
 (
4
4
9
6
) 
1
9
,8
%
 (
n
=
5
7
2
) 
0
,2
%
 (
n
=6
) 
1
9
,3
%
 (
n
=
2
7
6
) 
0
,1
%
 (
n
=2
) 
2
2
,0
%
 (
n
=
4
0
) 
0
%
 (
n
=0
) 
M
o
n
th
 9
: n
=1
1
0
3
/5
8
0
/8
7
 (
1
7
7
0
) 
1
4
,3
%
 (
n
=
1
5
8
) 
0
,3
%
 (
n
=3
) 
1
5
,2
%
 (
n
=
8
8
) 
0
,3
%
 (
n
=2
) 
2
1
,8
%
 (
n
=
1
9
) 
0
%
 (
n
=0
) 
M
o
n
th
 1
2
: n
=1
6
2
6
/8
2
1
/1
2
1
 (
2
5
6
8
) 
1
3
,7
%
 (
n
=
2
2
2
) 
0
,4
%
 (
n
=6
) 
1
1
,9
%
 (
n
=
9
8
) 
0
,4
%
 (
n
=3
) 
1
7
,4
%
 (
n
=
2
1
) 
0
%
 (
n
=0
) 
Ta
b
le
 1
8
. 
Ev
a
lu
a
ti
o
n
 o
f 
h
ep
a
to
to
xi
ci
ty
 in
 t
h
e 
“d
4
T-
b
a
se
d
 a
rm
”,
 s
u
b
g
ro
u
p
 “
C
D
4
 p
re
-A
R
T”
 (
se
e 
fi
g
u
re
 1
0
) 
  
A
ZT
-b
as
e
d
 a
rm
: 
n
=2
3
0
6
 (
2
1
.8
%
) 
 
P
re
-A
R
T 
C
D
4
 <
2
5
0
 
P
re
-A
R
T 
C
D
4
 2
5
1
-3
9
9
 
P
re
-A
R
T 
C
D
4
 >
4
0
0
 
n
=p
re
-A
R
T 
C
D
4
<2
5
0
/2
5
1
-3
9
9
/>
4
0
0
 
(t
o
ta
l o
f 
C
D
4
 v
a
lu
e
s)
 
G
O
T 
G
ra
d
e
 1
+2
 
G
O
T 
G
ra
d
e
 3
+4
 
G
O
T 
G
ra
d
e
 1
+2
 
G
O
T 
G
ra
d
e
 3
+4
 
G
O
T 
G
ra
d
e
 1
+2
 
G
O
T 
G
ra
d
e
 3
+4
 
P
re
-A
R
T:
 n
=7
8
2
/5
5
9
/3
0
2
 (
n
=1
6
4
3
) 
2
1
,4
%
 (
n
=
1
6
7
) 
0
,8
%
 (
n
=6
) 
1
0
,4
%
 (
n
=
5
8
) 
0
,4
%
 (
n
=2
) 
6
,0
%
 (
n
=1
8
) 
0
,0
%
 (
n
=0
) 
M
o
n
th
 1
: n
=6
04
/4
28
/2
09
 (
1
24
1
) 
1
5
,6
%
 (
n
=9
4
) 
3
,1
%
 (
n
=1
9
) 
1
0
,3
%
 (
n
=4
4
) 
1
,9
%
 (
n
=8
) 
1
1
,0
%
 (
n
=2
3
) 
0
,5
%
 (
n
=1
) 
M
o
n
th
 2
: n
=4
42
/3
37
/1
43
 (
9
22
) 
1
1
,5
%
 (
n
=5
1
) 
1
,1
%
 (
n
=5
) 
9
,8
%
 (
n
=3
3
) 
0
,9
%
 (
n
=3
) 
7
,7
%
 (
n
=1
1
) 
2
,1
%
 (
n
=3
) 
M
o
n
th
 3
: n
=5
19
/3
83
/1
87
 (
1
08
9
) 
9
,8
%
 (
n
=5
1
) 
1
,2
%
 (
n
=6
) 
8
,4
%
 (
n
=3
2
) 
0
%
 (
n
=0
) 
9
,1
%
 (
n
=1
7
) 
0
%
 (
n
=0
) 
M
o
n
th
 6
: n
=5
08
/3
83
/1
34
 (
1
02
5
) 
9
,4
%
 (
n
=4
8
) 
0
%
 (
n
=0
) 
5
,7
%
 (
n
=2
2
) 
0
,8
%
 (
n
=3
) 
9
,0
%
 (
n
=1
2
) 
0
%
 (
n
=0
) 
M
o
n
th
 9
: n
=4
11
/3
23
/1
24
 (
8
58
) 
5
,8
%
 (
n
=2
4
) 
0
%
 (
n
=0
) 
7
,1
%
 (
n
=2
3
) 
0
,6
%
 (
n
=2
) 
9
,7
%
 (
n
=1
2
) 
0
,8
%
 (
n
=1
) 
M
o
n
th
 1
2
: n
=3
2
4/
24
4
/1
08
 (
6
76
) 
9
,6
%
 (
n
=3
1
) 
0
,3
%
 (
n
=1
) 
8
,6
%
 (
n
=2
1
) 
0
,8
%
 (
n
=2
) 
9
,3
%
 (
n
=1
0
) 
0
%
 (
n
=0
) 
Ta
b
le
 1
9
. 
Ev
a
lu
a
ti
o
n
 o
f 
h
ep
a
to
to
xi
ci
ty
 in
 t
h
e 
“A
ZT
-b
a
se
d
 a
rm
”,
 s
u
b
g
ro
u
p
 “
C
D
4
 p
re
-A
R
T
” 
(s
ee
 f
ig
u
re
 1
1
) 
 6
8
 
  
d
4
T-
b
as
e
d
: 
n
= 
8
2
3
1
 (
7
7
.9
%
) 
 
P
re
-A
R
T 
C
D
4
 <
2
5
0
 
P
re
-A
R
T 
C
D
4
 2
5
1
-3
9
9
 
P
re
-A
R
T 
C
D
4
 >
4
0
0
 
n
=p
re
-A
R
T 
C
D
4
<2
5
0
/2
5
1
-3
9
9
/>
4
0
0
 
(t
o
ta
l o
f 
C
D
4
 v
a
lu
e
s)
 
H
B
 G
ra
d
e
 1
+2
 
H
B
 G
ra
d
e
 3
+4
 
H
B
 G
ra
d
e
 1
+2
 
H
B
 G
ra
d
e
 3
+4
 
H
B
 G
ra
d
e
 1
+2
 
H
B
 G
ra
d
e
 3
+4
 
P
re
-A
R
T:
 n
=4
4
9
8
/2
0
6
8
/3
3
5
 (
6
9
0
1
) 
3
1
,4
%
 (
n
=
1
4
1
4
) 
8
,7
%
 (
n
=3
9
2
) 
2
2
,1
%
 (
n
=
4
5
7
) 
4
,2
%
 (
n
=8
7
) 
2
7
,2
%
 (
n
=
9
1
) 
5
,1
%
 (
n
=1
7
) 
M
o
n
th
 1
: n
=3
8
1
4
/1
8
0
5
/2
4
4
 (
5
8
6
3
) 
3
1
,3
%
 (
n
=
1
1
9
3
) 
6
,1
%
 (
n
=2
3
1
) 
2
2
,8
%
 (
n
=
4
1
1
) 
2
,9
%
 (
n
=5
3
) 
3
3
,2
%
 (
n
=
8
1
) 
6
,1
%
 (
n
=1
5
) 
M
o
n
th
 2
: n
=2
5
7
3
/1
2
6
1
/1
8
8
 (
4
0
2
2
) 
2
2
,4
%
 (
n
=
5
7
7
) 
3
,1
%
 (
n
=8
0
) 
1
7
,0
%
 (
n
=
2
1
5
) 
1
,8
%
 (
n
=2
3
) 
2
1
,3
%
 (
n
=
4
0
) 
3
,2
%
 (
n
=6
) 
M
o
n
th
 3
: n
=3
3
7
2
/1
6
1
0
/2
2
2
 (
5
2
0
4
) 
1
7
,0
%
 (
n
=
5
7
3
) 
2
,1
%
 (
n
=7
1
) 
1
4
,6
%
 (
n
=
2
3
5
) 
1
,3
%
 (
n
=2
1
) 
1
9
,4
%
 (
n
=
4
3
) 
1
,4
%
 (
n
=3
) 
M
o
n
th
 6
: n
=2
9
9
7
/1
4
9
2
/2
0
3
 (
4
6
9
2
) 
1
1
,5
%
 (
n
=
3
4
6
) 
1
,0
%
 (
n
=2
9
) 
1
0
,7
%
 (
n
=
6
0
) 
0
,5
%
 (
n
=8
) 
9
,9
%
 (
n
=2
0
) 
0
,5
%
 (
n
=1
) 
M
o
n
th
 9
: n
=2
3
8
6
/1
1
7
1
/1
7
1
 (
3
7
2
8
) 
7
,9
%
 (
n
=1
8
8
) 
0
,8
%
 (
n
=2
0
) 
7
,9
%
 (
n
=9
3
) 
0
,7
%
 (
n
=8
) 
6
,4
%
 (
n
=1
1
) 
1
,8
%
 (
n
=3
) 
M
o
n
th
 1
2
: n
=1
7
9
0
/9
0
0
/1
3
2
 (
2
8
2
2
) 
6
,8
%
 (
n
=1
2
1
) 
0
,7
%
 (
n
=1
3
) 
7
,7
%
 (
n
=6
9
) 
0
,6
%
 (
n
=5
) 
8
,3
%
 (
n
=1
1
) 
0
,8
%
 (
n
=1
) 
Ta
b
le
 2
0
. 
Ev
a
lu
a
ti
o
n
 o
f 
a
n
em
ia
 in
 t
h
e 
“d
4
T-
b
a
se
d
 a
rm
”,
 s
u
b
g
ro
u
p
 “
C
D
4
 p
re
-A
R
T”
 (
se
e 
fi
g
u
re
 1
2
) 
  
A
ZT
-b
as
e
d
: 
n
=2
3
0
6
 (
2
1
.8
%
) 
 
P
re
-A
R
T 
C
D
4
 <
2
5
0
 
P
re
-A
R
T 
C
D
4
 2
5
1
-3
9
9
 
P
re
-A
R
T 
C
D
4
 >
4
0
0
 
n
=p
re
-A
R
T 
C
D
4
<2
5
0
/2
5
1
-3
9
9
/>
4
0
0
 
(t
o
ta
l o
f 
C
D
4
 v
a
lu
e
s)
 
H
B
 G
ra
d
e
 1
+2
 
H
B
 G
ra
d
e
 3
+4
 
H
B
 G
ra
d
e
 1
+2
 
H
B
 G
ra
d
e
 3
+4
 
H
B
 G
ra
d
e
 1
+2
 
H
B
 G
ra
d
e
 3
+4
 
P
re
-A
R
T:
 n
=8
2
1
/5
8
3
/3
1
0
 (
1
7
1
4
) 
3
0
,2
%
 (
n
=
2
4
8
) 
3
,7
%
 (
n
=3
0
) 
2
1
,6
%
 (
n
=
1
2
6
) 
0
,5
%
 (
n
=3
) 
2
8
,4
%
 (
n
=
8
8
) 
1
,6
%
 (
n
=5
) 
M
o
n
th
 1
: n
=7
0
1
/5
0
7
/2
1
7
 (
1
4
2
5
) 
3
4
,2
%
 (
n
=
2
4
0
) 
5
,1
%
 (
n
=3
6
) 
2
7
,2
%
 (
n
=
1
3
8
) 
2
,0
%
 (
n
=1
0
) 
4
5
,2
%
 (
n
=
9
8
) 
2
,3
%
 (
n
=5
) 
M
o
n
th
 2
: n
=4
5
2
/3
5
0
/1
4
4
 (
9
4
6
) 
3
2
,1
%
 (
n
=
1
4
5
) 
5
,1
%
 (
n
=2
3
) 
2
6
,3
%
 (
n
=
9
2
) 
1
,1
%
 (
n
=4
) 
3
2
,6
%
 (
n
=
4
7
) 
4
,9
%
 (
n
=7
) 
M
o
n
th
 3
: n
=5
5
6
/4
1
3
/1
9
4
 (
1
1
6
3
) 
2
6
,1
%
 (
n
=
1
4
5
) 
4
,9
%
 (
n
=2
7
) 
1
9
,9
%
 (
n
=
8
2
) 
1
,0
%
 (
n
=4
) 
2
2
,2
%
 (
n
=
4
3
) 
2
,6
%
 (
n
=5
) 
M
o
n
th
 6
: n
=5
4
8
/4
2
0
/1
6
6
 (
1
1
3
4
) 
1
6
,8
%
 (
n
=
9
2
) 
2
,6
%
 (
n
=1
4
) 
1
1
,4
%
 (
n
=
4
8
) 
1
,9
%
 (
n
=8
) 
1
0
,8
%
 (
n
=
1
8
) 
0
,6
%
 (
n
=1
) 
M
o
n
th
 9
: n
=4
4
8
,3
5
1
/1
4
9
/ 
(9
4
8
) 
1
4
,1
%
 (
n
=
6
3
) 
1
,8
%
 (
n
=8
) 
1
1
,4
%
 (
n
=
4
0
) 
0
,3
%
 (
n
=1
) 
1
0
,1
%
 (
n
=
1
5
) 
0
%
 (
n
=0
) 
M
o
n
th
 1
2
: n
=3
4
3
/2
6
0
/1
2
2
 (
7
2
5
) 
1
1
,7
%
(n
=4
0
) 
1
,2
%
 (
n
=4
) 
1
3
,1
%
 (
n
=
3
4
) 
0
,4
%
 (
n
=1
) 
4
,1
%
 (
n
=5
) 
0
,8
%
 (
n
=1
) 
Ta
b
le
 2
1
. 
Ev
a
lu
a
ti
o
n
 o
f 
a
n
em
ia
 in
 t
h
e 
“A
ZT
-b
a
se
d
 a
rm
”,
 s
u
b
g
ro
u
p
 “
C
D
4
 p
re
-A
R
T”
 (
se
e 
fi
g
u
re
 1
3
) 
  
69 
 
d4T-based: n= 8231 (77.9%) 
 Pre-ART VL<100.000 Pre-ART VL>100.000 
n=VL<100.000/VL>100.000 
(total of VL values) 
GOT grade 1+2 GOT grade 3+4 GOT grade 1+2 GOT grade 3+4 
Pre-ART: n=4271/1870 (6141) 15,3% (n=655) 0,2% (n=10) 27,9% (n=521) 0,9% (n=16) 
Month 1: n=3366/1458 (4824) 17,0% (n=572) 2,3% (n=76) 24,2% (n=353) 1,6% (n=23) 
Month 2: n=2501/1109 (3610) 15,8% (n=394) 0,8% (n=20) 20,9% (n=232) 0,6%(n=7) 
Month 3: n=3204/1345 (4549) 15,1% (n=484) 0,6% (n=20) 20,0% (n=269) 0,5% (n=7) 
Month 6: n=2949/1194 (4143) 19,9% (n=587) 0,2% (n=5) 21,2% (n=253) 0,3% (n=4) 
Month 9: n=1183/410 (1593) 15,1% (n=179) 0,2% (n=2) 15,4% (n=63) 0,5% (n=2) 
Month 12: n=1698/665 (2363) 12,5% (n=213) 0,3% (n=5) 16,2% (n=108) 0,5% (n=3) 
Table 22. Evaluation of hepatotoxicity in the “d4T-based arm”, subgroup “VL pre-ART”” (see figure 14) 
 
AZT-based: n= 2306 (21.8%) 
 
Pre-ART VL<100.000 Pre-ART VL>100.000 
n=VL<100.000/VL>100.000 
(total of VL values) 
GOT grade 1+2 GOT grade 3+4 GOT grade 1+2 GOT grade 3+4 
Pre-ART: n=1171/260 (1431) 11,8% (n=138) 0,6% (n=7) 26,5% (n=69) 0,4% (n=1) 
Month 1: n=931/204 (1135) 12,2% (n=114) 2,1% (n=20) 16,7% (n=34) 2,0% (n=4) 
Month 2: n=694/144 (838) 10,2% (n=71) 1,0% (n=7) 11,1% (n=16) 2,1% (n=3) 
Month 3: n=849/167 (1016) 8,1% (n=69) 0,7% (n=6) 12,0% (n=20) 1,2% (n=2) 
Month 6: n=774/149 (923) 7,4% (n=57) 0,3% (n=2) 7,4% (n=11) 0% (n=0) 
Month 9: n=669/117 (786) 6,4% (n=43) 0,4% (n=3) 6,0% (n=7) 0% (n=0) 
Month 12: n=504/103 (607) 8,5% (n=43) 0,2% (n=1) 5,8% (n=6) 1,9% (n=2) 
Table 23. Evaluation of hepatotoxicity in the “AZT-based arm”, subgroup “VL pre-ART”” (see figure 15) 
 
d4T-based: n= 8231 (77.9%) 
 Pre-ART VL<100.000 Pre-ART VL>100.000 
n=VL<100.000/VL>100.000 
(total of VL values) 
HB Grade 1+2 HB Grade 3+4 HB Grade 1+2 HB Grade 3+4 
Pre-ART: n=4408/1922 (6330) 24,7% (n=1088) 6,0% (n=265) 35,8% (n=689) 9,5% (n=183) 
Month 1: n=3777/1610 (5387) 26,4% (n=999) 4,2% (n=159) 33,2% (n=534) 6,6% (n=106) 
Month 2: n=2595/1131 (3726) 19,2% (n=497) 2,5% (n=64) 23,1% (n=261) 2,9% (n=33) 
Month 3: n=3361/1428 (4798) 16,4% (550) 1,6% (n=55) 15,7% (n=224) 2,2% (n=31) 
Month 6: n=3080/1251 (4331) 11,6% (n=356) 0,9% (n=27) 9,5% (n=119) 0,6% (n=8) 
Month 9: n=2448/977 (3425) 8,0% (n=195) 0,8% (n=20) 6,6% (n=64) 0,8% (n=8) 
Month 12: n=1889/715 (2604) 7,3% (n=137) 0,7% (n=14) 5,2% (n=35) 0,4% (n=3) 
Table 24. Evaluation of anemia in the “d4T-based arm”, subgroup “VL pre-ART”” (see figure 16) 
 
AZT-based: n= 2306 (21.8%) 
 VL<100.000 VL>100.000  
n=VL<100.000/VL>100.000 
(total of VL values) 
HB Grade 1+2 HB Grade 3+4 HB Grade 1+2 HB Grade 3+4 
Pre-ART: n=1221/273 (1494) 25,1% (n=306) 1,8% (n=22) 31,1% (n=85) 3,7% (n=10) 
Month 1: n=1047/231 (1278) 32,1% (n=336) 2,1% (n=22) 36,4% (n=84) 9,5% (n=22) 
Month 2: n=714/144 (858) 28,3% (n=202) 2,7% (n=19) 37,5% (n=54) 5,6% (n=8) 
Month 3: n=896/170 (1066) 22,2% (n=199) 2,0% (n=18) 27,1% (n=46) 5,3% (n=9) 
Month 6: n=853/159 (1012) 13,2% (n=113) 1,4% (n=12) 15,1% (n=24) 2,5% (n=4) 
Month 9: n=730/133 (863) 12,3% (n=90) 1,0% (n=7) 13,5% (n=18) 0,8% (n=1) 
Month 12: n=540/112 (652) 11,7% (n=63) 0,4% (n=2) 10,7% (n=12) 1,8% (n=2) 
Table 25. Evaluation of anemia in the “AZT-based arm”, subgroup “VL pre-ART”” (see figure 17) 
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d4T-based: n= 8231 (77.9%) 
 Pre-ART BMI<18,5 Pre-ART BMI>18,5 
n=BMI<18,5/BMI>18,5 
(total of BMI values) 
GOT grade 1+2 GOT grade 3+4 GOT grade 1+2 GOT grade 3+4 
Pre-ART: n=1645/3463 (5108) 26,7% (n=440) 0,7% (n=12) 17,0% (n=590) 0,4% (n=13) 
Month 1: n=1290/2866 (4156) 25,7% (n=331) 1,9% (n=25) 16,9% (n=483) 1,8% (n=53) 
Month 2: n=1027/2213 (3240) 24,1% (n=248) 1,1% (n=11) 14,9% (n=329) 0,5% (n=11) 
Month 3: n=1191/2778 (3969) 21,6% (n=257) 1,3% (n=16) 15,3% (n=426) 0,3% (n=9) 
Month 6: n=1041/2501 (3542) 21,5% (n=224) 0,6% (n=6) 19,2% (n=479) 0,1% (n=3) 
Month 9: n=378/950 (1328) 15,3% (n=58) 0,3% (n=1) 15,7% (n=149) 0,3% (n=3) 
Month 12: n=580/1396 (1976) 15,0% (n=879 0,5% (n=3) 13,5% (n=189) 0,3% (n=4) 
Table 26. Evaluation of hepatotoxicity in the “d4T-based arm”, subgroup “malnutrition pre-ART” (see figure 18) 
 
AZT-based: n= 2306 (21.8%) 
 Pre-ART BMI<18,5 Pre-ART BMI>18,5 
n=BMI<18,5/BMI>18,5 
(total of BMI values) 
GOT grade 1+2 GOT grade 3+4 GOT grade 1+2 GOT grade 3+4 
Pre-ART: n=187/826 (1013) 29,4% (n=55) 0,5% (n=1) 10,7% (n=88) 0,4% (n=3) 
Month 1: n=142/685 (827) 16,2% (n=23) 1,4% (n=2) 12,1% (n=83) 1,9% (n=13) 
Month 2: n=106/504 (610) 16,0% (n=17) 2,8% (n=3) 8,7% (n=44) 0,8% (n=4) 
Month 3: n=119/598 (717) 20,2% (n=24) 0% (n=0) 6,4% (n=38) 0,2% (n=1) 
Month 6: n=105/519 (624) 11,4% (n=12) 0% (n=0) 5,0% (n=26) 0,4% (n=2) 
Month 9: n=80/455 (535) 11,2% (n=9) 0% (n=0) 5,5% (n=25) 0,4% (n=2) 
Month 12: n=69/360 (429) 13,0% (n=9) 1,4% (n=1) 9,7% (n=35) 0,3% (n=1) 
Table 27. Evaluation of hepatotoxicity in the “d4T-based arm”, subgroup “malnutrition pre-ART” (see figure 19) 
 
d4T-based: n= 8231 (77.9%) 
 Pre-ART BMI<18,5 Pre-ART BMI>18,5 
n=BMI<18,5/BMI>18,5 
(total of BMI values) 
HB Grade 1+2 HB Grade 3+4 HB Grade 1+2 HB Grade 3+4 
Pre-ART: n=1727/3591 (5318) 39,7% (n=685) 13,4% (n=231) 24,1% (n=866) 5,0% (n=180) 
Month 1: n=1463/3202 (4665) 37,9% (n=554) 9,5% (n=139) 25,5%(n=818) 3,5% (n=113) 
Month 2: n=1059/2297 (3356) 28,1% (n=298) 5,3% (n=56) 17,9% (n=412) 1,8% (n=41) 
Month 3: n=1246/2908 (4154) 20,5% (n=256) 3,5% (n=44) 14,6% (n=424) 1,5% (n=43) 
Month 6: n=1028/2616 (3698) 12,8% (n=138) 1,1% (n=12) 10,2% (n=268) 0,7% (n=18) 
Month 9: n=855/2073 (2928) 9,7% (n=83) 1,1% (n=9) 7,1% (n=147) 0,6% (n=12) 
Month 12: n=650/1538 (2188) 8,9% (n=58) 0,5% (n=3) 6,2% (n=95) 0,5% (n=7) 
Table 28. Evaluation of anemia in the “d4T-based arm”, subgroup “malnutrition pre-ART” (see figure 20) 
 
AZT-based: n= 2306 (21.8%) 
 Pre-ART BMI<18,5 Pre-ART BMI>18,5 
n=BMI<18,5/BMI>18,5 
(total of BMI values) 
HB Grade 1+2 HB Grade 3+4 HB Grade 1+2 HB Grade 3+4 
Pre-ART: n=202/871 (1073) 42,1% (n=85) 5,4% (n=11) 24,1% (n=210) 1,7% (n=15) 
Month 1: n=167/749 (916) 43,1% (n=72) 8,4% (n=14) 32,0% (n=240) 2,0% (n=15) 
Month 2: n=113/510 (623) 38,1% (n=43) 6,2% (n=7) 28,2% (n=144) 3,5% (n=18) 
Month 3: n=125/625 (750) 28,8% (n=36) 6,4% (n=8) 23,0% (n=144) 2,2% (n=14) 
Month 6: n=119/589 (708) 16,0% (n=19) 2,5% (n=3) 13,2% (n=78) 1,4% (n=8) 
Month 9: n=94/510 (604) 16,0% (n=15) 3,2% (n=3) 10,8% (n=55) 0,2% (n=1) 
Month 12: n=72/385 (457) 18,1% (n=13) 0,0% (n=0) 9,1% (n=35) 0,3% (n=1) 
Table 29. Evaluation of anemia in the “AZT-based arm”, subgroup “malnutrition pre-ART” (see figure 21) 
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 d4T-based: n= 8231 (77.9%) 
 Pre-ART HB grade 1+2 Pre-ART HB grade 3+4 
n=HB grade 1+2/3+4 
(total of HB values) 
GOT Grade 1+2 GOT Grade 3+4 GOT Grade 1+2 GOT Grade 3+4 
Pre-ART: n=1876/488 (6676) 23,0% (n=431) 0,7% (n=13) 24,6% (n=120) 0,6% (n=3) 
Month 1: n=1480/339 (5350) 22,9% (n=339) 2,0% (n=29) 20,6% (n=70) 2,9% (n=10) 
Month 2: n=1052/226 (2698) 20,9% (n=220) 1,1% (n=12) 24,8% (n=56) 0,4% (n=1) 
Month 3: n=1350/307 (5065) 19,7% (n=266) 1,2% (n=16) 22,1% (n=68) 0,3% (n=1) 
Month 6: n=1203/259 (3163) 20,8% (n=250) 0,4% (n=5) 24,3% (n=63) 0,4% (n=1) 
Month 9: n=505/116 (1835) 16,2% (n=82) 0,2% (n=1) 11,2% (n=13) 0,9% (n=1) 
Month 12: n=680/127 (2656) 13,5% (n=92) 0,4% (n=3) 15,0% (n=19) 0,8% (n=1) 
Table 30. Evaluation of hepatotoxicity in the “d4T-based arm”, subgroup “anemia pre-ART” (see figure 22) 
 
 AZT-based: n=2306 (21.8%) 
 Pre-ART HB grade 1+2 Pre-ART HB grade 3+4 
n=HB grade 1+2/3+4 
(total of HB values) 
GOT Grade 1+2 GOT Grade 3+4 GOT Grade 1+2 GOT Grade 3+4 
Pre-ART: n=443/35 (1660) 18,7% (n=83) 0,9% (n=4) 25,7% (n=9) 5,7% (n=2) 
Month 1: n=373/28 (1311) 15,8% (n=59) 1,9% (n=7) 21,4%(n=6) 0,0% (n=0) 
Month 2: n=258/20 (972) 11,2% (n=29) 1,9% (n=5) 30,0% (n=6) 0,0% (n=0) 
Month 3: n=318/26 (826) 12,6% (n=40) 1,3% (n=4) 11,5% (n=3) 3,8% (n=1) 
Month 6: n=270/22 (1088) 12,6% (n=34) 0,4% (n=1) 18,2% (n=4) 0% (n=0) 
Month 9: n=223/16 (906) 10,3% (n=23) 0,9% (n=2) 25,0% (n=4) 0% (n=0) 
Month 12: n=182/15 (712) 12,6% (n=23) 1,1% (n=2) 13,3% (n=2) 0% (n=0) 
Table 31. Evaluation of hepatotoxicity in the “AZT-based arm”, subgroup “anemia pre-ART” (see figure 23) 
 
 d4T-based: n= 8231 (77.9%) 
 Pre-ART HB grade 1+2 Pre-ART HB grade 3+4 
n=HB grade 1+2/3+4 
(total of HB values) 
HB Grade 1+2 HB Grade 3+4 HB Grade 1+2 HB Grade 3+4 
Pre-ART: n= 1741/440 (5989) 51,3% (n=893) 41,0% (n=180) 52,8% (n=919) 42,1% (n=185) 
Month 1: n=1672/410 (5993) 47,1% (n=193) 37,8% (n=155) 47,1% (n=193) 37,8% (n=155) 
Month 2: n=1084/246 (4097) 46,5% (n=504) 4,4% (n=48) 48,4% (n=119) 21,1% (n=52) 
Month 3: n=3578/323 (5522) 35,2% (n=500) 2,5% (n=36) 40,9% (n=132) 14,9% (n=48) 
Month 6: n=1252/273 (4831) 23,2% (n=290) 1,1% (n=14) 31,9% (n=87) 6,2% (n=17) 
Month 9: n=980/208 (3828) 14,8% (n=145) 1,7% (n=17) 26,4% (n=55) 4,8% (n=10) 
Month 12: n=749/143 (2913) 16,3% (n=122) 0,7% (n=5) 25,2% (n=36) 3,5% (n=5) 
Table 32. Evaluation of anemia in the “d4T-based arm”, subgroup “anemia pre-ART” (see figure 24) 
 
 AZT-based: n=2306 (21.8%) 
 Pre-ART HB grade 1+2 Pre-ART HB grade 3+4 
n=HB grade 1+2/3+4 
(total of HB values) 
HB Grade 1+2 HB Grade 3+4 HB Grade 1+2  HB Grade 3+4 
Pre-ART: n=468/37 (1496) 75,6% (n=353) 8,1% (n=3) 60,6% (n=284) 56,2% (n=21) 
Month 1: n=427/33 (1505) 69,8% (n=298) 7,3% (n=21) 45,5% (n=15) 51,5% (n=17) 
Month 2: n=260/21 (996) 58,5% (n=152) 5,4% (n=14) 52,4% (n=11) 38,1% (n=8) 
Month 3: n=875/28 (1242) 45,4% (n=154) 6,5% (n=22) 64,3% (n=18) 14,3% (n=4) 
Month 6: n=312/23 (1200) 31,1% (n=97) 4,2% (n=13) 34,8% (n=8) 17,4% (n=4) 
Month 9: n=267/17 (1012) 28,8% (n=77) 1,9% (n=5) 29,4% (n=5) 0% (n=0) 
Month 12: n=194/15 (766) 25,3% (n=49) 1,5% (n=3) 6,7% (n=1) 6,7% (n=1) 
Table 33. Evaluation of anemia in the “AZT-based arm”, subgroup “anemia pre-ART” (see figure 25) 
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